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GI   Gastrointestinal 
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IV. Summary 
The gastrointestinal (GI) tract is innervated by both the enteric nervous system and 
the sensory nervous system, and it is the latter that is responsible for giving rise to 
conscious sensations arising from the GI tract, such as pain. In particular, the distal 
colon is a key source of visceral pain in both inflammatory bowel disease (e.g. 
ulcerative colitis and Crohn’s disease) and irritable bowel syndrome. In both 
conditions, pain relief is complicated by the GI side effects of commonly prescribed 
analgesics, such as non-steroidal anti-inflammatory drugs and opioids. Therefore, 
furthering knowledge about how sensory innervation of the GI tract is modulated in 
health and disease has the potential to identify new therapeutic avenues. Galanin is a 
neuropeptide that has various functions within the central and peripheral nervous 
systems, e.g. regulation of feeding and modulation of nociceptive pathways 
respectively. Galanin has been previously demonstrated to modulate the 
mechanosensitivity of vagal sensory afferents innervating the upper GI tract, but 
nothing is known about its role in the distal colon, i.e. the lower GI tract. Using mice, I 
therefore aimed to determine if galanin also modulates the lumbar splanchnic nerve 
(LSN), which innervates the distal colon, in both healthy and inflamed (hypersensitive) 
conditions. Using ex vivo LSN electrophysiological recordings I found that galanin 
dose-dependently inhibits LSN responses to mechanical stimuli and the mechanical 
hypersensitivity induced by acutely applied inflammatory mediators. Using galanin 
receptor agonists (GalR1: M671, GalR2: spexin), I identified that GalR1 mediates the 
inhibitory effects on LSN mechanosensitivity. Using a mouse model of colitis, I found 
that the LSN was hypersensitive to mechanical stimuli, but that galanin no longer 
produced any inhibitory effect. Immunohistochemistry experiments using 
thoracolumbar (T13-L1) and lumbosacral (L6-S1) dorsal root ganglia (DRG) 
retrograde labelled from the colon demonstrated that galanin is primarily expressed by 
putative nociceptors, but that no major expression changes occur during colitis. In 
summary, I have demonstrated that galanin inhibits LSN mechanosensitivity and 
inflammatory mediators induced mechanohypersensitivity, but that this inhibition is lost 
in an in vivo model. This work highlights the potential for targeting the galaninergic 
system to treat GI pain. 
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1.1 Visceral nociception  
One of the essential functions of the nervous system is to provide information about 
the threat or occurrence of injury and this function is mediated by nociception, the 
neural process of encoding noxious stimuli. Nociception normally only occurs at 
temperatures, pressures and other stimuli that can potentially damage tissues and the 
process is mediated by nociceptors, a specialized class of primary afferents that 
respond to these intense, noxious stimuli (Dubin and Patapoutian, 2010). Like other 
primary somatosensory afferents, nociceptors are pseudounipolar, the cell body is 
located in the dorsal root ganglion (DRG, body) or trigeminal ganglion (TG, head) and 
each cell sends a peripheral axon to innervate a peripheral structure and a central 
axon to synapse with second-order neurones in the dorsal horn (DH) of the spinal cord 
(Dubin and Patapoutian, 2010). Noxious stimuli are transduced by nociceptors and 
signals are transmitted through spinal pathways to areas of the brain where signals 
are integrated and perceived. Arrival of nociceptive signals in the spinal cord can also 
trigger spinal reflexes in which signals from the spinal cord cause activation of 
appropriate flexor muscles and inactivation of extensor muscles to withdraw the limb 
from noxious stimulus (Clarke and Harris, 2004).  
 
Sensory modalities for somatic sensation include temperature, touch, pain, prickle, 
wetness, and itch sensations that are mediated via receptors specific to different 
stimuli, although some receptors are themselves polymodal. By contrast, visceral 
conscious sensations are far more limited than somatic sensations as demonstrated 
by Bentley (Bentley and Smithwick, 1940) who used balloon distention of the jejunum 
in a conscious man to show that distention of the gastrointestinal (GI) tract causes 
pain, but that other mechanical stimuli (cutting, pinching, and local stretching) failed to 
produce a painful sensation. Visceral pain is poorly graduated and localised, often with 
the conscious sensation manifesting as referred pain (pain perceived at a different 
location to the site of noxious stimuli). In the colon, this is thought to be due to the 
relatively low density of afferent innervation, lack of anatomical specification (such as 
encapsulation), and widespread distribution of afferent pathways (Knowles and Aziz, 
2009; Sikandar and Dickenson, 2012). During tissue damage, mediators are released 
both from damaged cells and from immune cells involved in the inflammatory 
response. Nociceptors can be sensitized by these inflammatory mediators due to both 
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post-translational modification of ion channels and alteration in receptor expression, 
processes that result in lower threshold for activation and/or greater responsiveness 
to stimuli, overall causing an increase in neuronal excitability (Bhave and Gereau, 
2004; Okuse, 2007). A specific example of colonic sensory neurone sensitisation was 
shown by Jones, in which, the application of an inflammatory soup (bradykinin, 
adenosine triphosphate (ATP), histamine, prostaglandin E2, and noradrenaline) to 
receptive fields of the colon caused nociceptor hyperexcitability (Jones, 2005).  
 
As well as changes in visceral sensation associated with inflammation becoming better 
understood, the complex relationship between the gut microbiota and visceral pain is 
an emerging topic. Changes in the microbiota have been linked to immunological, 
neurological and inflammatory changes that are the hallmark signs in chronic pain 
conditions (see Section 1.3, Conte et al., 2006; Frank et al., 2007, Shankar et al., 
2015; Simrén, 2014). Reported changes in the microbiota include reduced levels of 
Bifidobacterum and Lactobacillus, as well as an increased Firmicutes to Bacteriodetes 
ratio (Jeffery et al., 2012). However, whether these changes are causative of disease 
pathology, or a response to an alternative initiating factor is inconclusive. Interestingly, 
preclinical studies have shown that mice raised in sterile conditions with no GI bacteria 
have a blunted response to inflammatory pain caused by carrageenan injection to the 
hind-paw (Amaral et al., 2008). A finding which thus implicates commensal bacteria 
as having an important role in the development of inflammatory hyperalgesia. 
Moreover, antibiotic-induced reduction of gut microbiota in mice also results in animals 
displaying a reduced visceral pain response to intracolonic application of capsaicin 
(Aguilera et al., 2015). However, in rats, early exposure to antibiotics increases 
susceptibility to colonic hypersensitivity in adulthood (O’Mahony et al., 2014) and thus 
overall, the role of gut microbiota in visceral pain is certainly complex and not yet fully 
understood. 
 
1.2 Anatomy of GI tract innervation and spinal thoracolumbar pathways 
Afferent neurones innervating the gut relay signals to a wide range of laminae (I, II, V, 
and X) of the spinal cord dorsal horn (Grundy et al., 2006). Here, second order 
neurones transmit the message to the brain via spinoreticular, spinohypothalamic, 
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spinomesencephalic and spinothalamic pathways to the thalamic and parabrachial 
structures in the brain (Fukudo, 2013; W Jänig and McLachlan, 1987; Knowles and 
Aziz, 2009). All pathways are in the anterolateral quadrant of the spinal cord with the 
spinoreticular, spinohypothalamic, and spinomesencephalic pathways mainly involved 
in autonomic reflexes and the spinothalamic pathway involved in conscious sensation. 
Hollow organs can sense varying intensity of stimuli, from smooth muscle contraction 
to increasing intraluminal pressure (De Winter et al., 2016). Noxious activation of 
afferent pathways innervating the viscera can result in reflex behaviours, such as 
nausea and variation in heart rate, as well as contributing to conscious sensations like 
pain. Sensory afferents innervating the colon convey a wide range of conscious 
sensations including bloating, urgency, fullness and pain (De Winter et al., 2016; 
Knowles and Aziz, 2009). 
 
The GI tract is innervated by both intrinsic and extrinsic pathways. The intrinsic 
pathway is located within the enteric nervous system (ENS) and mediates reflexes 
controlling secretion, blood flow and motility, independently of the central nervous 
system (CNS; Blackshaw et al., 2007). Transmission of sensory information from 
visceral organs to the CNS is mediated by extrinsic innervation of the GI tract by spinal 
thoracolumbar (TL; corresponds to lumbar splanchnic nerve, LSN), spinal lumbosacral 
(LS; corresponds to pelvic nerve) and vagal pathways. With respect to innervation of 
those areas of interest in inflammatory bowel disease (IBD), the vagal pathway 
innervates a wide variety of visceral organs, but makes only minimal contribution to 
sensory transduction from the distal colon (Berthoud et al., 1990; Berthoud and 
Neuhuber, 2000; Spencer et al., 2016). By contrast, the spinal TL pathway innervates 
the oesophagus, stomach, small intestine and colon, while the spinal LS pathways 
innervate the mid colon through to the rectum. Unlike vagal innervation of the GI tract, 
both TL and LS spinal pathways innervate regions associated with pain in IBD. The 
TL pathway includes afferents whose cell bodies are located in the lower thoracic and 
upper lumbar DRG (T10-L1), whereas afferents of the LS pathway have cell bodies in 
the lower lumbar and upper sacral DRG (L6-S1) (Christianson et al., 2006a; Figure. 1-
1). Overall, in mice, the proportion of TL and LS DRG neurones that project to the 
colon is 2.9% and 2.3% respectively with DRG T13 and L1 containing the highest 
number of colon-innervating neurones (Brierley et al., 2008; Robinson et al., 2004).  
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Figure 1-1. Neuroanatomy of the colon  
The three main sympathetic (blue) and parasympathetic (red) pathways innervating the colon 
are shown; vagal, splanchnic and pelvic nerves. The vagal afferents originate from cell bodies 
of the nodose ganglia (NG) and project to the medulla oblongata. The vagal nerve innervates 
the proximal colon. Thoracolumbar afferents originate from DRG neurones (T10-L1) and 
project to the dorsal horn of the spinal cord. Colonic thoracolumbar afferents innervate the 
more proximal region of the colon via the least splanchnic nerve and the descending colon via 
the lumbar splanchnic nerve (LSN). Colonic thoracolumbar afferents pass through the superior 
mesenteric ganglia (SMG), and inferior mesenteric ganglia (IMG). Lumbosacral afferents 
originate in DRG neurones (L6 and S1) and, like thoracolumbar afferents, project to the dorsal 
horn of the spinal cord. Lumbosacral afferents innervate the distal colon and the rectum and 
pass through the pelvic ganglia (PG).  
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In the GI tract, afferent fibres can be characterised based on the location of their 
receptive fields and their sensitivity to different mechanical stimuli (these include von 
Frey hair probe, distention, circular stretch, and mucosal stroking). Through such 
mechanical characterisation, five categories of colonic sensory neurones have been 
identified: muscular-mucosal, muscular, mucosal, mesenteric, and serosal (Feng and 
Gebhart, 2011) and it is the mesenteric and serosal groups that are thought to be 
primarily involved in colonic nociception (Brierley et al., 2004). It is also worth noting 
that there is a sub-population of sensory afferents called silent afferents that under 
physiological conditions are insensitive to mechanical stimuli, but can become 
sensitized and respond to mechanical stimuli during inflammation, and thus contribute 
to the hypersensitivity of visceral pain (Brookes et al., 2013; Feng and Gebhart, 2011). 
The proportion of the different afferent types differs between TL and LS pathways, 
such that the LSN contains mucosal (4%), muscular (10%), serosal (36%) and 
mesenteric (50%) afferent classes, whereas, the pelvic nerve contains 
muscular/mucosal (23%), serosal (33%), mucosal (23%), and muscular (21%) afferent 
classes (Brierley et al., 2004). The serosal and mesenteric afferent subtypes are of 
particular importance in terms of transducing pain and are mainly present in the LSN 
(Brierley et al., 2004; Hughes et al., 2009), and thus this thesis focuses on LSN 
function, which I will now discuss in more detail. 
 
The mesenteric afferent neurones are associated with blood vessels innervating the 
GI tract, such that in the colon about 83% are associated with mesenteric arteries, 
13% with mesenteric veins and 3% are located in the mesentery but away from blood 
vessels (Song et al., 2009) and it is the neurones closely associated with blood vessels 
that respond to higher intensities of circular stretch and distention compared to 
muscular afferents (Hughes et al., 2009; Jänig, 1996). Moreover, mesentery afferents 
can be subcategorised into serosal and mesenteric afferents mainly based on their 
location, such that mesenteric afferents are located mainly on mesenteric blood 
vessels and serosal afferents are associated with intramural blood vessels; although 
named serosal afferents, this is somewhat misleading as there are no afferent endings 
located in the serosal layer of the colon (Brookes et al., 2013).  
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The serosal and mesenteric afferents make up the majority of the LSN innervating the 
colon and their expression of a range of receptors enables responses to a wide range 
of chemical stimuli, including: prostaglandins, 5-HT, bradykinin, and glutamate 
(Blackshaw and Gebhart, 2002). These afferents also express receptors for certain 
inflammatory cytokines, such as interleukin 6 (IL-6) and interleukin 1 beta (IL-1β), and 
therefore can respond to cytokine signalling in inflammation (Andratsch et al., 2009; 
Binshtok et al., 2008). Inflammatory mediators, such as nerve growth factor (NGF), 
can induce mechanosensitivity (via disinhibition of the mechanically-gated ion 
channel, Piezo2; Prato et al., 2017) in a small subpopulation of afferents that under 
control conditions are insensitive to mechanical stimuli and this mechanism could be 
therapeutically important in treating IBD and/or irritable bowel syndrome (IBS) (Feng 
and Gebhart, 2011). 
 
Thirdly, colonic muscular afferents make up a small proportion of mechanosensory 
afferents in the LSN and respond to low intensity stretch stimulation. However, due to 
their responsiveness to mechanical noxious stimuli, it has been suggested that colonic 
muscular afferents have a role in nociception as wide dynamic range fibres (Brierley 
et al., 2004).  
 
Lastly, mucosal afferents account for the smallest proportion of afferents in the LSN. 
They are clustered in the lower region of the distal colon and show adapting responses 
to low-threshold mucosal stroking and probing but are insensitive to circular stretch 
stimuli. This suggests a role in either providing fine mucosal input to reflexes 
controlling motility and/or refining the quality of perceived stimuli (Brierley et al., 2004).  
 
 
1.3 The impact of chronic visceral nociception in chronic bowel disease 
Acute somatic pain is an important component of the body’s defence system by 
eliciting reflex and avoidance behaviours to protect the body from a hostile external 
environment (Woolf, 1995). However, visceral pain does not provide the same form of 
detect and protect mechanism. In some cases, visceral pain can be an indication of a 
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serious condition (such as appendicitis), but oddly, visceral pain cannot be evoked in 
every visceral organ (stimulation of solid organs, such as the liver and kidneys does 
not evoke visceral pain) and is not always linked to overt visceral injury (Cervero and 
Laird, 2004). For example, individuals with functional GI disorders, such as IBS, exhibit 
abdominal pain, discomfort, and altered bowel habits, but the underlying 
pathophysiological mechanisms are still poorly understood (Al Omran and Aziz, 2014). 
However, there are a group of chronic inflammatory disorders in which dysregulation 
of this protective function can lead to morbidity and the presence of chronic visceral 
pain reduces the patient’s quality of life. A study in 2014 showed that 87% of IBD 
patients experienced abdominal pain at least once a day during a flare up and 62% 
reported abdominal pain at least once a week between flare ups (i.e. when in 
remission). The study also found that 46% of respondents reported abdominal pain 
leading to absence from work and that 40% reported being woken from sleep as a 
result of abdominal pain (Lönnfors et al., 2014). In another study, 20% of IBD patients 
reported that pain interfered with their daily functions (IsHak et al., 2017).  
 
The clinical presentation of IBD includes diarrhoea, abdominal pain, bleeding, and 
fatigue with abdominal pain rating highly with regard to the impact of IBD on a patient’s 
quality of life (Mowat et al., 2011; Singh et al., 2011; Arnott et al., 2012). However, IBD 
is not just a single disease, but rather a term used to encompass Crohn’s disease (CD) 
and ulcerative colitis (UC), both of which are chronic, relapsing, inflammatory colon 
disorders. Overall, IBD is estimated to affect around 1.5 million Americans (with an 
incidence of 19.2 per 100,000 for UC and 20.2 per 100,000 for CD), 2.2 million 
Europeans (with an incidence of 24.3 per 100,000 for UC and 12.7 per 100,000 for 
CD), and several hundred thousand more worldwide (Ananthakrishnan, 2015; 
Molodecky et al., 2012). The peak incidence occurs between the ages of 20 and 40 
years of age, but it has also been suggested that IBD has a bimodal incidence with a 
second peak occurring between the ages of 60 and 70 years of age (Loftus, 2004; 
Molodecky et al., 2012). The incidence is similar between men and women but is 
influenced by ethnicity. In countries considered to have high incidence, the risk is 3-
fold higher for the Jewish population, especially Ashkenazi Jews, whereas a low 
prevalence is seen in African American and Hispanic populations (Mahid et al., 2008; 
Reddy and Burakoff, 2003). The cause of IBD is idiopathic and generally results from 
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multiple genetic mutations causing an acquired immunological response to certain 
commensal enteric bacteria (Kostic et al., 2014; Morgan et al., 2012). The onset of the 
disorder is thought to be triggered by an environmental event, such as infection, or the 
prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs; Berg et al., 2002). An 
initial infection can cause acute inflammation, which in a genetically susceptible host 
leads to reduced immunoregulation and, therefore, chronic inflammation (Sator, 
2006). During “acute flares”, nociceptive sensory pathways can become sensitized by 
inflammation leading to visceral hypersensitivity (the increased responsiveness of the 
gut to stimulation) and this can persist in periods of remission from inflammatory flare 
ups for a proportion of patients (Bielefeldt et al., 2009).  
 
Another common chronic disorder in which visceral pain has a negative impact on the 
patient’s quality of life is IBS, which has a prevalence of 22% in the UK (Gwee, 2005) 
and is thought to affect 10-15% of the population in developed countries (Card et al., 
2014). A prevailing feature of IBS is transient noxious events leading to long-lasting 
sensitisation of the neuronal pain circuit, similar to the visceral hypersensitivity 
previously described for IBD (Barbara et al., 2011). The key difference between IBS 
and IBD is the aetiology of the symptoms. For IBD, the symptoms result from overt 
mucosal inflammation, whereas, the diagnosis of IBS is symptomatic with no obvious 
inflammation being observed and it is considered a functional disorder, i.e. no 
underlying disease causes the symptoms (Naliboff et al., 2012). 
 
For IBD, early phase pharmacological treatment with antibiotics, corticosteroids, anti-
TNFα therapy or immunomodulators has been shown to reduce inflammation and, as 
a result, visceral pain. However, there is still a large subset of patients that experience 
discomfort and pain even in the presence of reduced inflammation suggesting that 
visceral pain is discontinuous with the disease activity (Bernstein, 2014). Current 
treatments to manage abdominal pain in IBS and IBD are limited either by their 
effectiveness or by their adverse effects and the range of treatments available for the 
management of visceral pain is diverse, which likely reflects the complexity of visceral 
pain mechanisms in IBS and IBD (Szigethy, 2018).  
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One set of drugs that can be used to control visceral pain are NSAIDs that act by 
reducing prostaglandin (mediators known to promote inflammation) production by 
inhibiting the enzyme that synthesizes them, cyclooxygenases (COX). Although 
NSAIDs effectively reduce abdominal pain in the short term, there is evidence linking 
their use with an increased relapse frequency and therefore exacerbating IBD 
(Kefalakes et al., 2009). Long-term use of non-selective NSAIDs has been shown to 
produce GI toxicity in the form of ulcerations, perforation and diverticulitis in the distal 
colon (Lanas et al., 2006). NSAIDs that act through selective inhibition of COX-2, such 
as celecoxib and etoricoxib, are often used due to their improved GI profile. However, 
there has been controversy over the safety of COX-2 inhibitors, with Rofecoxib having 
been withdrawn due to cardiovascular side effects (Miao et al., 2009; Biancone et al., 
2003). Recently, it has been shown that current COX-2 inhibitors are no worse than 
other NSAIDs with regard to cardiovascular toxicity (such as ibuprofen or naproxen; 
Nissen et al., 2017), thus, so long as the patient has no underlying cardiovascular risks 
they are generally used for chronic conditions. The anti-spasmodic drug hyoscyamine 
is a non-selective acetylcholine muscarinic receptor inhibitor, which acts to cause the 
intestinal smooth muscle to relax and thus reduce spasms associated with colonic 
pain. However, such anti-spasmodic drugs also reduce GI motility, which can lead to 
constipation and bowel occlusion, and thus themselves induce pain. Anti-spasmodics 
have been shown to be effective in IBS patients (Ford et al., 2008) but do not show as 
much effectiveness in IBD patients, although remissive patients or those with mild 
chronic pain may still find antispasmodics effective. Opioids, such as tramadol and 
morphine, are also used to treat severe cases of chronic pain in IBD patients act by 
antagonising opioid receptors. Although opioids reduce activity of the pain pathway at 
various points, their use is also associated with a range of adverse effects including: 
nausea, vomiting, reduced gut motility leading to constipation (of particular concern 
when treating IBD/IBS patients), and being highly addictive leading to substance 
abuse (Dasgupta et al., 2018; Mowat et al., 2011). 
 
Another class of drugs that have been extensively used for treatment of IBS related 
abdominal pain are antidepressants (Drossman et al., 2009). Besides their positive 
effects on an individual’s mood (depression is a common comorbidity of chronic pain), 
antidepressants are also useful for patients with functional abdominal pain without 
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depression due to their central pain-modulatory action (Morgan et al., 2005). Targeting 
serotonin (selective serotonin reuptake inhibitors; SSRIs) and noradrenaline 
(serotonin-noradrenaline reuptake inhibitors; SNRIs) has been shown to have 
potential in treating IBD chronic pain (Grover and Drossman, 2011; Mikocka-Walus et 
al., 2007). Although there is relatively little data supporting SSRI treatment for 
abdominal pain, fluoxetine has been shown to reduce abdominal pain in non-
depressed IBS patients with colonic hypersensitivity (Kuiken et al., 2003). Considering 
the central roles of serotonin and noradrenaline in the descending modulation of pain, 
SNRIs seem like good candidates for treating chronic visceral pain. Indeed, SNRIs 
have been shown to increase the sensory threshold of mice in response to colorectal 
balloon distension (Chial et al., 2003). However, like all drugs, SNRIs do cause some 
side effects including: nausea, palpitations, sweating and disrupting sleep (Brennan et 
al., 2009). Like SNRIs, tricyclic antidepressants (TCAs) also inhibit both serotonin and 
noradrenaline reuptake, but they also have other functions, including inhibition of 
voltage-gated ion channels, opioid receptor activation and possible neuroimmune anti-
inflammatory effects (Dharmshaktu et al., 2012). In addition, TCAs also inhibit 
muscarinic acetylcholine receptors and histamine receptors leading to antimuscarinic 
and antihistaminic side effects (e.g. drowsiness, xerostomia, and palpitations). A large 
study by Drossman et al., involving 216 women with IBS, showed numerical trends, 
but not statistically significant decrease in ISB-associated pain, from a 12-week 
treatment with the TCA desipramine, a major drawback being the 25% dropout rate 
due to side effects, although those patients that stayed to the end of the study did 
experience a significant benefit of desipramine compared to placebo (Drossman et al., 
2003). 
 
Serotonin is a key neurotransmitter in the GI tract that stimulates the release of other 
neurotransmitters to influence peristalsis and water secretion, as well as acting directly 
on visceral sensory nerves to cause pain (Crowell, 2004). Therefore, directly targeting 
mechanisms through which serotonin acts on the GI tract is an attractive therapeutic 
target, as demonstrated by alosetron, a serotonin type 3 (5-HTR3) receptor antagonist, 
being shown to relieve symptoms of diarrhoea predominant IBS (IBS-D) patients 
(Quartero et al., 2005). However, alosetron has also been associated with side effects 
of severe constipation and ischemic colitis. Tegaserod is a serotonin type 4 (5-HTR4) 
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receptor antagonist that has been shown to reduce abdominal pain, bloating and 
constipation in constipation predominant IBS (IBS-C) patients (Layer et al., 2007). It is 
well tolerated but can have the adverse effect of diarrhoea. The success of alosetron 
and tegaserod demonstrates that modulation of colonic sensory afferent signalling 
provides good potential for the development of future novel treatments for visceral pain 
associated with IBD and IBS. 
 
1.4 Modulation of colonic afferent excitability 
The frequency and intensity of action potentials transmitted from peripheral nerve 
endings to the spinal cord is the mechanism by which noxious stimuli are perceived. 
Inhibition of mechanosensitivity in colonic afferents has been demonstrated as an 
effective therapeutic approach in the treatment of visceral pain for some patients. For 
example, rectal application of lidocaine jelly (coating the first 4 cm of the rectum) treats 
pain associated with IBS in a subset of patients (Verne et al., 2005, 2003). Therefore, 
pharmacological modulation of visceral afferent excitability offers an attractive 
therapeutic avenue, but through using more selective compounds than lidocaine, 
which simply switches off all nerve function and is thus not a practical long-term 
solution. 
 
Under physiological conditions neurones have a resting membrane potential of 
approximately -60 mV, which is maintained by the regulated movement of ions across 
the plasma membrane. A variety of ion channels and receptors have the potential to 
change the membrane potential leading to the generation of action potentials through 
depolarisation of the membrane. Visceral sensory neurones are heterogenous with 
regard to their expression profile, thus endowing them with differing sensitivity to 
various stimuli. Neuronal sensitivity to different stimuli is also prone to modulation, 
especially during inflammation when a plethora of mediators are released (Brierley et 
al., 2005a; Brierley et al., 2005b; Feng et al., 2012; Hughes et al., 2009). Experimental 
animal models of colitis are also associated with colonic afferent sensitisation and 
hypersensitivity to colonic distension (Feng et al., 2012; Hughes et al., 2009), and thus 
provide a good experimental model of investigating the molecular mechanisms that 
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drive changes in colonic afferent excitability in chronic visceral pain conditions, such 
as IBD. 
 
To understand how any novel treatment might modulate visceral afferent excitability, 
the different noxious stimuli that can excite and sensitise afferent terminals in the GI 
tract all need to be considered as they all play a role in the pathogenesis of IBD-
associated pain (Fig. 1-2). The noxious stimuli involved in IBD include direct noxious 
mechanical stimulation (such as that arising from occlusion or distension of the colon) 
and inflammatory mediators (such as ATP, histamine, bradykinin etc.). 
 
 
Figure 1-2. Mechanisms modulating excitability of visceral afferent endings  
Following release of inflammatory mediators and tissue acidosis, several receptors and proton 
sensing ion channels are activated leading to intracellular changes which act to increase 
neuronal excitability by depolarizing the membrane (predominantly through cation influx), 
recruiting voltage-gated ion channels (such as Navs) and leading to action potential 
generation. GPCRs and cytokine receptors for inflammatory mediators and neuropeptides 
activate intracellular signalling pathways leading to posttranslational changes and ultimately 
sensitisation of other ion channels (indicated by dotted arrows). BK – bradykinin, 5-HT – 5-
hydroxytryptamine, TNFα – tumour necrosis factor alpha, CGRP – calcitonin gene-related 
peptide, ASIC – acid-sensing ion channel. Modified from Schaible et al. (2011). 
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Transduction of mechanical stimuli is vital for conveying GI sensations and is the 
primary cause of colonic pain. Multiple mechanisms have been implicated in the 
transduction of mechanical stimuli including direct activation of mechanically-gated ion 
channels, such as Piezo2 (Brierley, 2010; Prato et al., 2017). In addition to Piezo2, 
other ion channels have been implicated in visceral mechanosensation. For example, 
acid-sensing ion channels (ASICs) are part of the epithelial Na+ channel (ENaC) family 
of cation channels and are activated by protons, but also appear to modulate 
responses to mechanical stimuli (Omerbašić et al., 2015), although ASICs are not 
themselves mechanotransducers (Drew et al., 2004). ASIC1a, ASIC2, and ASIC3 
have all been associated with mechanosensitivity in the colon through the use of 
knockout (KO) mice, as will now be discussed. ASIC1a is expressed by 30% of TL 
colonic afferents (Hughes et al., 2007) and ASIC1a KO mice show increased 
mechanosensitivity in LSN afferents (Page, 2005a). ASIC2 is expressed in 50% of 
colonic thoracolumbar DRG neurones and in a similar manner to ASIC1a KO mice, 
ASIC2 KO mice display increased mechanosensitivity in serosal LSN afferents, 
although, mesenteric LSN afferents remained unaffected (Page, 2005a). Lastly, 
ASIC3 is expressed by approximately 75% of colonic thoracolumbar DRG neurones 
(Hughes et al., 2007) and by contrast to the phenotypes of ASIC1a and ASIC2 KO 
mice, ASIC3 KO mice showed reduced mechanosensation in mesenteric and serosal 
LSN afferents and muscular/mucosal pelvic afferents (Bielefeldt and Davis, 2008; 
Page, 2005a). Furthermore, using in vivo experiments, as opposed to the ex vivo 
electrophysiological recording mentioned above, ASIC3 KO mice also showed a 
significant reduction in the visceromotor response (VMR; electromyogram (EMG) 
response) to colorectal distension (CRD) (Jones, 2005). Sensitivity to protons means 
that during tissue acidosis, as occurs in in inflammation, ASICs contribute to altering 
basal excitability thereby sensitising afferents. Overall, the contribution of ASICs to 
specific aspects of visceral mechanotransduction and afferent sensitisation influences 
the encoding of noxious mechanical stimuli. 
 
The Piezo family of cation channels consists of 2 members in mammals, Piezo1 and 
Piezo2, both of which are very large membrane proteins containing between 24-36 
transmembrane segments. Piezos may be relevant to colonic mechanosensitivity as 
they have been shown to be rapidly-adapting mechanosensitivity transducers in DRG 
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neurones and are currently the only known mechanotransducer (Coste et al., 2010). 
Piezo2 KO mice have reduced touch and mechanical hypersensitivity during 
inflammation (Murthy et al., 2018; Ranade et al., 2014). Intriguingly, Piezo2 is 
expressed in just under 50% of all sensory neurones and its expression profile in 
colonic sensory neurones (Hockley et al., 2019) suggests that it plays a key role in 
colonic mechanosensitivity, although this remains to be tested. 
 
Transient receptor potential (TRP) channels are predominantly non-selective cation 
channels that transduce a range of mechanical, thermal and chemical stimuli. TRP 
channels also undergo significant post-translational modification and thus can 
contribute to the hypersensitivity that follows inflammation. There are seven sub-
families of the TRP superfamily (TRPC, TRPV, TRPA, TRPM, TRPN, TRPP and 
TRPML), some of which have been associated with visceral mechanosensitivity, e.g. 
TRPV1, TRPV4 and TRPA1 (Brierley et al., 2008, 2009; Hughes et al., 2007). TRPV1 
is expressed by 80% of TL and 50-60% LS colonic DRG neurones (Christianson et 
al., 2006b; Robinson et al., 2004) and pelvic nerve sensory afferents isolated from 
TRPV1 KO mice show reduced mechanosensitivity (Brierley et al., 2008). However, 
TRPV1 is not directly mechanically gated and therefore it likely influences 
mechanosensation indirectly by affecting neuronal excitability. TRPV4 also plays a 
role in mechanosensation, such that deletion of TRPV4 or application of a TRPV4 
antagonist reduces afferent mechanosensitivity in the colon (Brierley et al., 2008). 
Overall, the reduction in afferent mechanosensitivity observed in electrophysiology 
experiments on isolated colon-nerve preparations from TRPV4 KO mice correlates 
with observations in vivo, such that the VMR to CRD is also reduced in TRPV4 KO 
mice and in mice in which TRPV4 has been knocked down using siRNA (Brierley et 
al., 2008; Cenac et al., 2008). Lastly, TRPA1 also contributes to the 
mechanosensitivity of serosal, mesenteric and mucosal, but not stretch sensitive 
afferents in LSN and PN (Brierley et al., 2009). TRPA1 is expressed by approximately 
50% of both TL and LS colonic afferents and both TRPA1 KO mice and rats treated 
with TRPA1 antisense oligonucleotides to knock down TRPA1 expression show a 
reduced VMR to CRD (Brierley et al., 2009; Yang et al., 2008). Moreover, in a model 
of bradykinin-induced colonic hypersensitivity, wildtype mice showed an increase in 
mechanosensitivity after bradykinin application, whereas TRPA1 KO mice showed no 
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change in mechanosensitivity after bradykinin application, suggesting that TRPA1 has 
perhaps a more significant role in sensitisation and mechanical hypersensitivity 
(Brierley et al., 2009) 
 
The algogenic mediator, ATP, has also been suggested to be relevant to visceral 
nociceptor activation during colonic distension. This is because in hollow organs 
mechanical stress has been suggested to trigger the release of ATP from the 
epithelium, which in turn activates nociceptors (Burnstock, 2009). This could be a 
particularly prominent pathway during colonic inflammation as ATP release is 
enhanced during colitis. Moreover, ATP release has been proposed to regulate the 
inflammatory response through P2X7 receptor activation and nuclear factor kappa-
light-chain-enhancer of activated B cells (NFκB) signalling in sensory neurones 
(Shinoda et al., 2009; Wan et al., 2016).  
 
Visceral hypersensitivity to CRD has been seen in both IBS and IBD. Colons in 
individuals with IBD display overt inflammation, whereas those in individuals with IBS 
do not, however, in both cases mediators have been identified that are specific to the 
disease condition. In IBD, these are pro-inflammatory mediators, such as IL-10, TNF-
α, and histamine (Gasche et al., 2000; Song et al., 2014). In IBS, mediators of 
hypersensitivity were first identified as being present by using supernatants made from 
colon biopsies of IBS patients that induced hypersensitivity when applied to mouse 
colon (Cenac et al., 2007). Recently, 5-oxoETE has been identified as a mediator in 
IBS-C that contributes to hypersensitivity without causing tissue inflammation 
(Bautzova et al., 2018). This shows that a mixture of mediators released from within 
the GI tract has the capability to sensitise colonic afferents and it has also been seen 
that the combination of inflammatory mediators released might differ between acute 
and chronically inflamed tissues (Feghali and Wright, 1997).  
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1.5 Neuropeptides 
Neuropeptides are small neurotransmitter peptide molecules that are involved in a 
wide range of functions including analgesia (e.g. enkephalins) and nociception (e.g. 
substance P). The difference between neuropeptides and peptide hormones is the cell 
types they are released from and that respond to the molecule. Neuropeptides are 
released from neuronal cells and bind to receptors expressed by a selective population 
of neurones, whereas peptide hormones are released by neuroendocrine cells and 
travel via the blood to peripheral tissues (Fricker, 2012). Neuropeptides are co-
released with small molecule neurotransmitters; however, unlike many small molecule 
neurotransmitters, neuropeptides are not recycled back into the cell, but are broken 
down by peptidases.  
 
Further differences exist between small molecule neurotransmitters and 
neuropeptides. Firstly, small molecule neurotransmitters are usually synthesised in the 
nerve terminal from precursors, whereas neuropeptides are encoded by genes and 
synthesised as large precursor or preprocursor peptides in the cell soma and made 
bioactive by enzymatic cleavage either in the Golgi apparatus or vesicles. 
Preprocursors also general contain signal peptides which are short peptides found at 
the N-terminus that function to prompt translocation of the protein. Furthermore, 
whereas small molecule neurotransmitters containing vesicles are docked at the active 
zone and only require small changes in intracellular Ca2+ to neurotransmitter release, 
neuropeptides are stored in large dense core vesicles (LDCV), which are only released 
during high frequency firing that causes large, sustained increases in intracellular 
Ca2+. One neuropeptide of particular interest with regard to GI function is galanin. 
 
1.6 Galanin 
Galanin is a neuropeptide that is expressed in many different parts of the body, 
including extrinsic nerves innervating the distal colon and other cell types in the colon, 
including epithelial cells and enterochromaffin cells (Lang et al., 2014). The broad 
expression of galanin in the colon suggests that it could potentially influence the 
excitability of colonic sensory afferents. Galanin is a 29/30-amino acid peptide 
(mouse/human) discovered by the Mutt lab, which isolated galanin from porcine 
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intestinal extracts (Tatemoto et al., 1983). The human GAL gene is located on 
chromosome 11q13.2, spans 6.6 Kb, contains 6 exons and produces a 124-amino 
acid long precursor protein (preprogalanin) that undergoes post-translational 
modification in which it is proteolytically cleaved to produce galanin (Kofler et al., 1996; 
Rökaeus and Brownstein, 1986) (Figure. 1-2A). Preprogalanin contains the signalling 
peptide, progalanin-message peptide (PGMP), galanin message-associated peptide 
(GMAP) and galanin (Yamamoto et al., 2014). This is discussed further in the next 
section. 
 
In adult mice, galanin has a widespread distribution in both the CNS and peripheral 
nervous system (PNS) supporting the hypothesis that it plays a role in many 
physiological functions (see section 1.8). In the CNS of mice, it is highly expressed in 
the hypothalamus and brainstem with relatively low expression in the olfactory bulb, 
septal nuclei, thalamus, and parabrachial and spinal trigeminal nuclei (Cheung et al., 
2001). In the PNS, galanin-like immunoreactivity has been observed in both the 
myenteric plexus and submucous plexus of the stomach, duodenum, ileum and colon 
with galanin positive fibres detected in the circular muscle layer, lamina muscularis 
mucosae and the lamina propria (Rökaeus et al., 1984). In the GI tract, galanin is 
expressed most highly in the duodenum tissue with lower levels of expression in the 
stomach and the colon tissue (Kaplan et al., 1988).  
 
1.7 Galanin peptide family 
The GAL gene protein product is proteolytically cleaved into galanin and the 59-amino 
acid peptide GMAP (Figure. 1-3A). The function of GMAP remains unclear, but it has 
been suggested to have a role in modifying nociception in the spinal cord and has also 
been reported to have antifungal activity (Rauch et al., 2007).  
Another protein in the galanin family, but one that is encoded by a different gene, is 
galanin-like protein (GALP; Fig 1-2B). Originally described as a putative endogenous 
ligand of galanin receptor 2 (GalR2), GALP shares some homology (amino acids 9-
21) with the first 13 amino acids of galanin and an overall homology of 43% of galanin. 
GALP has high affinity for GalR2 and is thought to have a role in energy homeostasis 
and reproduction (Lawrence and Fraley, 2010). GALP is also expressed in the mucosa 
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of the GI tract and is thought to play a role in stimulating feeding behaviour (Mensah 
et al., 2017). A splice variant of the GALP gene, which omits exon 3 causing a frame 
shift, also exists and is called alarin. Like GALP, alarin has been suggested to 
stimulate feeding behaviour, as well as influencing luteinizing hormone secretion. 
However, unlike GALP, the lack of homology of alarin to galanin means that it does 
not bind to any galanin receptor, but as yet no receptor for alarin has been identified 
(Boughton et al., 2010; Santic et al., 2006). 
 
 
 
 
 
 
 
31 
Figure 1-3. Organisation of the galanin and GALP genes 
The first exon of the mouse galanin gene encodes the 5′-untranslated regions of the 
preprogalanin mRNA, exon 2 encodes the signalling peptide, exon 3 encodes the first 13 
residues of galanin with exon 4 and 5 encoding the remaining 16 residues, as well as most of 
galanin message associated protein (GMAP), leaving exon 6 to encode the remaining section 
of GMAP and the 3′-polyadenylation sequence. For the GALP gene, exon 1 is non-coding and 
exons 2-6 encode preproGALP. The section of homology with galanin is between residues 9 
– 21 and is the same as the first 13 residues of galanin. Exons 2 – 5 encode the GALP protein 
and post-translational splicing of GALP leads to a frame shift and the exclusion of exon 3, 
resulting in the alarin precursor. Precursors contain signalling peptides at their N-terminus that 
prompt their translocation in the cell and are cleaved into the final proteins by endopeptidases. 
Adapted from Picciotto et al., 2008 
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1.8 Galanin receptor signalling 
Galanin is widely expressed in the CNS and PNS of many species (Meister et al., 
1990; Pérez et al., 2001) and carries out its role through binding to three G protein-
coupled receptors (GalR1, GalR2, and GalR3; Branchek et al., 2000, 1998), which  
have overlapping expression patterns in the CNS and the PNS (Freimann et al., 2015). 
Binding of galanin to its receptors has the potential to trigger signalling via multiple 
pathways depending upon which G proteins are coupled to the receptors. For 
example, GalR1 and GalR3 are mostly Gi-coupled resulting in inhibition of adenylate 
cyclase and the opening of G protein-coupled inwardly rectifying K+ (GIRK) channels, 
which leads to neuronal hyperpolarization. These actions are mediated by Gi/o α-
subunits and βγ-subunit heterodimer G-proteins. By contrast, GalR2 is predominantly 
Gq-coupled leading to release of intracellular Ca2+ and the stimulation of protein kinase 
C (PKC), events associated with neuronal excitation (Freimann et al., 2015) (Figure. 
1-4).  
 
With regard to nociception, activation of GalR1/3 would be expected to produce anti-
nociceptive effects, whereas GalR2 activation would cause pro-nociceptive effects. 
Behavioural and electrophysiological studies support this theory, such that GalR1 KO 
mice showed increased hyperalgesia after hind-paw tissue injury and inflammation 
(Malkmus et al., 2005). In addition, intraplanar injection of the GalR2 agonist AR-
M1896 potentiated capsaicin-induced inflammatory pain, an effect blocked by a PKC 
inhibitor or mimicked by a PKC activator (Jimenez-Andrade et al., 2005).  
 
GalR1 is abundantly expressed in olfactory structures, amygdala, thalamus, 
hypothalamus and laminae I - III of the spinal cord and thus has the potential to 
contribute to a variety of physiological processes. The complexity of galaninergic 
signalling is further enhanced by the fact that galanin receptors can form dimers. 
GalR1, for example, can form both homodimers and heterodimers with other galanin 
receptors as well as with other GPCRs such as 5-hydroxytryptamine (5-HT) receptors, 
neuropeptide Y (NPY) receptors, and dopamine D1-like receptors (Fuxe et al., 1998; 
Lang et al., 2014; Wirz et al., 2005). These heterodimers may provide one molecular 
mechanism for galanin peptides to modulate the function of different neuronal 
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networks in the CNS. There is evidence of GalR1-5-HT1A heterodimer existence in 
the limbic system of rats, and as such it has been suggested that modulation of the 
galaninergic system could provide a new avenue to the treatment of depression 
(Borroto-Escuela et al., 2010; Fuxe et al., 1998). 
  
Unlike GalR1, the expression of GalR2 does not fluctuate during development 
(Burazin et al., 2000). However, like GalR1, GalR2 forms heterodimers with other 
galanin receptors (Fuxe et al., 2012) and non-galanin receptors, such as the NPY Y1-
receptor (NPYY1), which has been observed in the amygdala of rats and involved in 
anxiolytic behaviour (Narváez et al., 2018). GalR2 is highly expressed in the 
hippocampus, particularly in the dentate gyrus, and the mammillary nuclei of the 
hypothalamus. Of more relevance to the current study, GalR2 has also been shown 
to be expressed in small and intermediate primary sensory neurones in DRGs 
(Brumovsky et al., 2006). GalR2 signals through multiple classes of G proteins 
activating many different intracellular pathways. For example,  GalR2 largely signals 
via Gq/11-type proteins which activate phospholipase C (PLC) causing Ca2+ release 
from intracellular stores, activating PKC and opening of Ca2+ activated chloride 
channels (CaCC) (Fathi et al., 1998). GalR2 has also been shown to couple to G12/13-
type proteins causing activation of Rho A (small GTPase) (Wittau et al., 2000). In 
addition to its ability to couple to different G proteins, galanin has also been 
hypothesised to have a biphasic concentration-dependent action when acting at 
GalR2, such that GalR2 switches from Gq (low galanin concentration) to Gi (high 
galanin concentration) signalling, but this has yet to be confirmed (Hulse et al., 2012; 
Malin and Molliver, 2010). 
 
In comparison to GalR1 and GalR2, GalR3 is still poorly defined, possibly due to the 
absence of a transfected cell line expressing sufficient GalR3 protein to functionally 
characterise its signalling, even though of course such studies do not necessarily 
recapitulate what happens in vivo (Robinson et al., 2013). However, in spite of 
expression problems GalR3 has been suggested to couple to Gi/o in a similar manner 
to Gal1 (Smith et al., 1998).  
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When comparing galanin’s affinity for its different receptors, radioligand binding 
analysis using [125 I]-galanin, has shown galanin to have the highest affinity for GalR1 
(9.84 pKd), followed by GalR2 (9.53 pKd), and with the lowest affinity for GalR3 (9.01 
pKd) (Smith et al., 1998). Galanin’s affinity for GalR heterodimers and heterodimers 
with 5-HT receptors remains unknown. 
 
 
 
Figure 1-4. GalR transduction mechanisms 
Both GalR1 and GalR3 predominantly signal via Gi/o resulting in hyperpolarisation through 
activation of GIRKs and in addition inhibition of AC takes place. AC inhibition can also occur 
via GalR2, although GalR2 signals predominantly through Gq/11 causing stimulation of PLC, 
which cleaves PIP2 to form DAG and IP3, the latter causing a release of Ca2+ from intracellular 
stores. As well as causing direct depolarisation, the increase in intracellular Ca2+ concentration 
causes activation of CaCC, an efflux of Cl- and depolarisation. Lastly, it has also been shown 
that PKC activation via DAG leads to activation of MAPK. PIP2 - phosphatidylinositol 
bisphosphate, GIRKs - G protein-coupled inwardly-rectifying potassium channels, AC - 
adenylyl cyclase, PLC - phospholipase C, IP3 - inositol trisphosphate, CaCC - Ca2+ activated 
chloride channels, PKC – protein kinase C, DAG - diacylglycerol, MAPK - mitogen-activated 
protein kinase 
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1.9 Role of galanin in peripheral inflammatory pain 
There is evidence to suggest that during inflammation the expression of galanin mRNA 
is increased, mainly in the acute inflammatory phase. For example, in the 
uroepithelium of rats with cyclophosphamide-induced cystitis (Girard et al., 2008). 
However, inflammation appears to lead to lower galanin peptide levels despite 
upregulated mRNA expression in inflamed tissues, as was seen in arthritic ankle joints 
(Qinyang et al., 2004) and eczematous skin (El-Nour et al., 2004). By contrast, GalR 
expression has been more consistently reported to be upregulated in inflammatory 
conditions. For example, elevated GalR1 expression is observed in peripheral tissues 
in multiple experimental inflammatory models (Marrero et al., 2000; McDonald et al., 
2007; Saban et al., 2002). 
 
In DRG neurones, in a peripheral model of inflammatory pain (hind-paw injection of 
carrageenan), it has been shown that galanin mRNA levels decrease in the DRG 
neurones, but simultaneously increase in the dorsal horn of the spinal cord (Zhang et 
al., 1998). In the same model, like galanin, GalR1 mRNA is also downregulated in 
DRG, but GalR2 mRNA shows increased expression (Sten Shi et al., 1997; Xu et al., 
1996). However, in a model of chronic arthritis (via hind-paw adjuvant injections), 
galanin mRNA initially displays a decrease in expression, similar to the previous 
studies, but then in the later stages, e.g. after 21 days, its expression increases (Calzà 
et al., 2000, 1998), which could suggest that galanin plays a greater role in chronic 
nociception compared to acute. 
 
1.10 Role of galanin in GI tract sensory afferent neurones 
Generally, galanin is co-expressed with a variety of small molecule neurotransmitters 
including acetylcholine, GABA, serotonin, glutamate, and dopamine, as well as 
numerous other neuropeptides including calcitonin gene-related peptide (CGRP), 
vasopressin, substance P, and NPY (Freimann et al., 2015; Webling et al., 2012).  
Since its discovery, many neuronal and non-neuronal roles have been suggested for 
galanin, including roles associated with metabolic and osmotic homeostasis (Landry 
et al., 2000), immunity (Lang and Kofler, 2011), endocrine function (Sundkvist et al., 
1992), reproduction (Rossmanith et al., 1996), cognition (Kinney et al., 2002) and 
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cancer (Kwiatkowski et al., 2016). This study will focus specifically on the role of 
galanin in nociception. 
 
In a recent study using single-cell RNA-sequencing on colon-innervating DRG sensory 
neurones (identified through retrograde tracing of the distal colon), we demonstrated 
that galanin and GalR1-3 are expressed by both TL (representing LSN innervation of 
the distal colon) and LS (representing PN innervation of the distal colon) DRG 
populations (Fig. 1-5; Hockley et al., 2019). In the study, 314 colonic sensory afferent 
neurones were arranged by unbiased clustering into 7 subtypes based upon their gene 
expression. With the exception of 2 neurones, the TL population (DRG T10-L1, n = 
159) was split into 5 groups, whereas the LS population (L5-S2, n = 155) was split into 
7 groups (2 almost exclusively consisting of LS neurones, i.e. n = 121/123). The five 
subgroups consisting of neurones from both TL and LS were defined with the prefix 
“m” for mixed. The five mixed groups consisted of mNeurofilament a (mNFa) and 
mNeurofilament b (mNFb), typically associated with myelinated neurones. Then 
mNon-peptidergic (mNP) consisting of non-peptidergic, putative nociceptors. Finally, 
mPeptidergic a (mPEPa) and mPeptidergic b (mPEPb), two putative peptidergic 
nociceptor groups. The two LS exclusive groups are defined with the prefix “p” for 
pelvic nerve: pNeuroFilament (pNF, likely mechanosensory) and pPeptidergic (pPEP, 
likely nociceptive). The pNF group is similar to mNFa/mNFb and pPEP is similar to 
mPEPa/mPEPb, however each group possesses a distinct pattern of expression 
suggesting functional disparity between the classes of neurones.  When examining 
the expression of galanin in more detail, it is expressed predominantly in mPEPb and 
pPEP, both groups of peptidergic nociceptors. GalR1 is also expressed in mPEPb and 
mPEPa subgroups of peptidergic nociceptors, overlapping with galanin expression. 
GalR2 is expressed at a much lower level and almost exclusively in mPEPb, whereas 
GalR3 is also expressed at a much lower level but is present in all subgroups. 
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Figure 1-5. Galanin receptor expression in colonic DRG neurones. 
Expression profile of galanin (top left), GalR1 (top right), GalR2 (bottom left), and GalR3 
(bottom right) within 314 colonic sensory neurones grouped into 7 neuronal subtypes based 
upon clustering described by Hockley et al. (2019). Each black dot represents a single colonic 
sensory neurone isolated from TL or LS DRG. A probability density for each subtype is also 
displayed and coloured by subtype (mNP = dark blue, mNFa = brown, mNFb = purple, mPEPa 
= orange, mPEPb = red, pNF = green, and pPEP = light blue). Expression values are displayed 
in Transcript-Per-Million (Log[TPM]). Galanin is expressed predominantly in two peptidergic 
populations associated with nociception (mPEPb and pPEP), GalR1 is present in one of the 
peptidergic nociceptive groups that galanin is also present in (mPEPb), as well as two others 
(mNFb and mPEPa), GalR2 is expressed at a much lower level, but mainly in mPEPb, 
whereas GalR3 is present at low levels in all groups.  
 
Galanin is also expressed by non-neuronal cell types in the colon including 
macrophages and fibroblasts, (Koller et al., 2019; Yamamoto et al., 2014). Similar to 
galanin, GalR1 is also expressed in non-neuronal cells, including epithelial cells and 
smooth muscle cells, which demonstrates galanin’s role in GI motility (Lorimer and 
Benya, 1996). GalR1 and GalR2 have also been shown to be expressed in 
enterochromaffin-like (ECL) cells where galanin has an inhibitory effect on histamine 
release from ECL cells (Zeng et al., 1998). 
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In a study looking at the nociceptive flexor reflex model of decerebrated rats after 
intrathecal application, galanin has been shown to produce a biphasic dose-
dependent effect on nociception through activation of GalR1 and GalR2 (Xu et al., 
2000). There are also multiple studies showing under both normal conditions and in 
inflammation, that the effects of exogenous galanin are predominantly inhibitory (Hua 
et al., 2004; Xu et al., 2000). With the development of the GalR1 selective agonist, 
M617 (Lundström et al., 2005), and the GalR2 antagonist, M871 (Sollenberg et al., 
2006), it has been suggested that spinal interneurons in the dorsal horn  expressing 
GalR1 could mediate some of the inhibitory anti-nociceptive actions of galanin. Results 
gained through the use of GalR1 KO mice show that after partial sciatic nerve injury 
there is shortened latency in response to nocifensive behaviours on a hot plate 
compared to wildtype animals, i.e. greater thermal hyperalgesia (Malkmus et al., 
2005), but by contrast there was no significant change in mechanosensation 
(Blakeman et al., 2003). This suggests no difference to acute nociception, but an 
increase in hyperalgesia after tissue damage and inflammation (Blakeman et al., 2003; 
Malkmus et al., 2005). By contrast to GalR1 KO mice, GalR2 KO mice did not 
significantly differ in phenotype to wildtype mice across a range of measures including: 
behaviour, reproductive physiology, feeding and body weight regulation, and seizure 
susceptibility, i.e. GalR2 appears not to have a dominant role in nociception (Gottsch 
et al., 2005; Shi et al., 2006). It is also thought that the galaninergic system plays a 
role in regulation of the activity of muscle in the GI tract and modulation of mucosal 
secretive process, as well as regulating the sensitivity of sensory neurones (Brown et 
al., 1990). 
 
The role of galanin in GI afferent fibre excitability has been demonstrated in the upper 
GI tract where a galanin-mediated reduction in mechanosensitivity has been observed 
in gastro-oesophageal vagal afferents; however, a minority of neurones also shown 
enhanced mechanosensitivity (Page et al., 2007). In these studies GalR1 activation 
was shown to underpin the reduction of neuronal excitability observed and GalR2 
activation was demonstrated as mediating the increase neuronal excitability; 
interestingly, although galanin inhibited the function of more fibres than it enhanced, 
similar GalR1 and GalR2 expression profiles were observed when analysing mRNA 
levels in vagal sensory ganglia (Page et al., 2007). One explanation for the disparity 
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in GalR expression and the effects of galanin in gastro-oesophageal vagal afferents is 
the presence of six upstream open reading frames (uORF) in mouse GalR2 mRNA, 
which inhibit expression of the primary ORF leading to less GalR2 protein synthesis, 
i.e. the mRNA level does not necessarily correlate with the protein expression level 
(Kerr et al., 2015).  In contrast with the observed roles of GalR1 and GalR2, no 
evidence for GalR3 function in GI afferents has been produced, even though it is 
expressed in vagal sensory ganglia (Page et al., 2007). Indeed, in a previous study it 
was shown in GalR1 KO mice that GalR3 did not contribute to any effect in the upper 
GI tract (Page et al., 2007).  
 
Although the main source of pain in many chronic conditions affecting the GI tract 
originates in the colon, e.g. in IBD and IBS, to date, the role of galaninergic signalling 
in colorectum nociception is unknown. Moreover, because single-cell RNA-
sequencing data demonstrates co-expression of GalR1 with receptors for certain 
inflammatory mediators (e.g. bradykinin and 5-HT) and ion channels such as TRPV1 
that are modulated by inflammatory mediators (Hockley et al., 2019), it is possible that 
galanin could inhibit mechanical hypersensitivity induced by inflammatory mediators 
and plays a role in in vivo models of acute colitis. 
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1.11 Principle aims 
Based on the literature expression profiles (Fig. 1-5), I hypothesised that galanin would 
inhibit LSN activity predominantly through GalR1 receptor, similar to what has been 
shown in gastro-oesophageal vagal afferents (Page et al., 2005b). Therefore, the aims 
of this thesis were to: 
• Determine galanin’s role in modulation of LSN activity to mechanical stimuli 
• Determine the contribution of different GalRs to the effects produced by galanin 
• Determine the ability of galanin to modulate acute LSN mechanical 
hypersensitivity 
• Compare the role of galanin in modulating LSN activity between healthy and 
inflamed colons 
• Determine if galanin and/or GalR expression changes in colonic afferents in 
colitis. 
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Chapter 2: Materials and Methods 
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This research was conducted under the Animals (Scientific Procedures) Act 1986 
Amendment Regulations 2012 following ethical review by the University of Cambridge 
Animal Welfare and Ethical Review Body (AWERB). All experiments were carried out 
under Project Licences 70/7705 and P7EBFC1B1 by myself unless otherwise stated 
and those conducted on animals were only conducted by those holding a Home Office 
Personal Licence. 
 
2.1 Whole-nerve electrophysiological recordings from mouse LSN  
2.1.1 Ex vivo mouse LSN afferent preparations 
This preparation was conducted broadly as described previously (Brierley et al., 2004). 
In brief, adult (8-25 weeks) C57BL/6J male and female mice (Envigo) were killed by 
cervical dislocation and exsanguination, and the distal colon (from the splenic flexure 
to rectum) with associated LSN removed. To remove the LSN, the skeletal muscle and 
neurovascular bundles were cut from the spinal column while maintaining LSN 
innervation of the colon. Faecal material was gently flushed from the colon with Krebs 
buffer and the colon tied to either end of a cannula, using fine thread (polyester, 
Gutermann) and serosally superfused (7 mL min-1) with carboxygenated Krebs buffer 
(95% O2, 5% CO2). The input port was connected to a syringe pump (Harvard 
apparatus), this was used for continuous intraluminal perfusion of Krebs (200μL min-
1; Fig. 2-1A and B). The Krebs buffer (in mM: 124 NaCl, 4.8 KCl, 1.3 NaH2PO4, 2.5 
CaCl2, 1.2 MgSO4·7H2O, 11.1 glucose, and 25 NaHCO3) was supplemented with 
indomethacin (3 μM, non-selective cyclo-oxygenase inhibitor, to block prostanoid 
production), nifedipine (10 μM, voltage gated calcium channel blocker) and atropine 
(10 μM, non-selective muscarinic receptor antagonist) to block smooth muscle 
contraction. The bath was maintained at 32-34°C. The LSN inferior and superior 
mesenteric ganglia were identified at the point of the iliac bifurcation and the superior 
mesenteric ganglia was isolated from the abdominal aorta and cleaned of surrounding 
connective tissue. Suction electrode recordings of multiunit activity were made 
between the two ganglia on one of the two intermesenteric nerves.  
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Figure 2-1 – Schematic of electrophysiological recording technique  
(A) Photo of dissection pinned out in sylgard-lined chamber. In the mesentery, the LSN can 
be seen in the aortic neurovascular bundle. (B) Whole-nerve recording of LSN multiunit 
activity. The colon is cannulated and intraluminally perfused in the physiological (oral to aboral) 
direction. The LSN was cleared of surrounding connective tissue and whole-nerve suction 
electrode recordings were made (B - adapted from Brierley et al., 2018). 
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2.1.2 Electrophysiological protocols for characterization of LSN afferent properties 
Borosilicate glass suction electrodes were used to record multi-unit activity from whole 
LSN. Signals were amplified, band pass filtered (gain 5Kz; 100-1300 Hz; Neurolog, 
Digitimer Ltd, UK), and digitally filtered for 50 Hz noise (Humbug, Quest Scientific, 
Canada). Traces were digitized at 20 kHz (micro1401; Cambridge Electronic Design, 
UK), and action potential firing counts were determined using a threshold of twice the 
background noise (usually around 100 μV). All signals were displayed on a PC using 
Spike 2 software. The baseline pressure was set up at 2-3 mmHg and the preparation 
was left for approximately 30 minutes until a stable baseline was observed before 
initiating the experimental protocols. 
 
The distention protocol used to investigate mechanosensitivity consisted firstly of five 
phasic distensions to establish the baseline response to distension. Each distension 
raised the intraluminal pressure from 0 to 80 mmHg within two seconds, a pressure 
that has been shown to activate both mechanoreceptors and nociceptors in LSN 
recordings, with higher pressures evoking pain behaviour in rodents (Hughes et al., 
2009; Ness and Gebhart, 1988). Galanin (20 mL) was serosally perfused via bath 
application between distensions four and five, followed by a further eight distensions 
to allow for the maximal drug effect to be observed (Fig. 2-2A). A ramp distension 
protocol was used to investigate the activity of different neuronal populations and for 
this the luminal outflow cannula was blocked and the subsequent increase in pressure 
was observed until the desired maximum of 80 mmHg was reached (typically 3-4 
minutes), at which point the luminal outflow was re-opened. The protocol used to 
investigate the effects of an inflammatory soup on LSN activity included an initial ramp 
distension and 3 phasic distensions, followed by intraluminal perfusion of an 
inflammatory soup that has previously been shown to induce mechanical 
hypersensitivity (10 μM histamine, 10 μM prostaglandin E2, 10 μM 5HT, 1 μM 
bradykinin, and 1 mM ATP; Su and Gebhart, 1998) for 20 minutes prior to and during 
subsequent ramp and phasic distensions (Fig. 2-2B). 
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Figure 2-2 – Protocols used for LSN recordings.  
(A) The mechanosensitivity protocol consisting of 12 phasic distensions to 80 mmHg for 1 
minute at 9 minute intervals. Galanin or vehicle application (20 mL) after a baseline response 
to distension has been established, typically after the fourth distension. (B) Inflammatory soup 
protocol consisting of ramp and phasic distensions from 0 to 80 mmHg, before and during 
intraluminal perfusion of inflammatory soup (pretreated 20 mins before ramp and distensions). 
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2.1.3 Analysis of electrophysiological recordings 
To establish the most appropriate time point to measure the effect of galanin, 
recordings using a variety of galanin concentrations were analysed to determine when 
the effect of galanin was at its greatest. From this analysis, the maximal effect of 
galanin upon phasic distension was observed in response to the third distension after 
galanin application and thus this response was routinely measured and compared to 
the baseline response to phasic distension (average of second to fourth distension). 
 
A phasic distension of 80 mmHg leads to an increase in LSN activity, which peaks, 
drops by ~65% and then stays at a plateau that is maintained throughout the 
remainder of the distension. The parameters measured during each distension are 
shown in Fig. 2-3. Peak changes and time profiles of LSN activity were determined by 
subtracting baseline firing (average over 60 seconds before distention) from increases 
in LSN activity following distension. The effect of galanin at each concentration was 
measured by the change in LSN activity before and after galanin application using 
Student’s t-test. During phasic distensions, peak firing was defined as the maximal 
firing rate observed during distensions, which usually occurred within the first 15 
seconds. The response to phasic distention can also be split into two distinctive 
phases. Phase I is the initial peak in LSN activity in response to the dynamic change 
in pressure, which lasts the first 15 seconds of the distension. Phase II is the plateau 
activity seen during the subsequent 45 seconds. By contrast, ramp distention leads to 
a slow and steady increase in activity until the end of the distention. For ramp 
distension analysis, the activity was measured at every 5 mmHg and changes in LSN 
activity were compared at each interval between groups using a repeated measures 
two-way ANOVA with Sidak’s post-hoc test. 
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Figure 2-3. Parameters measured from a response to phasic distention.  
Peak firing is determined by the maximal firing frequency observed in the first 15 seconds (A). 
The response to distention was split into two phases from which the average rate is calculated, 
phase 1 (seconds 1-15 of the distention; B) which represents the spike in activity due to the 
change in pressure and phase 2 (seconds 16-60 of the distention; C) representing the stable 
plateau stage of the response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
2.2 Immunohistochemistry on retrograde labelled dorsal root ganglion 
neurones 
2.2.1 Retrograde labelling of colonic sensory neurones 
The procedure for retrograde labelling of colonic sensory neurones was conducted as 
previously described (Hockley et al., 2019). In brief, C57BL/6J mice were 
anaesthetized with isoflurane (4% induction and 1-2% maintenance) before shaving 
their abdomen and then a midline laparotomy (~1.5 cm incision) performed to reveal 
the distal colon. A piece of sterile suture thread was passed under the colon to further 
secure the injection site on the distal colon. Five injections of 0.2 μL Fast Blue (2% in 
saline, Polysciences GmbH, Germany) were made into the wall of the distal colon 
using a glass needle at a rate of 0.4 μL min-1 using a microinfusion pump (Harvard 
Apparatus). After the abdominal cavity was flushed with saline to remove any excess 
Fast Blue dye, the muscle and skin layers were sutured and secured using 4-6 Michel 
clips. Postoperative care and analgesia (buprenorphine 0.05-0.1 mg kg-1) was 
provided and a glucose enriched, soft diet provided, with regular checks of body 
weight. After a minimum of three days, animals were killed using sodium pentobarbital 
(200 mg kg-1 intraperitoneal (i.p.) injection) and transcardially perfused with phosphate 
buffered saline (PBS) followed by paraformaldehyde (4% in PBS; pH 7.4). Dorsal root 
ganglia (DRG; T13 – L1) were removed and further fixed in 4% paraformaldehyde for 
30 minutes at 4 °C before cryoprotection in 30% sucrose overnight at 4 °C. The tissue 
was then embedded in Shandon M-1 Embedding Matrix (Thermo Fisher Scientific), 
snap frozen in liquid nitrogen, and stored at -80 °C until needed. Cryostat (Leica, 
CM3000; Nussloch) sections (12 μm) were collated across 10 slides (Superfrost Plus, 
Thermo Fisher Scientific) for each DRG. Surgery was performed by Dr James Hockley 
and I acted as a surgical assistant. 
 
 
2.2.2 Immunohistochemistry 
DRG sections or wholemount preparations were washed with PBS (twice for 2 
minutes) and then blocked using antibody diluent (10% donkey serum, 5% bovine 
serum albumin (BSA) and 0.2% Triton X-100 in 0.1 M PBS) for one hour. In cases 
where a mouse primary antibody was used, an additional block for one hour at room 
temperature using mouse IgG blocking reagent (Vector Laboratories) was carried out. 
This was followed by overnight incubation at 4 °C with the appropriate primary 
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antibodies (Table 1). The sections were then washed three times for five minutes with 
PBS and then incubated for 2 hours at room temperature with the appropriate 
fluorophore conjugated secondary antibodies and/or isolectin B4 (IB4) from Griffonia 
simplicifolia-Alexafluor-488 (2.5 μg mL-1; Cat #: I21411, Invitrogen, UK), a marker for 
non-peptidergic, small diameter, C-fibre sensory neurones. No labelling was observed 
in control experiments where the primary antibody was excluded or in the presence of 
a blocking peptide (galanin, Cat #: 2696, Tocris) for the anti-galanin antibody (see 
section 7.1). 
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Primary Antibody Conc. Company Catalogue # RRID 
Rabbit anti-galanin 1:1000 Theodorsson Lab Kind gift - 
Guinea pig anti-TRPV1 1:1000 Alomone Labs AGP-118 AB_2721813 
Goat anti-Gfrα3 1:300 R&D Systems AF2645 AB_2110295 
Goat anti-CGRP 1:500 Abcam AB36001 AB_725807 
Goat anti-trkA 1:1000 R&D Systems AF1056 AB_2283049 
Goat anti-trkC 1:500 R&D Systems AF1404 AB_2155412 
Table 1 – List of primary antibodies used, RRID – Research Resource Identifiers 
 
 
Secondary Antibody Conc. Company Catalogue # RRID 
Donkey anti-rabbit 
IgG-Alexafluor-488   
1:1000 Invitrogen  A-21206  AB_2535792 
Donkey anti-rabbit 
IgG-Alexafluor-568   
1:1000 Invitrogen  A10042  AB_2534017 
Donkey anti-goat 
IgG-Alexafluor-568   
1:1000 Invitrogen  A-11057  AB_2534104 
Donkey anti-guinea 
pig IgG-Alexafluor-
488   
1:1000 Jackson Immuno 
Research 
 706-165-148  AB_2340460 
Table 2 – List of secondary antibodies used, RRID – Research Resource Identifiers 
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2.2.3 Imaging and quantification 
Sections were imaged using an Olympus microscope (BX51) with QImaging camera 
(Surrey, Canada) and the relative intensities of the DRG neurones after 
immunostaining were measured using ImageJ 1.51n (NIH, USA). The mean 
background intensity was subtracted to control for variability in illumination between 
images. Percentages of relative intensities were determined by comparison with the 
least (0%) and most (100%) intensely labelled cells for each section. Relative 
intensities were calculated as a percentage by subtracting the relative intensity of the 
darkest neuronal profile (a) from the relative intensity of the cell of interest (b) and 
comparing this to the relative intensity of the brightest neuronal profile (c) with the 
relative intensity of the darkest neuronal profile subtracted. To summarise, the relative 
intensity of a cell as a percentage = (b – a)/(c – a) (Fang et al., 2002). Cells with 
intensity values greater than the mean intensity of the darkest neuronal profiles from 
all the sections plus five times its standard deviation (SD) were considered positively 
labelled. 
 
 
2.3 Chemically induced colitis models in mice 
2.3.1 Trinitrobenzenesulfonic acid (TNBS) model of colitis 
C57BL/6J mice of either sex (8-12 weeks old) were weighed two days prior to the start 
of the procedure with their weight and stool content/consistency (see 1.3.3) being 
monitored daily throughout the experiment, which lasted 3 days. Based on a paradigm 
described previously (Wirtz et al., 2007), mice were firstly anaesthetised with ketamine 
(100 mg kg-1) and Xylazine (10 mg kg-1) and TNBS (Sigma, cat #: P2297 [0.85 mg, 
1.9 mg, and 3.8 mg]) dissolved in ethanol (concentrations used were 30%, 40%, and 
50%) was administered intracolonically to induce colitis. 100 μL of a TNBS mixture 
was instilled using a sufficiently lubricated (petroleum jelly) Luer Stubs (22 gauge; 
blue; LS22S Linton Instruments) attached to a 100 μL Hamilton syringe using 5 cm of 
PE-50 tubing (BTPE-50 Linton Instruments) and inserted approximately 4 cm internally 
from the anal verge; control mice received an ethanol-only solution at the appropriate 
concentration. The mouse was then maintained in a head down orientation for a further 
2 minutes to prevent expulsion of the fluid and promote even distribution.  
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2.3.2 Dextran sulfate sodium salts (DSS) model of colitis 
C57BL/6J mice of either sex (8-12 weeks old) were weighed two days prior to the 
procedure with their weight and stool content/consistency (see 1.3.3) being monitored 
daily throughout the treatment. Based on a paradigm described previously (Chassaing 
et al., 2014), 3% DSS supplemented drinking water was administered with control 
mice receiving the same drinking water without DSS. In the pilot studies, the mice 
received DSS treated water for 5 days after which it was replaced with normal drinking 
water for a further 3 days, but based on the severity of weight loss by day 8 the decision 
was made to reduce the period on normal drinking water post-DSS to 2 days instead 
of 3 . On day 7 the mice were killed and relevant tissue samples and measurements 
were obtained (Manicassamy and Manoharan, 2014; Wirtz et al., 2007). The 
experimenter was blinded during the experiment, drinking water being labelled A and 
B, being unblinded after results were analysed.   
 
2.3.3 Disease activity index (DAI) for assessing colitis 
Oral administration of DSS or intracolonic instillation of TNBS leads to the 
development of clinical signs of colonic inflammation including weight loss, diarrhoea, 
faecal bleeding and infiltration of granulocytes. The DAI score (Table 3) was used to 
evaluate the onset and extent of disease using a previously established scoring 
system (Manicassamy and Manorhan, 2014). 
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Score Weight 
Loss 
Stool 
Consistency 
Blood in Stool 
0 None Normal Normal 
1 1 – 5 %     
2 5 – 10 % Very Soft Slight bleeding 
3 10 – 15 %     
4 > 15 % Watery diarrhoea Gross bleeding 
Table 3 – Disease activity index (DAI) scoring system (Manicassamy and Manorhan, 2014). 
 
 
2.3.4 Histology: H&E with alcian blue staining 
An approximately 1 cm section of colon was removed ~4 cm internally from the rectum, 
fixed in 4% paraformaldehyde for 4 hours and cryoprotected in 30% sucrose overnight. 
The tissue was then embedded in O.C.T. (VWR Q-path Chemicals), snap frozen in 
liquid nitrogen, and stored at -80 °C until needed. Cryostat sections (20 μm) were 
collected and stored at -20 °C until needed. 
 
Slides were washed in tap water for 2 minutes before staining for 5 minutes with 
haematoxylin (1:2 dilution with tap water; Sigma). Slides were then washed in tap 
water for 3 minutes, followed by 0.3% HCl in ethanol for 30 seconds and then 
immediately washed in tap water for a further 2 minutes, before being incubated in tap 
water until the tissue developed a deep blue appearance. Slides were then stained 
with alcian blue (1% W/V in 3% acetic acid; Polysciences Inc) for 10 minutes and 
washed in tap water for 2 minutes before being immersed in 100% ethanol for 30 
seconds. Slides were then stained with eosin (Acros Organics) for 90 seconds, 
washed in tap water for 1 minute and then dehydrated in 100% ethanol for 30 seconds 
followed by 70% ethanol for 30 seconds. Slides were then cleared using Histoclear 
(National Diagnostics) for 30 seconds before mounting coverslips with mowiol 
mounting media. Imaging was carried out using a NanoZoomer S60 Digital slide 
scanner (Hamamatsu). Histopathological scoring was done based on inflammation, 
crypt damage and ulceration (Table 4; Ren et al., 2011). 
 
 
 
 
 
 
54 
Score Inflammation Crypt Damage Ulceration 
0 None Crypts intact None 
1 Increased number of 
granulocytes in lamina propria 
Loss of basal one third 
of crypt 
1-2 foci of ulceration 
2 Confluence of inflammatory 
cells extending to submucosa 
Loss of basal two thirds 
of crypt 
3-4 foci of ulceration 
3 Transmural extent of infiltrate Entire crypt loss Confluent or extensive 
erosion 
4 - Change in epithelial 
surface with erosion 
- 
5 - Confluent erosion - 
Table 4 – Histopathological assessment of colon sections. Scoring for all 3 criteria produces 
a maximum score of 11 (Ren et al., 2011). 
 
 
2.3.5 Myeloperoxidase assay (MPO) assay 
Colon tissue (40 mg) was extracted ~4 cm internally from the rectum and washed in 
PBS by vortexing for 30 seconds before centrifuging at 13,500 g for 5 minutes at 4 °C. 
The supernatant was discarded, and the pellet homogenized using a sonic 
dismembrator (Fisher Scientific), followed by two 10 minute freeze/thaw cycles to lyse 
cell membranes. The samples were then sonicated in 500 µL CTAB buffer (50 mM 
hexadecetyltrimethylammonium bromide, CTAB, Sigma) in 50 mM potassium 
phosphate buffer at pH  6.0) for 90 seconds followed by centrifugation at 13,500 g for 
5 minutes at 4 °C. In addition to colon samples, hind-paw tissue samples from animals 
that had been administered intra-plantar complete Freund’s adjuvant in a separate 
study in the lab conducted by Dr Gerard Callejo, were used as a positive control. 
 
MPO assays were performed in duplicates on 96 well microtiter plates. In each well, 
10 µL of sample supernatant was combined with 80 µL 0.75 mM H2O2 (Sigma) and 
110 µL TMB solution (2.9 mM 3,3′,5,5′-Tetramethylbenzidine, TMB, in 14.5% DMSO, 
Sigma) and 150 mM sodium phosphate buffer at pH 5.4). Optical density was then 
immediately read at 605 nm for 10 minutes at 30 second intervals using a CLARIOstar 
plate reader (BMG Labtech). CTAB buffer was added instead of sample for the 
negative control and the positive control used horseradish peroxidase (Vector 
Laboratories, SA-5704). 
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2.3.6 Biotinylated hyaluronan binding protein (HABP) staining 
Colon samples collected from the distal portion region of the colon (~4 cm internally 
from the rectum) were post fixed in 4% PFA for 1 hour at 4 °C and incubated overnight 
at 4 °C in 30% sucrose for cryoprotection. The colon samples were then embedded in 
Shandon M-1 Embedding Matrix (Thermo Fisher Scientific), frozen using liquid 
nitrogen, and stored at -80 °C. Embedded samples were cut using a Leica Cryostat 
(CM3000; Nussloch, Germany) into 20 μm sections and mounted on glass slides 
(Superfrost plus, Thermo Fisher Scientific). The slides were washed twice with PBS-
Tween before being blocked with an antibody diluent solution (0.2% Triton X-100 and 
5% bovine serum albumin in PBS) for one hour at room temperature. Biotinylated 
hyaluronan binding protein (amsbio, Cat #: AMS.HKD-BC41 [1:200]) was incubated 
on the slides at 4 °C overnight.  
 
On the second day, sections were washed three times in PBS-Tween and incubated 
for two hours at room temperature with Alexafluor 488 conjugated streptavidin 
(Invitrogen, Cat #: S11223 [1:1000]). Slides are then washed three more times with 
PBS-Tween before being mounted and imaged using an Olympus BX51 microscope 
(Tokyo, Japan) and QImaging camera (Surrey, Canada). All sections were imaged 
with the same exposure time (200 ms) and an excitation wavelength of 488 nm with 
the same brightness and contrast adjustments being made to all images in ImageJ. 
Negative controls (slides not incubated with the streptavidin conjugate) did not show 
any fluorescence. 
 
2.4 Quantifying levels of galanin in distal colon tissue 
2.4.1 Tissue extract sample preparation 
Dissection of tissue was carried out on ice as quickly as possible to prevent 
degradation of galanin by proteases. Colon tissue (30 mg) ~4 cm internally from the 
rectum was dissected out and placed in 1.5 mL microfuge tubes, which were then 
immersed in liquid nitrogen for quick freezing. The tissue samples were then stored at 
-80 °C until needed.  
 
For 30 mg of tissue, 1.8 mL of complete extraction buffer (100 mM Tris, 150 mM NaCl, 
1 mM triethylene glycol diamine tetra-acetic acid (EGTA), 1 mM ethylene diamine 
tetraacetic acid (EDTA), 1% Trition X-100, 0.5% sodium deoxycholate and 1 mM 
 
 
56 
phenylmethane sulfonyl fluoride (PMSF)) was added and the sample was 
homogenized using a sonic dismembrator (Fisher Scientific). Samples were then 
placed on a shaker for constant agitation for 2 hours at 4 °C, before being centrifuged 
for 20 minutes at 13,500 g at 4 °C. The supernatants were then aliquoted and stored 
at -80 °C until needed. 
 
2.4.2 Galanin ELISA 
An ELISA was used (Peninsula Laboratories International, Cat #: S-1208; detection 
range 0.01 – 10 ng/ml−1) to establish the galanin concentration in samples of colon 
tissue. In brief, 50 μL of sample or standard (provided with the kit) and 25 μL of 
antiserum was added to each well and incubated at room temperature for 1 hour. 25 
μL of the biotinylated tracer was added to each well and incubated at room 
temperature for 2 hours. The plate was then washed 5 times with enzyme 
immunoassay (EIA) buffer before adding 100 μL of streptavidin horseradish 
peroxidase (HRP) to each well and further incubating for 1 hour at room temperature. 
The plate was then washed another 5 times with EIA buffer, then 100 μL of TMB 
solution was added to each well and incubated at room temperature for a further 1 
hour. The reaction was terminated by adding 100 μL of 2 N HCl to each well and the 
optical density was read (using CLARIOstar Monochromator Multimode Microplate 
Reader, BMG Labtech) at an absorbance of 450 nm within 10 minutes of stopping the 
reaction. The concentration of galanin was determined according to the 
manufacturer’s instructions relative to the standard curve provided. 
 
2.5 Single Cell qPCR of colon-innervating DRG neurones 
2.5.1 Primary culture and cell picking 
After retrograde labelling of afferents innervating the distal colon (as described in 
2.2.1), colon-innervating TL (T13-L1) and LS (L6-S1) DRG were dissected and 
dissociated as two separate cultures using previously published protocols (Hockley et 
al., 2016). Dissected DRG were trimmed of axons and connective tissue before being 
incubated in Lebovitz L-15 Glutamax (Thermo Fisher Scientific, UK) medium 
containing 1 mg mL-1 collagenase (Sigma-Aldrich, UK) and 6 mg mL-1 BSA at 37 °C 
for 15 minutes. This was followed by a 30 minute incubation at 37 °C with L-15 media 
containing 1 mg mL-1 trypsin (Sigma-Aldrich) and 6 mg mL-1 BSA. The DRG were then 
gently triturated with a 1 mL Gilson pipette before collecting, after brief centrifugation 
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at 1000 rpm, of dissociated cell-containing supernatant. Trituration and centrifugation 
cycles were then repeated five times. Collected neurones were then plated onto poly-
D-lysine-coated coverslips (BD Biosciences, UK) and incubated at 37 °C in L-15 media 
containing 2 % penicillin/streptomycin, 24 mM NaHCO3, 38 mM glucose and 10 % 
foetal bovine serum. 
 
Fast Blue positive colonic sensory neurones were detected by 365 nm fluorescence 
illumination (Cairn Research, UK) and individual neurones were manually collected 
using a micromanipulator controlled (PatchStar, Scientifica, UK) pulled glass pipette 
on an adapted inverted Olympus microscope. Neurones were visually assessed prior 
to collecting and only those not associated with satellite glia cells and free from debris 
were captured and photographed (DCC1545M, ThorLabs Inc) for cell size analysis. A 
maximum of 20 neurones per culture, per mouse was collected within 8 hours of 
plating to minimise the potential for changes in gene expression. A small volume of 
bath solution was also collected at the end of collecting samples for each culture to 
provide negative controls as these were subjected to exactly the same protocols as 
samples containing isolated individual neurones. Labelled neurones were selected 
randomly. 
 
2.5.2 Single-cell qPCR 
Primary cultures of colon-innervating TL and LS neurones were collected as described 
above. Each cell was collected into a tube containing 5 μL CellDirect 2x reaction buffer 
(Invitrogen, UK), 2.5 μL 0.2x primer-probe mix, 0.1 μL SUPERase-in (Ambion, TX, 
USA), 1.2 μL TE buffer (Applichem, Germany) and 0.2 μL Superscript III Reverse 
Transcriptase-Platinum Taq mix (Invitrogen, UK) and immediately frozen on dry ice. 
Reverse transcription and preamplification of cDNA was done by thermal cycling (50 
°C for 30 minutes, 95 °C for 2 minutes, then 24 cycles of 95 °C for 15 seconds, 60 °C 
for 4 minutes). Samples were diluted 1:5 in TE buffer and TaqMan qPCR assays were 
run for each gene of interest (TaqMan assay ID: Galanin-00439056, GalR1-00433515, 
GalR2-00726392, GAPDH-99999915, TRPV1-01246302 and Gfra3-00494589; 
Applied Biosystems) using the following cycling protocol of 50 °C for 2 minutes, 95 °C  
for 10 minutes then 40 cycles of 95 °C for 15 seconds, 60 °C for 1 minute. All single-
cell RT-PCR products should express glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), which was used as a reference gene and bath control samples were 
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negative controls. As described above, an image of each cell was taken for post-hoc 
cell size analysis. Relative expression of marker genes were normalised to GAPDH 
quantification cycles (CT) using ΔΔCT. In total, 240 colonic sensory neurones were 
collected (60 from healthy TL, 60 from healthy LS, 60 from DSS-treated TL and 60 
from DSS-treated LS) from 6 mice (male, 8-12 weeks, 3 healthy and 3 treated with 
DSS).  
 
2.6 Statistics 
All statistical analyses were performed using GraphPad Prism 6. Half-maximal 
inhibitory concentration (IC50) values were derived by a sigmoidal dose-response 
(variable slope) curve using GraphPad Prism software. For ramp distensions, a 
repeated measures two-way ANOVA with Sidak’s post-hoc test was used. Both basal 
firing and phasic distension data were analysed using a repeated measures one-way 
ANOVA with Tukey’s post-hoc test. For the validation of the DSS model, DSS data 
were compared to control data using Student's t-test. Statistical significance was set 
at P < 0.05. Data are presented as mean ± SEM, N = number of animals, and n = 
number of cells. 
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Chapter 3 – Galanin inhibits the lumbar 
splanchnic nerve afferent response to 
mechanical stimuli and inflammatory mediators 
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3.1 Introduction 
3.1.1 Sensation evoked by mechanical activation of colonic afferents 
Mechanosensitivity of visceral afferents is central to the relay of conscious 
sensation in response to bowel distension. One example would be the pain arising 
following distention around a faecal bolus in a fully or partially occluded bowel 
(Brookes et al., 2013). The sensitivity of visceral afferents to mechanical stimuli can 
be modulated by inflammatory mediators, as demonstrated by the visceral 
hypersensitivity to barostat balloon distension observed in irritable bowel 
syndrome (IBS) patients (Mertz et al., 1995).  
 
Pain signalling from the GI tract is relayed by primary afferent neurones to the 
brain via multiple pathways, including the spinomesencephalic, 
spinohypothalamic, spinoreticular, and spinothalamic tracts (Almeida et al., 2004). 
The spinothalamic tract, with thalamic projections to the insula, anterior cingulate 
cortex and somatosensory cortex mediates conscious sensation (Almeida et al., 
2004). The spinomesencephalic pathways provide intensity and localisation of 
stimulus, as well as motivational-affective pain behaviours and integration into 
higher motor responses. The other pathways activate autonomic responses to 
visceral sensory input (Almeida et al., 2004; Palecek and Willis, 2003).  
 
In humans, 15 – 40 mmHg pressure in the upper colon (>16 cm internally of the 
external anal sphincter) induces pain (Ray and Neill, 1947). This pain is abolished 
following a procedure in which part of the sympathetic nerve trunk in the 
thoracolumbar region is destroyed and can provide pain relief by blocking 
signalling of sympathetic nociceptors in the lumbar region (Bentley and Smithwick, 
1940; Ray and Neill, 1947). Pain induced by distention of the distal colon (≤16 cm 
internal from the external anal sphincter) is however unaffected by 
sympathectomy, further demonstrating dual innervation of the GI tract by the LSN 
and PN (Ray and Neill, 1947). 
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Various stimuli can be used to activate visceral pain pathways. These include in 
vivo slow ramp distensions, rapid phasic distensions by balloon or fluid filling the 
bowel, chemically induced contractions, and ex vivo blunt probe, or circumferential 
stretch and stroke around distinct receptive fields of afferent fibres (Ray and Neill , 
1947; Brierley et al., 2004). These methodologies have enabled the successful 
identification of various mechanistic and biochemical pathways relevant to visceral 
pain. It is also important to understand the rationale and limitations behind their 
uses when interrogating visceral afferent function.   
 
3.1.2 Experimental stimulation 
In rodents, in vivo activation of the pelvic pain pathway using colorectal distension 
(CRD) can be monitored using pseudoaffective reflexes and the visceromotor 
response (VMR) (Ness et al., 1990). A typical protocol would consist of a series of 
balloon inflations within the colon to a set intracolonic pressure distensions (15, 
30, 45, and 75 mmHg) at 5-10 minute intervals (Shinoda et al., 2009). Responses 
to CRD initially decrease, due to tachyphylaxis, but then stabil ise after 4-6 
distensions, enabling the effects of intervention (e.g. pharmacological compound 
administration) to be investigated (Kamp et al., 2003; Sivarao et al., 2007).  
 
VMR involves both ascending and descending pathways of the brainstem, 
although it does not require higher order processing (Ness and Gebhart, 1988). In 
mice, the response itself is initiated by the LS sensory pathway innervating the 
colon (i.e. pelvic nerve), as demonstrated by severing of the LSN (TL sensory 
pathway) having little effect on VMR following CRD (Kyloh et al., 2011). However, 
following inflammation, the TL pathway has also been shown to contribute to the 
VMR (Traub, 2000). These findings are consistent with observations seen in 
humans where bilateral sympathectomy (T7 – L3) does not affect the VMR to CRD 
within 16 cm of sphincter, showing that the response is mediated by pelvic pathway 
(Ray and Neill, 1947). By contrast, CRD in the colon above 16 cm from the 
sphincter is mediated by the TL pathway (Ray and Neill, 1947). In summary, VMR 
during CRD poorly models TL activation and associated behaviours. 
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Different pressures used for CRD can elicit different sensations in humans, low 
pressures evoking urge (8 mmHg) and high pressures evoking pain (16 mmHg) 
(Kwan et al., 2002). Comparably, relaxation of the anal sphincter occurs at 13 
mmHg in rats and VMR at 22 mmHg (Ness and Gebhart 1988). From  in vivo S1 
afferent fibre (PN) recordings and jejunal afferents, rapid phasic distensions evoke 
a greater nerve discharge than slow ramp distension to the same pressure (Booth 
et al., 2007; Sengupta and Gebhart, 1994). This demonstrates that the experience 
of pain is dependent on temporal properties of the stimulus and not just the 
magnitude of stimulation.  
 
A different approach to studying pain is measuring afferent firing to noxious stimuli 
in ex vivo preparations, which can be conducted in both rodent and human tissue 
(Hockley et al., 2018). These include recordings from the PN and LSN innervating 
the distal colon as either a tubular or flat sheet (opened along the mesenteric 
border) preparation. Examples of these preparations include: intracellular 
recordings from L6 DRG neurones combining the characterisation of high and low 
threshold mechanosensors with subsequent immunohistochemistry (Malin et al., 
2009), extracellular recordings from LSN and pelvic afferent fibres characterising 
the role of NaV1.9 in visceral pain (Hockley et al., 2014), and chemically-induced 
contractions of a mouse colon to model the occlusion observed in human bowel 
diseases (Zagorodnyuk et al., 2012).  
 
3.1.3 Colonic mechanosensitivity and mechanotransduction 
Several experimental models have been used to further our understanding of the 
molecular mechanisms responsible for mechanotransduction at afferent terminals 
of colonic sensory neurones. A number of ion channels have been implicated in 
visceral mechanosensation, including TRPV4, Piezo2, TRPA1 and ASICs (Coste 
et al., 2010; Harrington et al., 2018). Moreover, numerous receptors and ion 
channels that are not themselves mechanosensitive can modulate afferent 
mechanosensitivity, either through intracellular signalling pathways (e.g. GPCRs 
like angiotensin II type I, bradykinin receptor B2 receptors, or protease-activated 
receptor 2 (PAR2)) (Coelho et al., 2002), or through modulating electrical excitability 
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(Hockley et al., 2014; Peiris et al., 2017). Voltage-gated K+ ion channels also 
contribute to membrane excitability and play a key role in action potential 
repolarisation meaning that they strongly regulate neuronal firing rate. Two 
currents in particular play an important role, the transient IA current and the 
sustained rectifying IK current (Cobbett et al., 1989).   
 
Many of the receptors and ion channels mentioned are brought into play during 
inflammation, such that inflammatory mediators bind to receptors and activate 
secondary messenger pathways that act to both regulate baseline activity and the 
response to mechanical stimuli due to the sensitising effects that they have on 
mechanically sensitive ion channels and/or those ion channels regulating 
membrane excitability. An example of this would be the release of ATP as a 
consequence of tissue damage leading to the activation of P2X receptors and 
other purinoceptors causing an increase in intestinal afferent mechanosensation 
(Kirkup et al., 1999; Wynn et al., 2003). During inflammation afferent hypersensitivity 
is also affected by coordinated reduction in IA and IK currents and an increase in 
tetrodotoxin-resistant (TTX-R) Na+ currents leading to increased neuronal 
excitability (Beyak et al., 2004; Dang et al., 2004; Stewart et al., 2003).  
 
Multiple inflammatory mediators are released in inflamed tissues and act 
synergistically to sensitise afferent endings. Whilst one mediator (for example 
bradykinin) could cause sensitisation, an inflammatory soup (IS) is used to better 
mimic the mix of mediators present in inflammatory conditions (Shinoda et al., 
2009). For this reason, an IS consisting of bradykinin, ATP, PGE2, 5-HT, and 
histamine is often used to induce a robust afferent hypersensitivity to mechanical 
stimulus and direct stimulation of afferents (Su and Gebhart, 1998). The IS is used 
to investigate how afferent function is influenced by inflammation and also 
characterise ‘silent’ afferents, those afferents that are mechanically insensitive, 
but become responsive to mechanical stimuli following exposure to chemical and 
inflammatory mediators (Brierley et al 2005a, Brierley et al 2005b). Intracolonic 
application of IS increases resting activity in approximately 60% of fibres and also 
reduces the activation thresholds for a subset of high-threshold fibres and 
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sensitises silent afferents (Feng and Gebhart 2011), thus correlating with the 
hyperalgesia and allodynia experienced by those individuals with inflammatory 
pain. The use of an IS also produces in vivo hypersensitivity to CRD following 
TNBS treatment (a model of colitis), which correlates with afferent hypersensitivity 
in subsequent ex vivo afferent analysis (Kiyatkin et al., 2013).  
 
3.1.4 Galanin and inflammatory mediators 
The expression of galanin and its receptors is altered throughout pain pathways in 
experimental inflammatory conditions and therefore it is likely to have functional 
implications for modulating inflammatory pain. For example, in DRG sensory 
neurones galanin levels are reduced following hind-paw injection of carrageenan, 
but at the same time galanin expression is increased in the dorsal horn (Ji et al., 
1995; Zhang et al., 1998). In the same model, GalR1 is transiently downregulated 
and GalR2 is upregulated in DRG neurones (Sten Shi et al., 1997; Xu et al., 1996). 
To date, the expression of galanin and its receptors in colonic afferent terminals, 
and how these change under inflammatory conditions, remains unclear.  
 
Functionally, galanin modulates mechanosensitivity in gastro-oesophageal vagal 
afferents in a predominantly inhibitory manner in healthy mice most likely through 
GalR1 activation with GalR2 playing a minor role in potentiation (Page et al., 2007, 
2005b). However, the role of galanin in peripheral pain signalling remains unclear. 
Galanin has been reported to have pro-nociceptive effects via GalR2 and anti-
nociceptive effects through GalR1 when capsaicin is injected into the hind-paw of 
mice (Jimenez-Andrade et al., 2006, 2004). Based on previous studies (Page et al., 
2007, 2005b) and the comparative expression profiles of GalRs in colonic sensory 
neurones (Hockley et al., 2019), I hypothesized that galanin would inhibit LSN 
mechanosensitivity and, furthermore, that galanin would show antinociceptive 
effects in the presence of inflammatory mediators. 
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3.2 Aims 
1. To investigate the effects of galanin on the response of LSN afferents to 
mechanical distension in an ex vivo, intact distal colon preparation. 
 
2. To determine the contribution of GalR1 and GalR2 to the any effect mediated 
by galanin on LSN function. 
 
 
3. To investigate the effect of an IS on LSN activity and how this is modulated by 
galanin.  
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3.3 Results 
3.3.1 Galanin is present in the distal colon and likely involved in nociceptive 
signalling 
TRPV1 and IB4 are markers of two major classes of nociceptors, peptidergic 
(TRPV1) and non-peptidergic (IB4). TRPV1 expressing nociceptors project 
predominantly to laminae I and IB4-stained nociceptors project to laminae II 
(Snider and McMahon, 1998). When examining sections of mouse lumber spinal 
cord it was observed that galanin immunofluorescence was present in neurones in 
the dorsal horn of the spinal cord and shows signs of co-localisation mainly with 
TRPV1 and, to a lesser extent, IB4, suggesting that galanin is expressed at nerve 
terminals in neurones involved in nociception (Fig 3-1B and C). 
 
In transverse sections of the distal colon, galanin immunofluorescence was seen 
in multiple layers throughout the colon, but particularly in the circular muscle layer 
(Fig. 3-1E). Previous work has demonstrated that galanin is expressed in multiple 
cell types of the colon including macrophages and epithelial cells (Koller et al., 
2019). The high level of galanin expression between the muscle layers suggests 
that galanin is expressed by fibres of the myenteric plexus. A detailed analysis of 
galanin expression in colonic sensory DRG neurones was also conducted (see 
Section 5.3.2). 
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Figure 3-1. Expression of galanin in the spinal cord and distal colon. 
(A) Diagram of transverse lumbar spinal cord sections with enlargement and detail of the 
dorsal horn (black box), outlining the Rexed laminae. In the spinal cord dorsal horn, galanin 
shows high coexpression with TRPV1 (marker of laminae I; B) and low colocalisation with IB4 
(marker of laminae II; C) using IHC. (D) Diagram of a transverse section of colon showing 
location of myenteric plexus. Galanin is particularly localised between the muscle layers of the 
colon (indicated with white arrowhead) suggesting localisation in the myenteric plexus (E). 
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3.3.2 Galanin inhibits mechanically evoked neuronal excitation in LSN sensory afferent 
neurones 
To determine the effects of galanin on peripheral terminals of colonic sensory 
neurones, I used whole-nerve, ex vivo electrophysiological recordings of the LSN with 
intact tubular colonic preparations that enable control over intraluminal pressure. The 
LSN is particularly relevant in the transduction of conscious sensation from the colon, 
including pain signalling, as it has been shown to be predominantly composed of 
nociceptors (Brierley et al., 2004; Hughes et al., 2009). Using this ex vivo preparation, 
phasic distension of the colon to a noxious pressure (80 mmHg; Ness and Gebhart, 
1991) led to a robust peak phase of increased afferent firing, followed by a slight 
decrease and a sustained phase of firing for the rest of the 1 minute distension (Fig. 
3-2 and see Fig. 2-3 for details of analysis). Responses to repeated distensions, 
following 9 minute intervals, decreased for the first 3-4 distensions until stabilising for 
subsequent distensions (Fig. 3-2B). This response remained stable for the remainder 
of the protocol (Fig. 3-2A). 
 
Once a stable response had been established (e.g. after 3 distensions), galanin was 
applied by 20 mL bath application and the effects of the application on subsequent 
responses to mechanical distention were observed. In initial experiments, the peak 
effect of galanin application was observed to occur approximately 20-30 minutes after 
bath superfusion during the third post-galanin distension before washing off (Fig. 3-
2C). Therefore, the third post-galanin distention timepoint was used to measure the 
maximum effect of galanin application in subsequent experiments.  
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Figure 3-2. Repeated phasic distensions produce a robust LSN response that is 
inhibited by galanin  
(A) Example raw trace and rate histogram of the colonic LSN response to repeated rapid 
phasic intraluminal distension (0 to 80 mmHg), showing a robust LSN response to a repeated 
noxious mechanical stimulus. Below, expanded sections of basal activity (left) and a single 
action potential has been expanded further (black box, right). (B) Percentage activity from the 
first distension of peak firing frequency over the first 12 distensions showing the initial 
decrease in response that eventually stabilises around distension 3-4. (C) Percentage peak 
firing frequency of the first 6 post-galanin (20 mL, 500 nM) distensions compared to the control 
response established pre-galanin. N = 5  
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Using a range of galanin concentrations (1 nM, 10 nM, 100 nM, 500 nM, and 1 μM), it 
was observed that galanin inhibited LSN activity in a dose-dependent manner, with 
the peak effect of galanin occurring at 500 nM (Fig. 3-3A). For example, peak firing 
frequency (53.3 ± 6.4 spikes/s vs 25.2 ± 2.6 spikes/s, N = 5, P = 0.0008, unpaired t-
test), phase I average firing frequency (average of initial 15 seconds of 1 minute phasic 
distension: 30.3 ± 2.8 spikes/s vs 12.8 ± 1.1 spikes/s, N = 5, P = 0.0005, unpaired t-
test)  and phase II average firing frequency (average of last 45 seconds of 1 minute 
phasic distention: 18.6 ± 3.1 spikes/s vs 9.3 ± 2.1 spikes/s, N = 5, P = 0.013, unpaired 
t-test) were all significantly decreased by 500 nM galanin. Additionally, galanin also 
significantly inhibited spontaneous firing, with 500 nM galanin reducing basal 
spontaneous activity by a ~70% (1 minute average preceding phasic distension: 3.9 ± 
0.7 spikes/s vs 1.2 ± 0.5 spikes/s, N = 5, P = 0.0276, unpaired t-test). All inhibitory 
effects were dose-dependent having an IC50 of 153.7 nM for basal nerve activity (Fig. 
3-3Bi), an IC50 65.7 nM for peak firing in response to phasic distension (Fig. 3-3Bii), 
an IC50 84.8 nM for phase I average firing in response to phasic distension (Fig. 3-
3Biii) and an IC50 of 112.7 nM for phase II average firing in response to phasic 
distension (Fig. 3-3Biv). 
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Figure 3-3. Dose-dependent effect of galanin on LSN mechanosensitivity 
(A) Example raw trace and rate histogram of the colonic LSN response to repeated rapid 
phasic intraluminal distension (0 to 80 mmHg), showing reversible inhibition of the response 
by galanin. Below, expanded sections of basal activity before (left) and after (right) galanin 
application and a single action potential has been expanded further (black box). Galanin (500 
nM, 20 mL) bath application indicated by the black bar above the rate histogram. (Bi) Basal 
nerve activity is dose-dependently inhibited by galanin (white circle indicating vehicle) as are 
the peak (ii), phase I average (iii) and phase II average (iv) firing frequencies; N = 5 for 1 nM, 
10 nM, 500 nM and 1000 μM concentration, and N = 6 for 100 nM. 
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3.3.3 Galanin inhibits mechanically evoked neuronal excitation via GalR1 
Next, I investigated the effect of GalR agonists on LSN activity to determine the 
involvement of different GalRs in the effects produced by galanin, using the same 
protocol as conducted with galanin (Fig. 3-4A). As discussed in Section 1.6, GalR1 
signalling is predominantly Gi mediated leading to hyperpolarisation and therefore 
reduced neuronal excitability (Fuxe et al., 1998; Smith et al., 1998). 
 
The synthetic peptide M617 (galanin(1-13)-Gln(14)-bradykinin(2-9)-amide) is a 
selective agonist of GalR1 (Lundstrom et al., 2005; Sollenberg et al., 2010) and it 
significantly inhibited the LSN response to phasic distention for peak (Fig. 3-4Bi; P = 
0.0015, N = 4, paired t-test), phase I average (Fig. 3-4Bii; P = 0.0002 , N = 4, paired 
t-test) and phase II average (Fig. 3-4Biii; P = 0.0382, N = 4, paired t-test) firing 
frequency. The inhibitory effects of M671 were of a similar magnitude to those induced 
by galanin, e.g. M671 attenuated peak firing frequency by 41.4 ± 4.3%, phase I 
average firing frequency by 44.5 ± 5.9% and phase II average firing frequency  by 39.8 
± 6.8%, similar to 500 nM galanin which attenuated peak firing frequency by 49.4 ± 
8.5%, phase I average firing frequency by 51.2 ± 9.6% and phase II average firing 
frequency by 48.8 ± 10.6% (galanin N = 5, M617 N = 4).  
 
Spexin is an endogenous neuropeptide expressed in various nervous and endocrine 
tissues with relatively little known about its function, but it has been proposed to 
modulate cardiac (increased arterial pressure and decreased heart rate) and renal 
function (decreased urine flow rate), as well as having anti-nociceptive activity in mice 
(Toll et al., 2012). Unlike galanin, which has very similar affinity for all 3 GalRs, spexin 
has been reported to act as an agonist of GalR2/3 (Spexin EC50 for GalR2 = 161 nM, 
EC50 for GalR3 = 626 nM), but not GalR1 (Kim et al., 2014; Lv et al., 2019). Following 
application of spexin, no significant change in peak (Fig. 3-4Ci; P = 0.245, N = 4, paired 
t-test), phase I average (Fig. 3-4Cii; P = 0.741, N = 4, paired t-test) or phase II average 
(Fig. 3-4Ciii; P = 0.218, N = 4, paired t-test) firing frequency was observed.  
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Figure 3-4. Effects of GalR agonists on LSN mechanosensitivity in multi-unit recordings 
(A) Schematic of pressure protocol used for LSN electrophysiological recordings. Distensions 
used for analysis indicated with blue box, drug application indicated by black bar. M671 (GalR1 
agonist) significantly attenuates firing frequency in both peak (Bi; P = 0.0015, N = 4, paired t-
test), phase I average (Bii; P = 0.0002, N = 4, paired t-test) and phase II average (Biii; P = 
0.0382, N = 4, paired t-test) firing frequency. Spexin (GalR2/3 agonist) does not significantly 
modulate the peak (Ci), phase I average (Cii), or phase II average (Ciii) firing frequency in 
response to a distension pressure of 80 mmHg.  
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Next, the effects of a GalR2 antagonist on LSN activity was investigated to further 
determine the potential role of GalR2 in the overall inhibitory effect of galanin. The 
peptide M871 (galanin(2-13)–Glu–His–(Pro)3–(Ala–Leu)2–Ala amide) is a selective 
antagonist of GalR2/3 (with lower affinity for GalR3; GalR2 Ki = 13 nM, GalR3 Ki = >10 
μM) (Sollenberg et al., 2010, 2006) and thus it is possible that if galanin usually 
modulates all 3 GalRs that blockade of GalR2/3 might reveal a greater inhibition of 
LSN activity to suggest a tonic role for GalR2. An initial application of a low 
concentration of galanin (10 nM) superfused into the bath gave us a control response. 
After a washout period, another application of galanin (10 nM), this time mixed with 
M871 (1 μM) was given. By comparing the response to the first galanin application to 
the response from the second application, the effects M871 could be determined (Fig. 
3-5A).  
 
The initial application of galanin did not significantly reduce peak firing (Fig. 3-5Bi), 
phase I average firing (Fig. 3-5Bii), or phase II average firing (Fig. 3-5Biii) as expected 
from previous experiments (Fig. 3-3B). If GalR2 is significantly contributing to the 
whole-nerve response, adding M871 with a low dose of galanin might counteract the 
excitatory effect of any GalR2 activation and thus potentially reveal a significant 
inhibition of the LSN response to phasic distension at only 10 nM galanin. However, 
application of galanin + M871 did not  significantly change the LSN response to phasic 
distention in peak (Fig. 3-5Bi; P = 0.92, N = 3, repeated measures one-way ANOVA 
with Tukey’s test), phase I average (Fig. 3-5Bii; P = 0.93 , N = 3, repeated measures 
one-way ANOVA with Tukey’s test) or phase II average (Fig. 3-5Biii; P = 0.86, N = 3, 
repeated measures one-way ANOVA with Tukey’s test) firing frequency. These results 
support the lack of response from spexin and suggest that GalR2 does not significantly 
contribute to galanin’s inhibitory effect on LSN mechanosensitivity in the healthy intact 
colon.  
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Figure 3-5. Effects of the GalR2 antagonist M871 on mechanosensitivity in multi-unit 
LSN recording 
(A) Schematic of pressure protocol used for the electrophysiological recordings. Distensions 
used for analysis indicated with blue box, drug applications indicated by black bar. M871 (1 
μM) did not significantly change firing frequency in peak (Bi), phase I average (Bii) and phase 
II average (Biii) firing frequency, N = 3.  
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3.3.4 Galanin Inhibits chemically evoked neuronal excitation in LSN afferent neurones 
I next investigated the role of galanin in the afferent response to inflammatory 
mediators. To do this, whole-nerve recordings were made as before. A mixture of 
inflammatory mediators, an inflammatory soup (IS), as used previously (Hockley et al., 
2014; Su and Gebhart, 1998), was perfused intraluminally (Fig. 3-6A). Application of 
the IS (consisting of 1 mM ATP, 10 μM histamine, 10 μM PGE2, 1 μM bradykinin, and 
10 μM serotonin) was initiated after the third phasic distention and continued for the 
duration of the experiment (Fig. 3-6B). In another group, 500 nM of galanin was 
intraluminally perfused (Fig. 3-6C) and in a final group a mixture of both IS and 500 
nM of galanin was intraluminally perfused (Fig. 3-6D). These three groups along with 
a control group were compared to determine the effects of galanin on IS-mediated 
excitation and sensitisation of LSN activity.  
 
The basal LSN activity significantly increased by 77.9 ± 13.4% (P < 0.001, N = 6, one-
way ANOVA with Tukey’s test) following application of IS. As expected from previous 
experiments, galanin significantly reduced the basal activity of LSN by 64.5 ± 7.5 % 
(P < 0.001, N = 6, one-way ANOVA with Tukey’s test). A combination of IS and galanin 
did not significantly change the basal firing from the control group (Fig. 3-6Fi) 
suggesting that they cancel each other out. 
 
To further investigate colonic hypersensitivity caused by IS application and the effects 
of galanin upon this hypersensitivity, a slow ramp distention up to a noxious pressure 
of 80 mmHg was used, pressure up to 20 mmHg is considered innocuous (Ness and 
Gebhart 1988; Fig 3-6A). As others have reported, there was a linear correlation 
between whole-nerve activity and pressure, reaching a maximum firing rate of 23.99 
± 4.69 spikes s-1 (N = 6) in the control group. As expected, IS produced an increased 
maximum firing rate to 31.45 ± 4.48 spikes s-1 (Fig. 3-6B; N = 6), whereas galanin 
inhibited the maximum rate to 14 ± 5.69 spikes s-1 (Fig. 3-6C; N = 6). The combination 
of IS and galanin lead to a maximum firing rate of 27.43 ± 7.33 spikes s-1 that was not 
significantly different to control (Fig. 3-6D; N = 6). 
 
 
77 
 
Figure 3-6. Effects of galanin and IS on LSN response to ramp distension 
(A) Schematic of pressure protocol used in the multi-unit recordings. Ramp distensions 
demonstrated below indicated with blue box, intraluminal application of drug indicated by black 
bar above the protocol. (B) Example raw trace of ramp distension before and after the 
intraluminal application of IS, (C) galanin (500 nM), (D) and a combination of IS and galanin 
(500 nM) with (E) sample pressure histograms below. (F) Response profiles to ramp distension 
before and during intraluminal application of IS (Fi), 500 nM galanin (Fii) or a combination (Fiii) 
(two-way repeated-measures ANOVA with Sidak’s post-hoc test, N = 6). Significance indicated 
by # = P < 0.05, * = P < 0.01, ~ = P< 0.001 
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When examining responses to phasic distention, IS significantly increased the peak 
firing frequency (37.6 ± 13.7 %, P < 0.05, N = 6, one-way ANOVA with Tukey’s test) 
whereas galanin produced a significant decrease in peak firing in response to 
distension (41.4 ± 2.9 %, P < 0.01, N = 6, one-way ANOVA with Tukey’s post-hoc test). 
Intraluminal co-application of IS and galanin did not produce a significant change in 
peak afferent firing in response to phasic distension compared to control preparations 
(Fig. 3-7Fii). A similar pattern was observed for phase I average firing frequency (IS 
increased by 33 ± 13.1 %, P < 0.05, N = 6, one-way ANOVA with Tukey’s post-hoc test 
and galanin decreased by 36.3 ± 2.6 %, P < 0.01, N = 6, one-way ANOVA with Tukey’s 
post-hoc test) with intraluminal co-application of IS and galanin not producing a 
significant change in phase I average firing in response to phasic distension (Fig. 3-
7Fiii). IS application also significantly increased phase II average firing (48.8 ± 14.7 
%, P < 0.05, N = 6, one-way ANOVA with Tukey’s post-hoc test), however galanin did 
not produce a significant inhibition of sustained firing frequency. IS-induced 
mechanical hypersensitivity was lost when IS was combined with 500 nM galanin (Fig. 
3-7Fiv), indicating that galanin may directly prevent the development of mechanical 
hypersensitivity of LSN afferents induced by IS. 
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Figure 3-7. Effects of galanin and IS on LSN response to phasic distension 
(A) Schematic of pressure protocol used in the multi-unit recordings. Phasic distensions 
demonstrated below indicated with blue box, intraluminal application of drug indicated by black 
bar above the protocol. (B) example raw trace of phasic distension before and after the 
intraluminal application of IS (C) galanin (500 nM), (D) and a combination of IS and galanin 
(500 nM) with (E) sample pressure histograms below. (Fi) Changes in the basal nerve activity 
after intraluminal application of either IS, galanin, or a combination. Changes in peak (Fii), 
phase I average (Fiii), and phase II average (Fiv) firing frequency in response to phasic 
distension. Significant differences between groups tested by one-way ANOVA with Tukey's 
post-hoc test, * = P < 0.05, ** = P < 0.01, *** = P < 0.001 (N = 6).  
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3.4 Discussion 
Galanin is a neuropeptide with antinociceptive effects in both the central and 
peripheral nervous systems (Jimenez-Andrade et al., 2005; Liu and Hökfelt, 2002; 
Wiesenfeld-Hallin et al., 2005) and here I make the first report of the actions of galanin 
on colonic sensory activity. The data presented demonstrate potent inhibition of LSN 
responses to noxious mechanical stimulation and the mechanical hypersensitivity 
induced by an IS. Activation of GalR1 resulted in similar levels of inhibition to a 
comparable concentration of galanin, whereas neither a GalR2 agonist nor a GalR2 
antagonist produced any significant effect. Combined, these results suggest that 
galanin acts predominantly via the inhibitory GalR1 to inhibit LSN responses to 
mechanical activation. In conclusion, I have discovered that galanin has a role in 
modulation of extrinsic sensory afferents in the distal colon. This fits alongside the 
previously demonstrated inhibitory roles of galanin in the upper GI tract extrinsically 
and intrinsically (control of gut secretion and motility) and parallels the function of 
galanin in somatic sensory innervation (Flatters et al., 2003; Heppelmann et al., 2000; 
Page et al., 2005b). Overall, these inhibitory effects suggest that GalR1 could be a 
potential target for treating pain arising from the colon. 
 
Multi-unit recordings of LSN activity show that not only does galanin impact baseline 
firing, but that it can also inhibit responses evoked by distension of the distal colon to 
noxious pressures and the mechanical hypersensitivity induced by addition of 
inflammatory stimuli. This suggests the coupling of GalR1 to integral regulators of 
neuronal excitability. GalR1 predominantly couples to Gi (Branchek et al., 2000), 
therefore, one possibility is that through activation of GIRK1 by activated G-protein βγ- 
subunits neurones being hyperpolarised. This hypothesis is supported by the fact that 
GalR1 is co-expressed with GIRK1 in TL neurones, but little to no co-expression with 
other GIRKs (Hockley et al., 2019; Fig. 3-8). Multiple populations of sensory afferents 
innervate the distal colon with differing sensitivities to mechanical stimuli (e.g. stretch, 
stroke and von Frey hair probing of their receptive fields) (Brierley et al., 2004). These 
groups were not characterised in this study, although an inhibitory effect of galanin 
was observed across the full range of distension pressures from physiological through 
to noxious (i.e. 0 – 80 mmHg). This, alongside the multimodal effects of galanin of 
afferent firing to differing stimuli, infers GalR1 expression across multiple afferent 
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subtypes, further supported by mRNA expression in 3 of the 7 subtypes of colonic 
afferents (Hockley et al., 2019; Fig. 1-5).  
 
 
Figure 3-8. GalR1 coexpression against GIRK1 
Kcnj3 is the gene for GIRK1 which coexpresses with the GalR1 gene. Each triangle or circle 
represents a single colonic sensory neurone isolated from either TL DRG (triangle) or LS DRG 
(circle). The colours represent the different neuronal subtypes identified by Hockley et al. 
which are mNP (dark blue), mNFa (brown), mNFb (purple), mPEPa (orange), mPEPb (red), 
pNF (green), and pPEP (light blue). GalR1 and GIRK1 appear to be coexpressed particularly 
in mPEPa and mPEPb subtypes which are peptidergic nociceptive neurones. Expression is 
presented in Transcript-Per-Million (Log[TPM]). 
 
 
The effects of galanin are mediated by three different receptors that activate multiple 
second messenger pathways with the potential to modulate neuronal activity. GalR1 
and GalR3 are positively coupled to GIRKs giving rise to hyperpolarization. The data 
presented shows that GalR1 agonist (M617) produced a similar level of inhibition as a 
comparable concentration of galanin. This fits with a previous study using single unit 
electrophysiological recordings of vagal afferents in mice showing a lack of any 
residual effects in GalR1 KO mice, results indicating that GalR3 did not contribute to 
the inhibitory effect seen with galanin (Page et al., 2007). This is further supported by 
the fact that SNAP37889 (GalR3 selective antagonist) failed to reverse the inhibitory 
effects of galanin (Page et al., 2007; Swanson et al., 2005). All three mRNA transcripts 
are expressed in TL (LSN) DRG neurones with GalR2 and GalR3 expression being 
lower than GalR1 and GalR2, only being expressed in 1 of 5 groups (Hockley et al., 
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2019). Based on the widespread distribution of GalR1 mRNA in the central and 
peripheral nervous systems, it has been proposed that GalR1 mediates many of the 
inhibitory actions of galanin in nociception (Blakeman et al., 2003; Liu and Hökfelt, 
2002). In this study I tested this hypothesis by examining the effects of M617 (GalR1 
agonist) on colonic afferents and found potent inhibitory effects, similar to those of 
galanin, thus further supporting an antinociceptive role of galanin mediated by GalR1. 
GalR2 likely mediates excitatory effects of galanin as observed in the vagal innervated 
upper GI tract (Page et al., 2005b). My data shows that GalR2 has little to no 
contribution to the effect of galanin on LSN activity as the neuropeptide spexin (GalR2 
agonist) produced no significant change in mechanosensitivity of the LSN. 
 
As seen in previous studies, intraluminal application of an IS produced robust LSN 
activity and sensitised the response to mechanical stimuli (Su and Gebhart, 1998). 
Multiple mediators are released during inflammation and act synergistically to sensitise 
afferents, making the use of a single inflammatory mediator less likely to sufficiently 
recapitulate the effects of inflammation in the mouse model. Overall, my results 
demonstrate galanin’s inhibitory effect on the mechanosensitivity of healthy LSN and 
galanin’s ability to reduce IS-induced hypersensitivity. The previous study by Hockley 
et al. shows GalR1 does colocalise with bradykinin receptor B2, Serotonin receptor 5-
HT3, Histamine receptor H2 and H3, and prostaglandin E2 receptor EP1 and EP4. 
Colocalisation of GalR1 with these receptors is particularly prominent in peptidergic 
nociceptors (mPEPa and mPEPb; Hockley et al., 2019). 
 
In summary, I have found that galanin inhibits LSN activity predominantly through the 
action of the GalR1 receptor. Galanin has also been shown to reduce IS-induced 
hypersensitivity of the LSN supported by the previous study showing coexpression of 
galanin with various receptors of inflammatory mediators (Hockley et al, 2019), further 
supporting an anti-nociceptive role of galanin in the colon. 
 
 
 
84 
Chapter 4 – Validation of an inducible mouse 
model of colitis 
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4.1 Introduction 
4.1.1 Murine models of inflammatory bowel disease 
Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the GI 
tract.  Onset usually occurs in patients <30 years old and is characterised by a chronic 
relapsing-remitting course (Cosnes et al., 2011; Sawczenko and Sandhu, 2003). The 
clinical appearance of IBD is heterogenous and can be largely broken down into 
Crohn’s disease (CD) and ulcerative colitis (UC), which are differentiated by their 
manifestation and also hypothesised pathogenesis. Whereas UC is primarily seen in 
the mucosal and submucosal layers of the colon, CD often presents with transmural 
and discontinuous patches of inflammation that can also affect other regions of the GI 
tract, e.g. the terminal ileum (Baumgart and Sandborn, 2012; Danese and Romano, 
2011). The aetiology of both CD and UC is still not fully understood, however, genetic 
screening and epidemiologic studies implicate a combination of environmental factors, 
inherited susceptibility and altered immune responses as the cause (Ananthakrishnan, 
2015; de Souza et al., 2017). 
 
Due to their short gestation period, manageable size, genetic tractability and ease with 
which their environment can be manipulated, mice provide a versatile biological 
system to study disorders such as IBD, both with regard to their pathogenesis and 
potential treatment. Currently, there is no single animal model that fully recapitulates 
all the pathogenic features of IBD, likely owing to its complicated nature and our limited 
understanding of the mechanisms that drive IBD itself. Each model has its advantages 
and disadvantages for translating to human IBD and some of the main models will now 
be discussed. 
  
The complexity of IBD in humans is mirrored by the number of animal models for IBD 
(discussed below) and the transgenic mouse strains, which  exhibit IBD-like 
alterations, for example IL10 KO (Kühn et al., 1993; Strober et al., 2002; Wirtz et al., 
2017). Studying these animal models of colitis has provided essential tools to 
understanding disease mechanisms in both CD and UC. For example, results from 
preclinical studies using mouse models of colitis (i.e. IL-10 KO) highlighted the 
therapeutic benefit of anti-TNFα monoclonal antibodies in reducing colonic 
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inflammation (Gratz et al., 2002) which have since been successfully utilised clinically 
in treating IBD (Vavricka et al., 2017), Moreover, analysis of mouse colitis models has 
also led to advancement of the understanding of the immunoregulatory processes in 
the gut, resulting in the current hypothesis that an immune response against 
components of the host’s GI tract microbiota is involved in the initiation and 
perpetuation of IBD (Neurath, 2014; Saleh and Elson, 2011). 
 
Previously established colitis models can be generally divided into five categories 
dependent on their mode of induction. Firstly, there are specific mouse strains that can 
be bred to develop spontaneous forms of intestinal inflammation, e.g. the P1/Yit strain 
undergoes spontaneous enteric inflammation and a pathogenesis similar to human 
IBD (Matsumoto et al., 1998). Next, mice can be genetically modified to produce an 
IBD-like phenotype, for example knocking out IL-10 in mice leads to spontaneous 
development of colitis (Kuhn et al., 1993). The next category is antigen-specific 
experimental models of colitis, such as introduction of Helicobacter hepaticus into the 
stomach of immunodeficient mice, which leads to the development of chronic colitis 
that is similar to that observed in humans with IBD (Kullberg et al., 1998). A further 
distinct category involves modulating the cellular component of the inflammatory 
response, for example transferring CD4+CD45RBhigh T cells from healthy mice to a 
syngeneic recipient that lacks T and B cells results in colitis 5-8 weeks following 
transfer (Powrie et al., 1994). The final category is chemically-induced models of colitis 
that introduce a direct insult to the gut to generate the pathology, two widely used 
examples being intracolonic administration of 2,4,6-trinitrobenzenesulfonic acid 
(TNBS; Son et al., 1998) and orally administered dextran sulphate sodium (DSS; 
Okayasu et al., 1990). 
 
The onset and severity of colitis in most mouse models is variable and can depend on 
environmental factors, for example diet, housing conditions, and specified pathogen 
free environment influencing the microbiota of the mice (Mähler and Leiter, 2002). 
Some transgenic models (IL10-/-; Kuhn et al., 1993) can take months to manifest 
symptoms of colitis, rendering them impractical for high throughput studies, such as 
drug screening studies, that need a fast, reproducible model. The dissection of the 
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pain signalling pathways relevant to colitis, enables pharmacological testing of agents 
and identification of future therapeutic avenues. Chemically-induced colitis models, 
such as DSS and TNBS, are widely used in these types of studies due to their ease 
of reproducibility, similarity of pathogenesis, and lack of need for expensive mice and 
reagents (Axelsson et al., 1998; Crespo et al., 1999). The study of colitis in mice 
through chemically-induced epithelial barrier injury induces an IBD-like phenotype by 
exposing the host defence to the microbiota. Intestinal bacteria act as a buffer between 
the external environment and the host. Dynamic changes to bacterial colonies occur 
not only between individuals, but also in the change from health to disease (Manichanh 
et al., 2012). Indeed, changes in intestinal bacteria diversity have been demonstrated 
in patients with CD and UC compared to healthy samples (Ott, 2004).  
 
4.1.2 Chemically-induced models of colitis – TNBS  
Trinitrobenzene sulfonic acid (TNBS) is a haptenizing molecule that binds to 
endogenous or microbiota-derived proteins making them immunogenic to the host 
(Elson et al., 1996). TNBS is administered intracolonically in ethanol, the ethanol 
being essential for providing access for TNBS to the epithelial barrier, impairing 
the barrier function and permitting the translocation of haptenated luminal proteins 
into the tissue. Exposure to autologous haptenated antigenic material stimulates 
the development of a delayed-type hypersensitivity immune response and it has 
been suggested that the haptenization of luminal antigens by TNBS inhibits 
tolerance to the mouse’s own microflora. Moreover, the TNBS model is associated 
with increased numbers of activated T-cells and involvement of innate immune 
mechanisms as signs of mucosal acute inflammation can be observed in TNBS 
treated lymphopenic mice as also occurs in IBD (Fiorucci et al., 2002; Geremia et 
al., 2014). 
 
In the TNBS model, weight loss, bloody diarrhoea and colonic shortening all occur 
alongside histopathological transmural inflammation within the colon being observed, 
which is associated with an influx of macrophages and lymphocytes (Manicassamy 
and Manoharan, 2014). These features demonstrate that TNBS-induced colitis is a 
good experimental model for the study of colitis in CD, because it results in Th1 
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response to proinflammatory cytokine release (Fichtner-Feigl, 2005). However, in the 
literature many different protocols have been reported, e.g. different ethanol/TNBS 
concentrations (te Velde et al., 2006), and there are also strain differences in response 
(e.g. mild and spontaneous resolution in C57BL/6J mice vs. highly susceptible  SJL/J 
mice; te Velde et al., 2006). Furthermore, factors outside of experimental design, such 
as the presence of T-cell activating bacterial strains in the animal facility, can also 
greatly impact the variability of the study (Wirtz et al., 2017).  
 
4.1.3 Chemically-induced models of colitis – DSS  
Dextran Sulphate Sodium (DSS) is one of the oldest methods for inducing colitis, 
which is done by addition of a complex polymer of glucose and chlorosulphonic 
acid to drinking water. The onset and severity of DSS-induced disease is 
influenced by the molecular weight of DSS used, mouse strain, and concentration 
of the solution (usually between 1 and 5%; Wirtz et al., 2007). This model can be 
used to induce acute or chronic forms of colitis by alternating animals on and off 
DSS containing water, which simulates the relapsing and remitting aspects of 
certain GI conditions.  
 
DSS affects the colonic mucosa with the most marked disease severity being 
observed in the distal colon. Clinical signs include diarrhoea and rectal bleeding, 
weight loss, and colonic shortening and histological examination reveals mucosal 
haemorrhage, ulceration, superficial inflammation, goblet cell loss, crypt distortion 
and abscesses (Okayasu et al., 1990). Acute tissue injury is accompanied by 
infiltration of neutrophils, macrophages and lymphocytic cells, and although the 
exact mechanism by which DSS triggers the immune response is not completely 
understood, it is believed to cause toxicity to epithelial cells, which leads to 
impaired barrier integrity and permeability defects. It has been suggested that DSS 
associates with medium chain length fatty acids present in the colon, which are 
then absorbed and processed in epithelial cells leading to their death (Laroui et al., 
2012). The amelioration of DSS-induced colitis following the administration of 
antibiotics demonstrates that bacteria and microbial antigens are an important 
factor in DSS-induced colitis pathogenesis. 
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4.2 Aims 
 
The previous chapter demonstrates that galanin inhibits colonic afferent 
mechanosensitivity and that it can also inhibit the hypersensitivity induced by acute 
application of inflammatory mediators. To further investigate the role of galanin under 
inflammatory conditions in the distal colon, similar to that seen in IBD, an animal model 
of colitis is needed to examine both the expressional and functional changes of galanin 
in colonic afferents. 
 
Therefore, the aims of this chapter were to: 
• Establish an optimised protocol for a robust and reproducible murine 
model of colitis. 
• Fully validate the effects of the chosen model of colitis.  
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4.3 Results 
4.3.1 TNBS-induced colitis fails to produce robust and reproducible intestinal 
inflammation. 
The first model used was TNBS as it one of the most established inducible models of 
colitis in the literature. The initial pilot study used a very small number of mice for each 
group (N = 2), a low concentration of ethanol (30%) and three concentrations of TNBS 
to cover the range seen in literature. The aim was to establish an acute model of colitis 
with 100% survival and then repeat the experiment in a larger cohort with the same 
conditions that produced the best result from this pilot. 
 
Healthy C57BL/6J mice were anaesthetised and TNBS/ethanol, or ethanol alone, was 
intracolonically administered. Mice were assessed and weighed daily, and then killed 
on day three with measurements made and tissue samples collected from the 4 
groups. The 3.85 mg TNBS group were the only group to show any observable weight 
loss trend with the peak occurring on day 2 (13.9 ± 3.4 % weight loss, N = 2; Fig. 4-
1A). All groups showed an increase in the disease activity index (DAI) from one day 
after induction, however only the TNBS groups shown an increase in DAI on day 3, by 
which time the control group symptoms resolved (Fig. 4-1B). The colon lengths and 
macroscopic score did not consistently change in any treatment group (Fig. 4-1C and 
D). Colon wet weight to length ratio did appear to be increase in both the 1.95 mg and 
3.85 mg TNBS groups (but not the 0.85 mg group), which is indicative of the colon 
thickening observed in inflammation (Antoniou et al., 2016; Fig. 4-1E). H&E with alcian 
blue staining showed very limited indication of inflammation (1.95 mg TNBS group 
shown as an example; Fig. 4-1F), with crypt architecture still intact and no signs of 
ulceration or immune cell infiltration. In summary, the results from this first pilot 
suggested that the inflammation induced was too mild to produce consistent results.  
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Figure 4-1. First pilot study of TNBS-induced colitis 
(A) Body weight of 3.85 mg TNBS treated mice was reduced compared to untreated controls. 
(B) Disease activity index (DAI) is increased in colitis-induced mice. (C) Colon length is similar 
throughout all groups. (D) Macroscopic score is based on visual assessment of ulceration and 
hyperaemia of the colon and is not consistently different between control and TNBS groups. 
(E) Colon weight to length ratio increased in higher concentrations (1.95 mg and 3.85 mg) 
colitis-induced mice. (F) H&E with alcian blue staining of colonic tissue. Areas defined by black 
boxes are magnified in the lower images. Crypt structure remains intact with little sign of 
infiltration of immune cells in 1.95 mg group; scale bar for top images is 300 μm and for bottom 
images 100 μm. N = 2 for all groups. 
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To further optimise the model, a second pilot study using 40% ethanol and only the 
higher doses of TNBS (1.9 mg and 3.85 mg) was carried out, again using a small 
group size for initial characterisation (N = 2); one mouse in the 3.85 mg TNBS group 
was killed on day one due to overly severe DAI and weight loss leaving N = 1 for the 
3.85 mg TNBS group. 
 
As before, mice were assessed and weighed daily, before being killed on day three. 
None of the groups showed consistent weight loss over the three days (Fig 4-2A) and, 
as seen previously, all groups had an initial increase in DAI on day 1 (Fig 4-2B). 
However, in contrast to the initial study using 30% ethanol, all groups had a low DAI 
score on day 3, including the ethanol control group, i.e. no clear difference between 
TNBS and ethanol only groups was observed (Fig. 4-2B). In addition, the colon length 
and macroscopic score did not appear to consistently change in 1.95 mg TNBS group, 
but the 3.85 mg TNBS mouse showed a reduction in colon length and a small increase 
in macroscopic score (Fig. 4-2C and D). Furthermore, the colon wet weight to length 
ratio appeared to be slightly decreased in 1.95 mg and 3.85 mg TNBS treated mice, 
which is not consistent with the colonic thickening that is associated with inflammation 
(Fig. 4-2E). Lastly, H&E with alcian blue staining did show signs of inflammation in 
mice from the 1.95 mg TNBS group, with crypt architecture heavily disrupted in places 
and clear signs of mucosal ulceration and immune cell infiltration in both the mucosal 
and submucosal layers (Fig. 4-2F). 
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Figure 4-2. Second pilot study of TNBS-induced colitis 
(A) Body weight of 3.85 mg TNBS mice increased compared to ethanol control, but 1.95 mg 
TNBS showed no difference. (B) DAI increases in TNBS-treated mice, but also ethanol control 
mice. (C) Colon length is not consistently different between control and TNBS-treated mice. 
(D) The macroscopic score was increased in the 3.85 mg TNBS mouse but was not 
consistently different between the 1.9 mg TNBS group and ethanol control group (E) Colon 
weight to length ratio was not consistently different between the ethanol control group and 
TNBS groups. (F) H&E with alcian blue staining of colonic tissue. In 1.95 mg TNBS mice, there 
was active inflammation and crypt or surface epithelial damage compared to untreated 
controls. Areas defined by black boxes are magnified in the lower images; scale bar for top 
images is 300 μm and for bottom images 100 μm. 40% ethanol and 1.95 mg TNBS N = 2, 3.8 
mg TNBS N = 1. 
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The results from the second pilot were less conclusive of whether intestinal 
inflammation was developing in a robust manner or not and thus in a final attempt to 
optimise the model a third pilot was conducted using 50% ethanol and focusing on 1.9 
mg TNBS group due to the death of 1 mouse in the 40% ethanol / 3.85 mg condition. 
The third pilot study also had a higher number of replicates to add power to the 
observations (50% ethanol control N = 6, 1.95 mg TNBS N = 5).  
 
As per the previous pilot studies, the mice were assessed and weighed daily and killed 
on day three. Compared to the 50% ethanol control group, the 1.9 mg TNBS group 
did show significant weight loss (100.5 ± 1.4 % vs 90.9 ± 4.5 % starting weight, P < 
0.01, two-way ANOVA with Sidak’s post-hoc test; Fig. 4-3A). As observed in previous 
pilot studies, both the control group and the TNBS group showed an increased DAI 
score on day 1, but here the 1.95 mg TNBS group was significantly increased 
compared to the control group on day 3 (0.5 ± 0.2 vs 3 ± 1.35, P < 0.01, two-way 
ANOVA with Sidak’s test; Fig. 4-3B). Whereas the colon lengths did not significantly 
change between the 1.95 mg TNBS and control groups (Fig. 4-3C), the macroscopic 
score did significantly increase in the 1.95 mg TNBS group (0.2 ± 0.1 vs 1.8 ± 0.6, P 
< 0.05, unpaired t-test; Fig. 4-3D) and the colon wet weight to length ratio was also 
significantly increased in the 1.95 mg TNBS group (4.3 ± 0.2 vs 5.6 ± 0.4, P < 0.05, 
unpaired t-test; Fig. 4-3E). Lastly, H&E with alcian blue staining did show signs of 
inflammation in the 1.95 mg TNBS group, with crypt architecture heavily disrupted in 
most places and clear signs of mucosal ulceration and immune cell infiltration in the 
mucosal layer (Fig. 4-3F). 
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Figure 4-3. Third pilot study of TNBS-induced colitis 
(A) Body weight of TNBS treated mice was significantly reduced compared to untreated 
controls (** = P < 0.01, two-way repeated-measures ANOVA with Sidak’s post-hoc test). (B) 
DAI significantly increases in colitis-induced mice (** = P < 0.01, two-way repeated-measures 
ANOVA with Sidak’s post-hoc test). (C) Colon length was not significantly different between 
ethanol control and TNBS group. (D) Macroscopic score was significantly increased in TNBS 
treated mice (* = P < 0.05, unpaired t-test). (E) Colon weight to length ratio was significantly 
increased in TNBS mice (* = P < 0.05, unpaired t-test). (F) H&E with alcian blue staining of 
colonic tissue. In TNBS mice, there was active inflammation with infiltration of immune cells 
and crypt, or surface epithelial damage compared to untreated controls. Areas defined by 
black boxes are magnified in the lower images; scale bar for top images is 300 μm and for 
bottom images 100 μm. 50% ethanol N = 6, 1.95 mg TNBS N = 5. 
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4.3.2 DSS-induced colitis produced robust and reproducible intestinal inflammation. 
Due to the inconsistencies between the results of the three pilot studies for the TNBS 
model of colitis, an alternative model of inducible colitis was trialled. Oral 
administration of dextran sulphate sodium (DSS) via drinking water is widely reported 
to induce colitis (Manicassamy and Manoharan, 2014; Wirtz et al., 2007). An initial 
pilot study was conducted similar to previous TNBS pilot studies, with a relatively small 
number of mice in each group to avoid large scale unforeseen complications arising. 
 
Healthy C57BL/6J mice were given either 3% DSS in their drinking water (N = 5) or 
normal drinking water (N = 4) for 5 days, followed by normal drinking water for an 
additional 3 days. Every animal had their symptoms assessed and was weighed daily. 
The animals were killed on day 8 with measurements and tissue samples collected 
from the two groups. There was significant weight loss in the DSS group compared to 
the control group (day 8: 89.2 ± 2.5% vs 107.2 ± 0.9% starting weight, P < 0.001, two-
way ANOVA with Sidak’s post-hoc test; Fig. 4-4A) and a significant increase in DAI 
score (day 8: 2 ± 0.5 vs 0, P < 0.001, two-way ANOVA with Sidak’s post-hoc test; Fig. 
4-4B). Colon length was also significantly decreased in the DSS group compared to 
the control group (66.9 ± 1.4 mm vs 87.9 ± 3.7 mm, P < 0.01, unpaired t-test; Fig. 4-
4C), although there was no significant change in the colon wet weight to colon length 
ratio (Fig. 4-4E), suggesting there was colon shrinkage, which is associated with 
intestinal inflammation (Okayasu et al., 1990), but no thickening of the colon. There 
was no significant change in macroscopic score between the DSS and control groups. 
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Figure 4-4. Initial pilot study of 3% DSS induced colitis 
 
(A) Body weight of DSS treated mice was significantly reduced compared to untreated controls 
(** = P < 0.01, *** = P < 0.001, two-way ANOVA with Sidak’s post-hoc test). (B) DAI significantly 
increased in colitis-induced mice (*** = P < 0.001, two-way ANOVA with Sidak’s post-hoc test). 
(D) Colon length was significantly reduced in DSS mice (** = P < 0.001, unpaired t-test). (E) 
Macroscopic score did not significantly change between control and DSS groups (P = 0.06, 
unpaired t-test). (F) Colon weight to length ratio did not significantly change between control 
and DSS groups (P = 0.129, unpaired t-test). N = 5 for 3% DSS group, N = 4 for control group. 
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With the pilot study looking promising, to fully validate the DSS model a full study with 
3% DSS and control groups of N = 10 was conducted. The peak of observed 
symptoms in the initial pilot study showed a peak at day 7 and so for the full validation 
study day 7 was chosen as the end point. Healthy C57BL/6J mice were given either 
3% DSS in their drinking water for 5 days or normal drinking water, followed by normal 
drinking water for an additional 2 days, and weighed and assessed daily.  
 
The DSS mice showed significant weight loss by day 4 compared with the untreated 
mice (day 7: 82.1 ± 1.9% vs 103.9 ± 3.6 % starting weight, P < 0.001, two-way ANOVA 
with Sidak’s post-hoc test; Fig. 4-5A). DSS mice also showed a significant increase in 
DAI score (day 7: 9 ± 0.1 vs 0 DAI score, P < 0.001, two-way ANOVA with Sidak’s 
post-hoc test; Fig. 4-5B). There was also significant damage observed 
macroscopically in DSS treated mice compared to control (1.5 ± 0.2 vs 0 macroscopic 
score, P < 0.001, unpaired t-test; Fig. 4-5C). In addition, the colon length was 
significantly decreased in DSS mice compared to control mice (46.2 ± 1.4 mm vs 69.8 
± 1.7 mm, P < 0.001, unpaired t-test; Fig. 4-5D and E) and the colon wet weight to 
length ratio also significantly increased (7.6 ± 0.3 mg/mm vs 4.3 ± 0.2 mg/mm, P < 
0.001, unpaired t-test; Fig. 4-5F). The shortening of the colon and increased weight to 
length ratio suggest thickening of the colon wall, which has previously been reported 
in the DSS model of colitis (Marrero et al., 2000; Sánchez-Fidalgo et al., 2012).  
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Figure 4-5. DSS induces weight loss and macroscopic changes to the colon 
(A) Body weight of DSS treated mice was significantly reduced compared to untreated controls 
(* = P < 0.05, *** = P < 0.001, two-way repeated-measures ANOVA with Sidak’s post-hoc 
test). (B) DAI significantly increases in colitis-induced mice (*** = P < 0.001, two-way repeated-
measures ANOVA with Sidak’s post-hoc test). DAI = disease activity index; assessment of 
inflammation by clinical parameters. (C) Macroscopic score is based on visual assessment of 
ulceration and hyperaemia of the colon (P < 0.0001, paired t-test). (D) Images of healthy and 
colitis-induced colons from caecum (left side) to anus (right side). (E) Colon length was 
significantly reduced in DSS mice (P < 0.0001, paired t-test). (F) Colon weight to length ratio 
was significantly increased in DSS mice (P < 0.001, paired t-test). N = 10 for both groups. 
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H&E and alcian blue staining used to identify crypt architecture, the presence of goblet 
cells and identify immune cells. Using a histopathological scoring system based on the 
presence of inflammatory cells, crypt damage and ulceration (Ren et al., 2011),  
significant damage was also observed in DSS treated mice compared to healthy mice 
(Fig. 4-6A and C, 6.8 ± 0.7 vs 0.5 ± 0.2 histology score, P < 0.001, unpaired t-test). 
Furthermore, as others have observed (Kessler et al., 2008), we also found that the 
extracellular matrix polysaccharide hyaluronan (HA) disappeared from the colon 
epithelium during DSS-induced colitis with deposits occurring in the subepithelial 
layers (Fig. 4-6B). Further evidence of development of colitis was obtained by 
measuring the muscular layer of the colon, which was found to be significantly thicker 
in the DSS group compared to healthy group (174.9 ± 10.1 μm vs 81.6 ± 3.5 μm, P < 
0.001, unpaired t-test; Fig. 4-6D).  
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Figure 4-6. DSS induces changes in colon histology 
(A) H&E with alcian blue staining of colonic tissue. In DSS mice, there was active inflammation, 
and crypt or surface epithelial damage compared to untreated controls. Areas defined by black 
boxes are magnified in the lower images; scale bar for top images is 1 mm and for bottom 
images 250 μm. (B) Changes in hyaluronic acid binding protein (HABP; green) arrangement 
and distribution in colitis-induced and healthy colons. Scale bar is 500 μm. (C) Histology score 
defined previously (more detail in section 2.3.4) significantly increases in DSS mice (P < 
0.0001, N = 10, paired t-test). (I) Colonic muscle layer significantly thicker in DSS mice (P < 
0.0001, N = 10, paired t-test).  
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4.3.3 Myeloperoxidase (MPO) levels are not altered in mouse colons by DSS-
treatment. 
Myeloperoxidase (MPO) is part of the haem peroxidase superfamily and is found in 
certain immune cells including neutrophils, monocytes, and some tissue 
macrophages. Colonic MPO activity is a marker of tissue damage and is a measure 
of neutrophil infiltration (Masoodi et al., 2011; Palmen et al., 1995). For optimising the 
protocol, the time course of the reaction between the tissue supernatants for healthy 
tissue, inflamed tissue (complete Freund’s adjuvant, CFA hind paw model, performed 
by Dr Gerard Callejo) and a positive control (horseradish peroxidase; HRP) was tested 
with results of the reaction mixtures taken every 30 seconds (Fig 4-7A). From this, the 
peak of the reaction was at the 20th reading with clear differences between the three 
groups, which was then used for future experiments.  
 
As expected, the samples from the CFA treated hind paws showed significantly 
increased MPO activity compared to the samples from healthy mice (1.2 ± 0.1 vs 0.1 
± 0.1 U mg-1, P < 0.001, one-way ANOVA with Tukey’s test; Fig. 4-7B). However, colon 
samples from both models of chemically-induced colitis (1.95 mg TNBS / 50% ethanol 
and 3% DSS) did not have significantly different MPO activity to either healthy colonic 
tissue or 50% ethanol control groups, suggesting there is little change in the levels of 
neutrophils in these models of colitis across the time course used in this study. 
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Figure 4-7. MPO activity analysis  
(A) Time course of reaction between supernatants and reaction mixtures with readings taken 
every 30 seconds. (B) MPO activity in colon tissues from 1.95 mg TNBS / 50% ethanol and 
3% DSS administered mice on day 3 and 7 respectively with their control groups. Hind paw 
tissue from a mouse treated with CFA was used as a positive control of an inflammatory model 
previously established in the lab. Healthy and CFA samples N = 3, 1.95 mg TNBS / 50% 
ethanol and 3% DSS samples N = 5, and 50% ethanol control samples N = 6 
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4.4 Discussion 
The cause of IBD is not clear, but there is evidence of dysregulated mucosal immune 
responses, abnormal cytokine production, and intestinal tissue damage (Bouma and 
Strober, 2003; Hibi and Ogata, 2006; Strober et al., 2002). Experimental colitis models 
in mice have proved useful in studying pathogenesis of IBD and also in the study of 
colitic pain in general (Eijkelkamp et al., 2007; Larsson et al., 2006). There are a 
number of mouse models that exhibit histological and/or immunological characteristics 
of human IBD meaning that I needed to establish one to investigate the function of 
galanin in an in vivo setting. As discussed in Section 4.1, models established through 
genetic modifications to increase susceptibility to intestinal inflammation are time-
consuming, although are good models for studying the role of particular signal 
transduction pathways (Engelhardt and Grimbacher, 2014; Wirtz and Neurath, 2005). 
I chose to establish a chemically-induced model of colitis due to the relatively rapid 
onset and ability to use wildtype mice. Although these models are not novel, pilot 
studies and optimisation was needed to establish a reliable model of colitis as this was 
new to the lab. 
 
To study the effects of galanin in inflammatory pain, the TNBS model was first chosen 
as this has been previously reported as a robust and reproducible model of colitis.  
However, a lot of variation in methodology has been reported for the TNBS model, 
including mouse strain, age, number of TNBS administrations, concentration of 
TNBS/ethanol and study end points (Abad et al., 2005; Coccia, 2005). As the three 
initial experiments conducted in this study showed, the response was variable and fits 
with previous reports of TNBS resistance in C57BL/6J mice (Antoniou et al., 2016), 
especially compared to Balb/c and SJL/J strains (te Velde et al., 2006). A 
presensitization step (topical application of TNBS solution to a patch of skin 7 days 
before intracolonic application) with TNBS has been shown to increase the rate of 
successfully inducing inflammation (even in C57BL/6J mice; Wirtz et al., 2007), which 
would be a potential further option to explore, particularly if CD-like transmural 
inflammation is the pathology being investigated (Wirtz et al., 2017). As this study 
focussed more on colitis in general, rather than a particular pathway, switching to the 
DSS-induced model seemed more appropriate to rapidly establish a reproducible 
animal model. 3% DSS, administered for 5 days, induced marked colitis in C57BL/6J 
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mice as observed in previous studies (Manicassamy and Manoharan, 2014; Perše and 
Cerar, 2012). In this study, DSS treated mice showed a significant reduction in weight 
and an increased DAI score. Dissection of the colons also showed significant reduction 
in colon length, increased wet weight to length ratio, increased macroscopic score, 
and, histologically, more signs of mucosal inflammation. Importantly, not only were all 
the measurements consistent with development of colitis in DSS treated mice, the 
results from the DSS treated mice also showed significantly less variability than the 
TNBS treated mice.  
 
There are several factors outside of the experimental design that can have a large 
impact on the disease manifestation including; genetic heterogeneity of mouse inbred 
strains and the local microbiota of the animal facility (Bleich and Fox, 2015); it could 
be that one of these factors played a role in the negative MPO assay. Therefore, initial 
pilot studies were important to determine the optimal dosages and housing conditions 
(Mähler and Leiter, 2002). Sex-specific differences in susceptibility to experimental 
colitis exists and was taken into consideration, an example being that for DSS-induced 
colitis, male mice have a tendency to have increased susceptibility than female mice 
(Wirtz et al., 2017) and hence for this reason, studies in both models used only male 
mice.  
 
In summary, these results demonstrate  that I established a robust and reproducible 
mouse model of colitis and based on these results I used the DSS model for 
investigating the ability of galanin to modulate LSN function in inflammatory conditions.  
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Chapter 5 – Galanin does not inhibit DSS-
induced mechanical hypersensitivity of the 
lumbar splanchnic nerve 
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5.1 Introduction 
5.1.1 Galanin in the peripheral nervous system 
Galanin has widespread expression throughout the central (CNS) and peripheral 
nervous systems (PNS), as discussed in detail in Section 1.6. Galanin 
immunoreactivity and mRNA have been characterised in the CNS of the mouse 
(Cheung et al., 2001; Perez et al., 2001) and results show that galanin is 
coexpressed with an array of neurotransmitters (Jacobowitz et al., 2004). In addition 
to the numerous physiological functions of galanin in the CNS (e.g. its roles in 
feeding behaviour, energy homeostasis, osmotic regulation and water intake; 
reviewed in Lang et al., 2014), galanin has also been implicated in functional 
regulation of the PNS (Page et al., 2005b). For example, galanin is present in DRG 
neurones and has been shown to participate in the control of pain processing in 
the spinal cord (Liu and Hokfelt, 2002). Galanin also modulates neurotransmission 
in peripheral organs, such as the heart (Smith-White et al., 2003) and GI tract 
(Sarnelli et al., 2004).  
 
Galanin was originally isolated from the small intestine (Tatemoto et al., 1983) 
leading to the investigation of its role in the GI tract. Galanin is widely expressed 
throughout the GI tract with galanin-expressing enteric neurones and sensory 
afferents projecting to all layers of the wall of the GI tract (Melander et al., 1985). 
More recent analysis demonstrated that galanin is expressed in many different cell 
types in the colon including macrophages, epithelial cells and colonic sensory 
afferents (Hockley et al., 2019; Koller et al., 2019). Within the sensory afferents, 
galanin is predominantly expressed in two of the seven groups that have been 
identified through single-cell RNA-sequencing of retrograde labelled colonic 
sensory afferents, one of which represents peptidergic nociceptors and thus 
supports a potential role for galanin in nociceptive signalling in the distal colon 
(Hockley et al., 2019). Galanin has also been shown to have physiological roles in 
the GI tract including inhibition of gastric acid secretion (Kisfalvi et al., 2000), 
inhibiting pancreatic peptide release (Herzig et al., 1993; Lindskog et al., 1995), and 
modulation of GI motility (Umer et al., 2005).  
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5.1.2 Neurochemical characterisation of visceral sensory neurones 
The expression of known nociceptive protein markers in visceral afferents can be 
used to characterise galanin expressing neurones and further support the 
functional effects seen with exogenous galanin. In line with the focus of this thesis, 
the emphasis of the discussion here will be on spinal colonic innervation. 
Retrograde labelling studies of the rodent colon suggest that 3 – 15% of DRG (T8-
L1, L6-S1) neurones project to the colon, with a bimodal distribution amongst 
spinal cord levels: one at spinal cord level T8-L1 in mouse (T8-L2 in rat) and the 
other comprising L6-S1 in mouse (also L6-S1 in rat) (Brierley et al., 2008; 
Christianson et al., 2006a; Hockley et al., 2019; Jänig and McLachlan, 1987; Perry 
and Lawson, 1998). The TL pathway corresponds to afferent fibres of the LSN and 
the LS pathway that of afferent fibres tracking with the PN. 
 
Whilst thickly myelinated Aα/β-fibres are rare in viscerally projecting populations, 
thinly myelinated Aδ-fibres make up a significant proportion of the visceral afferent 
population, estimated at 19-26% of visceral afferents (Christianson et al., 2006a; 
Perry and Lawson, 1998), the rest being unmyelinated C-fibres. A recent study by 
Hockley et al., has used single-cell RNA-sequencing to categorise colonic 
afferents based on their transcriptomic profiles, directly linking the different 
subtypes to their inferred function (Hockley et al., 2019). From this study, it was 
seen that the receptor for neurotrophin-3, TrkC. shows almost no expression in 
the subtypes linked to nociceptive function (mPEPb and pPEP), suggesting that 
colonic afferents expressing TrkC have a non-nociceptive function; indeed, TrkC 
is considered a marker of proprioceptive neurones (Snider, 1994) and so its 
absence of expression in putative nociceptors and relatively low expression overall 
is to be expected in colonic sensory neurones. Both TRPV1 and Gfrα3 are 
expressed in nociceptive subtypes (Hockley et al., 2019). In a previous study 
supporting this, visceral afferent nociceptors were further characterised into high-
firing frequency (HF) and low-firing frequency (LF) populations based on 
differential responses to distension (Malin et al., 2009). Gfrα3 being shown to be 
a good marker for the HF nociceptor population and TRPV1 for the LF nociceptive 
population.  
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5.1.3 Changes in galanin expression in peripheral inflammation 
The expression of galanin and its receptors is altered throughout pain circuits in 
experimental inflammation conditions, which suggests that the function of galanin 
may also differ from health to disease. For example, galanin expression decreases 
in DRG neurons, but increases in DH neurons in response to hind-paw injections 
of the inflammatory stimulus carrageenan (Ji et al., 1995; Zhang et al., 1998). 
Moreover, the galanin concentration is reported to increase in DRG neurones in 
models of chemically-induced ileitis in pigs (Pidsudko et al., 2003) and cystitis in 
rats (Callsen-Cencic and Mense, 1997), although a similar study in rats reported no 
significant change (Zvarova and Vizzard, 2006). The galanin concentration also 
increases after noxious colorectal distension (in the absence of inflammation) (Lu 
et al., 2005) and in chronic diverticular disease (Simpson et al., 2008), indicative of 
a potential role in visceral, as well as, somatic pain modulation. 
 
In summary, galanin mRNA has been shown to be present in nociceptive neuronal 
subtypes in both the LSN and PN. However, previous studies show contradicting 
results over changes in galanin expression in DRG neurones during peripheral 
inflammation. Despite this, galanin expression has been shown to increase in 
colonic tissue after noxious mechanical stimuli and in chronic inflammatory 
conditions further supporting a potential role for galanin in nociceptive signalling.   
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5.2 Aims 
 
Results in Chapter 3 demonstrate that under physiological conditions galanin 
modulates LSN afferent function with an overall inhibitory effect on LSN 
mechanosensitivity. Galanin was also found to reduce the mechanical hypersensitivity 
induced by intraluminal application of an IS. From results in Chapter 4, it is clear that 
a robust model of colonic inflammation has been established. 
 
Therefore, the aims of this chapter were to; 
• Determine the expression of galanin in colon-innervating DRG neurones using 
immunohistochemistry. 
• Examine whether colonic sensory neurone galanin expression changes in the 
DSS model of colonic inflammation. 
• Investigate how colonic inflammation affects activity of the LSN and how this is 
modulated by galanin. 
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5.3 Results 
5.3.1 Validation of colonic Fast Blue labelling of DRG neurones 
The specificity of Fast Blue (FB) uptake by TL and LS colon innervating afferents 
following injections of FB into the distal colon wall was quantitatively investigated. 
Following transcardial perfusion with fixative (4% PFA), DRG from mice were removed 
from T, L and S regions: T7 – T13, L1 – L6, and S1 – S3. During surgery, injection 
sites were made primarily within the regions of the distal colon likely innervated by the 
LSN. Once dissected, individual DRG from FB-labelled mice were imaged using 
fluorescent microscopy to confirm uptake of FB into cells (Fig. 5-1). In DRG T9 – L1 
and L5 – S1, fluorescent cells could be seen under UV illumination, with maximal 
frequency observed in T13, L1, L6 and S1 for lumbosacral. Importantly, none or very 
few retrograde-labelled cells (<5 cells/DRG) were observed in DRG T7, L3, L4, S2 and 
S3 (Fig. 5-1). This is consistent with the expression pattern observed in previous 
studies and provides confirmation that off-target labelling of non-colon innervating 
neurones is unlikely to have occurred (Christianson et al., 2006a; Robinson et al., 
2004). As such, no alterations to surgical procedures (e.g. position or number of 
injection sites, concentration or quantity of FB injected) were made throughout the rest 
of the study. Due to the high numbers of FB-labelled cells observed, DRG T13 and L1 
are used to represent colonic afferents in the LSN pathways and L6 and S1 are used 
to represent afferents of the PN. 
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Figure 5-1. Validation of colonic FB labelling of DRG neurones.  
FB injections were made into the distal colon wall of the mouse and FB underwent retrograde 
transport to DRG. Representative bright-field (BF) and fluorescent images of whole DRG from 
FB-labelled mice. DRG from T13 and L1 (blue box) contain high numbers of FB-labelled cells, 
corresponding to the LSN afferent pathway, while DRG L6 and S1 (red box) also contain high 
numbers of FB-labelled cells, corresponding to the PN afferent pathway. L3 and L4 contain 
none or very few (<5 cells/DRG) FB-labelled cells. Scale bars 100 μm. 
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In later studies, DSS-treated mice were used to investigate the functional role of 
galanin in visceral afferents during inflammation. Therefore, in order to confirm that 
DSS treatment was not altering the extent of colonic innervation by extrinsic afferent 
fibres, comparison of the FB+ DRG neurone profiles from healthy and DSS-treated 
mice was made on DRG sections (Fig. 5-2A). Following comparable surgical 
procedures, the extent of FB labelling of TL and LS DRG from healthy and DSS-treated 
mice did not significantly differ (two-way ANOVA, P = 0.86, Fig. 5-2B). Furthermore, a 
size-frequency analysis showed no significant change in the general distribution (two-
way ANOVA, P = 0.76; Fig. 5-2C). 
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Figure 5-2. Comparison of FB-positive colonic sensory neurones isolated from healthy 
and DSS-treated mice.  
Comparison of the total number of colon-innervating FB labelled neurones in DRG isolated 
from healthy and DSS-treated mice. (A) Representative brightfield and fluorescent images of 
healthy and DSS-treated DRG sections showing FB labelling of neurones. Scale bars 100 μm. 
(B) FB-positive neurones as a percentage of the total number of neurones (N = 3 mice for both 
groups, n = 790 for healthy mice and n = 827 for DSS mice). (C) Mean frequency of cross-
sectional area of profiles (in 50 μm2 divisions) from healthy and DSS-treated mice. 
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5.3.2 Expression of galanin is unchanged by acute DSS-induced colitis   
In general, neuropeptides are preferentially released when a neurone undergoes high 
frequency firing (Lundberg, 1996). Thus, the presence of galanin in nociceptors would 
suggest that it is released during nociceptive signalling to modulate the activity of 
neurones expressing GalR. Firstly, we examined the protein expression of galanin in 
mouse colon-innervating TL and LS DRG neurones using immunohistochemistry 
(IHC, Fig. 5-3A). An anti-galanin antibody (Theodorsson and Rugarn, 2000) that 
produced no specific staining in control experiments was used. One control 
experiment included the primary antibody pre-incubated with galanin peptide and 
another experiment in which only the secondary antibody was used also showed no 
fluorescence (Section 7.1).  
 
The expression of galanin was determined in healthy mice compared to those that had 
undergone DSS-induced colitis. A similar proportion of galanin expressing neurones 
was observed in DSS-induced colitis mice compared to healthy mice (10.9 ± 2.7% vs 
5.5 ± 4% TL DRG neurones and 16.5 ± 3.5% vs 7.7 ± 0.5% LS DRG neurones (N = 
3)). Moreover, a similar proportion of galanin expressing, FB+ neurones was found in 
DSS-induced colitis mice (22.7 ± 4.7% vs 16.6 ± 4% TL DRG neurones and 21.7 ± 
1.9% vs 18.7 ± 5.5% LS DRG neurones (N = 3)) compared to healthy mice (Fig. 5-
3C), suggesting that galanin expression in colon-innervating DRG neurones is not 
altered by DSS-induced colitis. In agreement with this result, an ELISA measuring the 
galanin concentration in extracts from whole colon segments showed that the galanin 
concentration did not significantly differ between healthy and DSS treated mice (0.4 ± 
0.2 ng mL-1 vs 0.6 ± 0.3 ng mL-1; Fig. 5-3D). 
 
In healthy mice, there was also no significant difference between the mean neuronal 
area of FB+ and FB+ galanin+ colonic DRG neurones (FB+: 233.7 ± 9.4 μm2 vs FB+ 
galanin+: 212.1 ± 6.6 μm2, unpaired t-test; Fig. 5-3E). By contrast, in DSS-treated 
mice, the mean neuronal area of FB+ galanin+ cells was significantly smaller than that 
of the FB+ population (FB+ galanin+: 192.1 ± 4.5 μm2  vs FB+: 215.3 ± 4.4 μm2, P = 
0.033, unpaired t-test; Fig. 5-3F).   
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Figure 5-3. Galanin expression in colonic sensory neurones and whole colon.  
(A) Representative images of FB labelled neurones following FB colon injections and galanin 
immunofluorescence, scale bar is 50 μm; magnified example of co-localisation shown in the 
inset. No significant change in the number of galanin positive neurones is seen between 
healthy and DSS-treated mice in the TL and LS populations in the whole DRG (B) or colon-
innervating DRG neurones (C) (N = 3, unpaired t-test). (D) Galanin ELISA shows no significant 
change in galanin concentration in colon tissue between healthy and DSS-treated mice (N = 
8, unpaired t-test). Cross-sectional area histogram of FB+ (grey bars) and galanin positive 
(black bars) neurones from healthy (E) and DSS-treated (F) mice (N = 3). 
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5.3.3 Galanin is predominantly expressed in putative nociceptors 
To characterise the populations of sensory neurones expressing galanin, co-staining 
was performed with antibodies against a number of growth factor receptors and 
nociceptor markers, including Gfrα3 (high-threshold mechanoreceptors), TRPV1 
(nociceptors), CGRP (peptidergic neurones), TrkA (putative nociceptors), and TrkC 
(non-nociceptive neurones). Gfrα3 expression was shown previously to correlate with 
high-threshold stretch sensitive afferent fibres in the PN (Malin et al., 2009) and we 
observed high co-expression of galanin and Gfrα3 in DRG neurones (i.e. ≥90% of 
galanin+ neurones co-stained for galanin and Gfrα3; Fig. 5-4A, B and C). In DRG 
neurones, Gfrα3 staining was observed in 36.4 ± 2.6% of TL DRG neurones (N = 3, n 
= 1516) and 33.5 ± 2.8% of LS DRG neurones (N = 3, n = 850) and stained 97.4 ± 
2.1% of TL galanin+ DRG neurones (N = 3, n = 75) and 81.2 ± 8.7% of LS galanin+ 
DRG neurones (N = 3, n = 66)(Fig.5-4B). Gfrα3 also stained 43.3 ± 4.3% of TL (N = 
3, n = 407) and 48.3 ± 7.8% of LS (N = 3, n = 225) colonic neurones (i.e. FB+) and 
stained 90.6 ± 0.7% of TL (N = 3, n = 71) and 97.5 ± 1.3% of LS (N = 3, n = 48) of 
galanin positive colonic neurones, highlighting the expression of galanin in a putative 
nociceptive population (Fig. 5-4C).  
 
A significant reduction was observed in the number of TL DRG neurones expressing 
Gfrα3 in DSS-treated mice compared to healthy mice (36.4 ± 2.6% of healthy TL DRG 
neurones vs 11.1 ± 2.7% of DSS TL DRG neurones (DSS: N = 3, n = 608), P < 0.05, 
two-way ANOVA with Sidak’s post-hoc test), but no such difference was observed in 
the LS DRG population (33.5 ± 2.8% of healthy LS DRG neurones vs 20.9 ± 4.6% of 
DSS LS DRG neurones (DSS: N = 3, n = 1062)) or in galanin stained DRG neurones 
(97.4 ± 2.1% of healthy TL DRG neurones vs 91.6 ± 6.2% of DSS TL DRG neurones 
(DSS: N = 3, n = 52), 81.2 ± 8.7% of healthy LS DRG neurones vs 90.2 ± 5% of DSS 
LS DRG neurones (DSS: N = 3, n = 72); Fig. 5-4B). In colonic afferents, there was 
also no significant difference in the number of neurones expressing Gfrα3 between 
DSS-treated mice and healthy mice (43.3 ± 4.3% of healthy TL DRG neurones vs 27.2 
± 4.5% of DSS TL DRG neurones (DSS: N = 3, n = 251) 48.3 ± 7.8% of healthy LS 
DRG neurones vs 34.5 ± 7.1% of DSS LS DRG neurones (DSS: N = 3, n = 434) in 
DSS; Fig. 5-4C). No significant difference in galanin and Gfrα3 coexpression was 
observed between healthy and DSS treated mice (90.6 ± 0.7% of healthy TL DRG 
 
 
118 
neurones vs 72.2 ± 10.7% of DSS TL DRG neurones (DSS: N = 3, n = 38), 97.5 ± 
1.3% of healthy LS DRG neurones vs 90.2 ± 8.6% of DSS LS DRG neurones (DSS: 
N = 3, n = 59); Fig. 5-4C). 
 
In healthy mice, the mean neuronal area of FB-labelled Gfrα3+ DRG neurones was 
significantly smaller compared to FB-labelled DRG neurones (FB+: 240.3 ± 5.7 μm2 
vs FB+ Gfrα3+: 185.7 ± 6.3 μm2, P < 0.0001, unpaired t-test). Similar to healthy mice, 
in DSS-treated mice the mean neuronal area of FB+ Gfrα3+ DRG neurones was also 
significantly smaller than that of FB+ population (FB+: 219.4 ± 3.9 μm2 vs FB+ Gfrα3+: 
195.1 ± 4.8 μm2, P = 0.001, unpaired t-test). This shows Gfrα3 is expressed in smaller 
diameter DRG neurones in healthy mice and this does not change in DSS-treated 
mice. 
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Figure 5-4. Coexpression of galanin and Gfrα3 in colon-innervating DRG sensory 
neurones. 
(A) Representative images of FB staining representing colon-innervating DRG neurones, 
galanin and Gfrα3 immunofluorescence, scale bar is 50 μm; example of coexpression shown 
in the inset. No significant change in the galanin+ neuronal population is seen between healthy 
and DSS-treated mice in the TL and LS populations in the whole DRG (B) or colon-innervating 
DRG neurones (C) (N = 3, unpaired t-test). Cross-sectional area histogram of FB+ (grey bars) 
and Gfrα3+ (black bars) neuronal profiles from healthy (D) and DSS-treated (E) mice (N = 3). 
* 
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TRPV1 can be broadly considered as a nociceptive marker, and it is also expressed 
in a low firing frequency population of mechanically sensitive afferents that play an 
important role in the development of inflammatory hyperalgesia (Malin et al., 2009). 
TRPV1 was expressed by 59.1 ± 6.2% of TL DRG neurones (N = 3, n = 786) and 49.7 
± 1.3% of LS DRG neurones (N = 3, n = 1421) and 96 ± 1.6% of TL galanin+ DRG 
neurones (N = 3, n = 58) and 94 ± 2.9% of LS (N = 3, n = 136) galanin+ DRG neurones 
(Fig. 5-5B). TRPV1 was also expressed in 48.7 ± 1.9% of TL DRG neurones (N = 3, n 
= 380), 56.5 ± 6.4% of LS DRG neurones (N = 3, n = 240) with a high proportion of 
galanin stained colonic afferents (97 ± 1.4% of TL DRG neurones (N = 3, n = 48), 90.6 
± 6.4% of LS DRG neurones (N = 3, n = 53); Fig. 5-5C) suggesting that galanin is 
expressed in those neurones involved in inflammatory hyperalgesia. 
 
No significant difference in the number of TRPV1 expressing DRG neurones was 
observed between healthy and DSS conditions (59.1 ± 6.2% of healthy TL DRG 
neurones vs 60.1 ± 5.8% of DSS TL DRG neurones (DSS: N = 3, n = 914) and 49.7 ± 
1.3% of healthy LS DRG neurones vs 57.2 ± 5.9% of DSS LS DRG neurones (DSS: 
N = 2, n = 917)) or the in the number of galanin+, TRPV1 expressing DRG neurones 
between healthy and DSS conditions (96.0  ± 1.6% of healthy TL DRG neurones vs 
94.4 ± 3.3% of DSS TL DRG neurones (N = 3, n = 104) and 94.0 ± 2.9% of healthy LS 
DRG neurones vs 95.8 ± 1.1% of DSS LS DRG neurones (DSS: N = 2, n = 163); Fig. 
5-5B). In colonic afferents, there was also no significant difference in the proportion of 
TRPV1 expressing neurones between healthy and DSS conditions (48.7 ± 1.9% of 
healthy TL DRG neurones vs 46.3 ± 4.8% of DSS TL DRG neurones (DSS: N = 3, n 
= 406) and 56.5 ± 6.4% of healthy LS DRG neurones vs 65.5 ± 0.8% of DSS LS DRG 
neurones (DSS: N = 2, n = 365)). There was also no significant difference in the 
proportion of galanin and TRPV1 co-expressing FB labelled neurones between 
healthy and DSS conditions (97.0 ± 1.4 % of healthy TL DRG neurones vs 94.1 ± 3.9% 
of DSS TL DRG neurones (N = 3, n = 55), 90.6 ± 6.4% of healthy LS DRG neurones 
vs 98.8 ± 0.8% of DSS LS DRG neurones (N = 2, n = 73); Fig. 5-5C). 
 
 
In healthy mice, the mean neuronal area of FB-labelled TRPV1+ DRG neurones is 
significantly smaller than the FB-labelled DRG neurone population (FB+: 205.6 ± 5.1 
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μm2 vs FB+ TRPV1+: 175.3 ± 5.2 μm2, P < 0.0001, unpaired t-test; Fig. 5-5D). In DSS-
treated mice the mean neuronal area of FB+ TRPV1+ neurones was also significantly 
smaller than that of the general FB+ population (FB+: 173.1 ± 4.4 μm2  vs FB+ 
TRPV1+: 147.7 ± 4.1 μm2, P < 0.0001, unpaired t-test; Fig. 5-5E). This shows TRPV1 
is mainly expressed in small diameter neurones (i.e. putative nociceptors) and that this 
does not change under inflammatory conditions. 
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Figure 5-5. Coexpression of galanin with TRPV1 in colon-innervating DRG sensory 
neurones  
(A) representative images of FB staining representing colon-innervating DRG neurones, 
galanin and TRPV1 immunofluorescence. Example of co-localisation shown in the inset. Scale 
bar is 50 μm. No significant change in the galanin positive neuronal population is seen 
between healthy and DSS-treated mice in the TL and LS populations in the whole DRG (B) or 
in colon-innervating DRG neurones (C) (N = 3, unpaired t-test). Cross-sectional area 
histogram of FB+ (grey bars) and TRPV1+ (black bars) neuronal profiles from healthy (D) and 
DSS-treated (E) mice (N = 3). 
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CGRP was used as a marker of peptidergic neurones. In DRG neurones, CGRP was 
expressed in 41.9 ± 2.4% of TL DRG neurones (N = 3, n = 363) and in 42.4 ± 2.7% of 
LS DRG neurones (N = 3, n = 561), similar to what has been previously reported (Qiao 
and Grider, 2009). CGRP also displayed high coexpression with galanin in DRG 
neurones (86.5 ± 3.8% of TL DRG neurones (N = 3, n = 47), 89.3 ± 6.7% of LS DRG 
neurones (N = 3, n = 89); Fig. 5-6C). In colonic afferents, CGRP was expressed in 
33.3 ± 6.5% of TL DRG neurones (N = 3, n = 603) and in 27.8 ± 5.6% of LS DRG 
neurones (N = 3, n = 829), and also displayed high coexpression with galanin in colonic 
afferents (82.1 ± 9.4% of TL DRG neurones (N = 3, n = 51), 77.8 ± 9.1% of LS DRG 
neurones (N = 3, n = 72); Fig. 5-6B). 
 
When comparing healthy and colitic mice, no significant difference was observed 
between healthy and DSS-treated mice in the number of CGRP expressing DRG 
neurones (41.9 ± 2.4% of healthy TL DRG neurones vs. 33.2 ± 10.6% of DSS TL DRG 
neurones (DSS: N = 3, n = 736) and 42.4 ± 2.7% of healthy LS DRG neurones vs. 
39.3 ± 15.1% DSS LS DRG neurones (DSS: N = 2, n = 617)), or in the number of 
CGRP expressing galanin positive DRG neurones (86.5 ± 3.8% of healthy TL DRG 
neurones vs. 89.6 ± 5.6% DSS TL DRG neurones (DSS: N = 3, n = 53) and 89.3 ± 
6.7% of healthy LS DRG neurones vs. 81.2 ± 10.7% of DSS LS DRG neurones (DSS: 
N = 2, n = 108); Fig. 5-6B). Expression of CGRP in colonic DRG neurones also showed 
no significant difference in DSS-treated mice compared to healthy mice (33.3 ± 6.5% 
of healthy TL DRG neurones vs. 50.5 ± 5.1% of DSS TL DRG neurones (DSS: N = 3, 
n = 349), 27.8 ± 5.6% of healthy LS DRG neurones vs. 45.2 ± 5.6% of DSS LS DRG 
neurones (DSS: N = 2, n = 156); Fig. 5-6C) and no change in coexpression with 
galanin was observed (82.7 ± 1.9% TL DRG neurones (DSS: N = 3, n = 44), 86.6 ±  
0.6% LS DRG neurones (DSS: N = 2, n = 25); Fig. 5-6C). 
 
In healthy mice, there was no significant difference in the mean neuronal area between 
FB-labelled DRG neurones and FB-labelled CGRP-positive DRG neurones (FB+: 
221.6 ± 6.5 μm2 vs FB+ CGRP+: 192.1 ± 7.4 μm2, P < 0.062 , unpaired t-test; Fig. 5-
5D). There was also no significant difference in the profile area mean of FB+ CGRP 
expressing neurone compared to the FB+ DRG neurone population in DSS mice (FB+: 
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208.7 ± 6.8 μm2 vs FB+ CGRP+: 209.7 ± 9.5 μm2, P < 0.94, unpaired t-test; Fig. 5-
5E).   
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Figure 5-6. Coexpression of galanin with CGRP colon-innervating DRG sensory 
neurones. 
(A) representative images of Fast Blue (FB) staining representing colon-projecting DRG 
neurones, galanin and CGRP immunofluorescence. Example of coexpression shown in the 
inset. Scale bar is 50 μm. No significant change in galanin positive neuronal population is seen 
between healthy and DSS-treated mice in the thoracolumbar (TL) and lumbosacral (LS) 
populations in the whole DRG (B) or colon-projecting DRG neurones (C) (N = 3, unpaired t-
test). Cross-sectional area histogram of FB+ (grey bars) and CGRP+ (black bars) neuronal 
profiles from healthy (D) and DSS-treated (E) mice (N = 3). 
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TrkA was used as a second marker for peptidergic putative nociceptors (Gold and 
Gebhart, 2010). In DRG neurones, TrkA was expressed by 42.9 ± 2.3% of TL DRG 
neurones (N = 3, n = 1042) and 43.5 ± 2.8% of LS DRG neurones (N = 3, n = 887) 
and when examining galanin expressing DRG neurones, TrkA was expressed by 81.1 
± 7.7% of TL DRG neurones (N = 3, n = 61) and 84.4 ± 3.7% of LS DRG neurones (N 
= 3, n = 122) (Fig. 5-7B). TrkA was also expressed by 67.9 ± 3.2% of TL DRG neurones 
(N = 3, n = 466) and 49.3 ± 4.4% of LS DRG neurones (N = 3, n = 289). TrkA was also 
highly coexpressed with galanin in 75.5 ± 6.7% of TL DRG neurones (N = 3, n = 112) 
and 55.6 ± 2.5% of LS DRG neurones (N = 3, n = 90) (Fig. 5-7C), further supporting 
the hypothesis that galanin plays a role in nociceptive signalling.  
 
No significant difference in the number of TrkA expressing DRG neurones was 
observed between healthy and DSS-treated mice (42.9 ± 2.3% of healthy TL DRG 
neurones vs 34.5 ± 8.2% TL DRG neurones (N = 3, n = 933) and 43.5 ± 2.8% of 
healthy LS DRG neurones vs 41.0 ± 3.7% of DSS LS DRG neurones (DSS: N = 2, n 
= 1316)), however, in DSS treated mice, coexpression with galanin significantly 
reduced in the LS DRG neurones population (84.4 ± 3.7% of healthy LS DRG 
neurones vs 37.4 ± 2.9% of DSS LS DRG neurones (DSS: N = 3, n = 97), P < 0.001, 
two-way ANOVA with Sidak’s post-hoc test) but not the TL DRG neurones population 
(81.1 ± 7.7% of healthy TL DRG neurones vs 91.9 ± 3.9% of DSS TL DRG neurones 
(DSS: N = 3, n = 52); Fig. 5-7B). In colonic DRG neurones, again, there was no 
significant difference between healthy and DSS mice (67.9 ± 3.2% of healthy TL DRG 
neurones vs 57.4 ± 8.3% of DSS TL DRG neurones (DSS: N = 3, n = 213), 49.3 ± 
4.4% of healthy LS DRG neurones vs 56.4 ± 6.8 % of DSS LS DRG neurones (DSS: 
N = 3, n = 387); Fig. 5-7C). However, interestingly, the coexpression with galanin 
significantly increased in the LS DRG neurones population (55.6 ± 2.5% of healthy LS 
DRG neurones vs 90.4 ± 3.9% of DSS LS DRG neurones (DSS: N = 3, n = 66), P < 
0.01, two-way ANOVA with Sidak’s post-hoc test), but not the TL population (75.5 ± 
6.7% of healthy TL DRG neurones vs 72.5 ± 4.3% of DSS TL DRG neurones (N = 3, 
n = 38); Fig. 5-7C). 
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In healthy mice, there was no significant difference in the profile area means of DRG 
neurones between the FB+ population and FB+ TrkA+ expressing population (FB+: 
236.6 ± 6.5 μm2 vs FB+ TrkA+: 256.8 ± 7.8 μm2, P = 0.062, unpaired t-test; Fig. 5-7D). 
There was also no significant difference in the mean neuronal area of DRG neurones 
between FB+ TrkA expressing and the FB+ population in DSS mice (FB+: 213.5 ± 4.1 
μm2 vs FB+ TrkA+: 223.6 ± 6.1 μm2, P = 0.16, unpaired t-test; Fig. 5-7E).   
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Figure 5-7. Coexpression of galanin with TrkA colon-innervating DRG sensory 
neurones. 
(A) Representative images of FB staining representing colon-innervating DRG neurones, 
galanin and TrkA immunofluorescence. Example of co-localisation shown in the inset. Scale 
bar is 50 μm. No significant change in the galanin positive neuronal population is seen 
between healthy and DSS-treated mice in the TL and LS populations in the whole DRG (B) or 
colon-projecting DRG neurones (C) (N = 3, unpaired t-test). Cross-sectional area histogram 
of FB+ (grey bars) and TrkA+ (black bars) neurones from healthy (D) and DSS-treated (E) 
mice (N = 3). 
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Lastly, TrkC was used as a marker of non-nociceptive neurones (Stephens et al., 
2005) and therefore, as expected, showed low expression in colonic afferent 
populations (8.3 ± 1.9% of TL DRG neurones (N = 3, n = 345), 1.5 ± 0.9% of LS DRG 
neurones (N = 3, n = 295)) and no coexpression with galanin in either TL or LS 
populations (0% TL DRG neurones (N = 3, n = 58) and LS DRG neurones (N = 3, n = 
62) (Fig. 5-8B). In DRG neurones in general, TrkC was expressed by 11.9 ± 1.2% of 
TL DRG neurones (N = 3, n = 1189) and 11.6 ± 1.9% of LS DRG neurones (N = 3, n 
= 856) and showed no coexpression with galanin in TL DRG neurones (N = 3, n = 66) 
or LS DRG neurones (N = 3, n = 65) DRG neurones (Fig. 5-7B). 
 
No significant difference was observed between healthy and DSS-treated mice in the 
number of TrkC expressing DRG neurones (11.9 ± 1.2% of healthy TL DRG neurones 
vs 12.5 ± 4.6% of DSS TL DRG neurones (DSS: N = 3, n = 535) and 11.6 ± 1.9% of 
healthy LS DRG neurones vs 18.8 ± 4.9% DSS LS DRG neurones (DSS: N = 2, n = 
515)) or galanin+ DRG neurones (0% of healthy TL DRG neurones vs 6.9 ± 0.9% DSS 
TL DRG neurones (DSS: N = 3, n = 41) and 0% of healthy LS DRG neurones vs 0% 
of DSS LS DRG neurones (DSS: N = 3, n = 39); Fig. 5-8B). TrkC expression in colonic 
afferents also showed no significant change when comparing DRG neurones from 
healthy mice with those from DSS mice (8.3 ± 1.9 % of healthy TL DRG neurones vs 
11.1 ± 2.3% of DSS TL DRG neurones (DSS: N = 3, n = 140), 1.5 ±  0.9% of healthy 
LS DRG neurones vs 1.8 ± 0.75% of DSS LS DRG neurones (DSS: N = 3, n = 323) in 
DSS; Fig. 5-8C), nor was any change in the coexpression with galanin observed (0% 
of healthy TL DRG neurones vs 5.9 ± 2.4% of DSS TL DRG neurones (DSS: N = 3, n 
= 40), 0% of healthy LS DRG neurones vs 3.2 ± 1.4% of LS DRG neurones (N = 3, n 
= 73); Fig. 5-8C). 
 
In healthy mice, the mean neuronal area of FB-labelled TrkC+ DRG neurones was 
significantly larger than FB-labelled DRG neurones (FB+: 159.3 ± 4.1 μm2 vs FB+ 
TrkC+: 265.8 ± 21.8 μm2, P < 0.0001, unpaired t-test; Fig. 5-8D). In DSS-treated mice, 
the mean neuronal area of FB-labelled TrkC+ neurones was also significantly larger 
than that of FB-labelled DRG population (FB+: 215.5 ± 6.3 μm2 vs FB+ TrkC+: 347.7 
± 28.4 μm2, P < 0.0001, unpaired t-test; Fig. 5-8E). This shows TrkC is expressed in 
larger diameter DRG neurones that are less likely to be involved in nociception.  
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Figure 5-8. Co-expression of galanin with TrkC colon-innervating extrinsic neurones. 
(A) representative images of FB staining representing colon-innervating DRG neurones, 
galanin and TrkC immunofluorescence. Example of coexpression shown in the inset. Scale 
bar is 50 μm. No significant change in galanin positive neuronal population was seen between 
healthy and DSS-treated mice in the thoracolumbar (TL) and lumbosacral (LS) populations in 
the whole DRG (B) or colon-innervating DRG neurones (C) (N = 3, unpaired t-test). Cross-
sectional area histogram of FB+ (grey bars) and TrkC+ (black bars) neuronal areas from 
healthy (D) and DSS-treated (E) mice (N = 3). 
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5.3.4 DSS induces mechanical hypersensitivity in the LSN  
Using a ramp distention from 0 to 80 mmHg, we observed that the LSN isolated from 
DSS treated mice produced a greater response at non-nociceptive pressure, but not 
at nociceptive pressure, compared to the LSN from healthy mice (20 mmHg: 6.9 ± 5.0 
spikes s-1 vs 19.8 ± 4.7 spikes s-1,  P = 0.0184, N = 6, unpaired t-test, and 80 mmHg: 
34.7 ± 8.1 spikes s-1 vs 39.7 ± 3.2 spikes s-1, P = 0.137, N = 6, unpaired t-test, Fig. 5-
10A and B). In addition, the basal firing of LSN from DSS treated mice was significantly 
greater than that of healthy mice (3.9 ± 1.4 spikes s-1 vs 28.4 ± 13.4 spikes s-1, P = 
0.012, N = 6, unpaired t-test). These data suggest that DSS induced a state of 
hypersensitivity in the LSN.  
 
 
 
Figure 5-9. DSS-treated mice display LSN hypersensitivity 
(A) Representative frequency histograms of ramp distensions, 0 – 80 mmHg in colons isolated 
from healthy and DSS-treated mice. (B) DSS increases the LSN response to non-noxious (20 
mmHg), but not noxious (80 mmHg) pressures; unpaired t-test between groups *P < 0.05.  
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5.3.5 Galanin does not inhibit DSS-induced mechanical hypersensitivity 
Finally, we investigated if the inhibition of LSN activity by galanin observed in healthy 
mice (Fig. 3-2) was maintained in the LSN isolated from mice undergoing DSS-
induced colonic inflammation. As observed previously, here in a second cohort of 
mice, 500 nM galanin inhibited basal nerve firing (3.9 ± 1.4 spikes s-1 vs 0.6 ± 0.4 
spikes s-1, P = 0.017, N = 5, paired t-test; Fig. 5-11B), the peak firing frequency (53.3 
± 12.8 spikes s-1 vs 25.2 ± 5.2 spikes s-1, P = 0.015, N = 5, paired t-test; Fig. 5-11C), 
phase I average firing frequency (31.8 ± 2.9 spikes s-1 vs 12.5 ± 1.9 spikes s-1, P = 
0.021 , N = 5, paired t-test; Fig. 5-11D) and phase II average firing frequency (18.6 ± 
6.0 spikes s-1 vs 9.3 ± 4.3 spikes s-1, P = 0.032, N = 5, paired t-test; Fig. 5-11E) in 
response to a phasic distension to 80 mmHg. The activity of the LSN between healthy 
and DSS-treated mice suggested the LSN in DSS-treated mice was sensitised with 
increased hypersensitivity to mechanical distension. The LSN basal activity in DSS-
treated mice was significantly greater than LSN basal activity in healthy mice (3.9 ± 
1.4 spikes s-1 vs 28.4 ± 13.6 spikes s-1, P = 0.0053, N = 5 for healthy and N = 6 for 
DSS-treated, unpaired t-test; Fig. 5-11B and F). Neither the peak firing frequency (53.3 
± 12.8 spikes s-1 vs 65.7 ± 16.6  spikes s-1, P = 0.275, N = 5 for healthy and N = 6 for 
DSS-treated, unpaired t-test; Fig. 5-11C and G) nor phase I average firing frequency 
(31.8 ± 2.9 spikes s-1 vs 46.3 ± 5.9 spikes s-1, P = 0.116, N = 5 for healthy and N = 6 
for DSS-treated, unpaired t-test; Fig. 5-11D and H) is significantly different between 
healthy and DSS-treated mice. However, phase II firing frequency (18.6 ± 6.0 spikes 
s-1 vs 34.1 ± 9.9 spikes s-1, P = 0.037, N = 5 for healthy and N = 6 for DSS-treated, 
unpaired t-test; Fig. 5-11E and I) is significantly greater in DSS-treated mice compared 
to healthy mice. 
 
However, when measuring LSN activity in nerves isolated from DSS mice, galanin had 
no significant effect upon basal nerve firing (28.4 ± 13.6 spikes s-1 vs 26.6 ± 12.1 
spikes s-1, P = 0.62, N = 6, paired t-test; Fig. 5-11F), nor was any effect of galanin 
observed on the peak firing frequency (65.7 ± 16.6 spikes s-1 vs 66.6 ± 22.3 spikes s-
1, P = 0.81, N = 6, paired t-test; Fig. 5-11G), phase I average firing frequency (46.3 ± 
5.9 spikes s-1 vs 51.2 ± 8.8 spikes s-1, P = 0.24, N = 6, paired t-test; Fig. 5-11H) or 
phase II average firing frequency (34.1 ± 9.9 spikes s-1 vs 41.9 ± 14.0 spikes s-1, P = 
0.54, N = 6, paired t-test; Fig. 5-11I) induced by a phasic distension to 80 mmHg. 
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These results indicate that the inhibitory action of galanin upon LSN activity observed 
in the LSN when isolated from healthy mice is lost in tissue isolated from mice with 
acute colitis. 
 
 
Figure 5-10. Galanin does not inhibit DSS-induced LSN hypersensitivity 
(A) Example frequency histogram of the LSN response to repeated phasic intraluminal 
distension (0 – 80 mmHg), showing that the reversible inhibition by galanin of LSN 
mechanosensitivity in healthy mice (Fig. 3-2) is lost in DSS-treated mice; black bar – 500 nM 
galanin application. 500 nM galanin inhibits baseline (B), peak (C) phase I (D) and phase II 
(E) responses of the LSN to phasic distension of the colon to 80 mmHg in healthy mice, but 
has no such effect on baseline (F), peak (G), phase I (H) or phase II (I) responses of the LSN 
to phasic distension of the colon to 80 mmHg when the colon has been isolated from DSS 
treated mice (paired t-test, N = 5 for healthy and N = 6 for DSS). 
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5.4 Discussion 
In a previous study, galanin mRNA was shown to be present in putative nociceptive 
populations (mPEPb and pPEP) (Hockley et al., 2019). The results shown here 
support this RNA-sequencing data by demonstrating at a protein level that galanin is 
expressed in likely nociceptive populations of colonic afferents, as evidenced through 
co-localisation with multiple nociceptive markers: TRPV1, TrkA and Gfrα3. We found 
the level of expression of these markers in healthy whole DRG was similar to 
previously published results: TRPV1 (Christianson et al., 2006a), TrkA (Qiao and 
Grider, 2009), and Gfrα3 (Baudet et al., 2000). Previous work has also showed that 
galanin displays low coexpression with TrkC, a marker for non-nociceptive neurones 
(Ogihara et al., 2016). There is a low number of non-nociceptive neurones innervating 
the distal colon (Sengupta et al., 1990; Sengupta and Gebhart, 1994), but of the small 
number of TrkC positive neurones observed in the current study, galanin showed little 
coexpression, suggesting that galanin has little to no function within this population. 
Coupled with galanin’s high coexpression with nociceptive markers, these data 
suggest that galanin is expressed predominantly in a nociceptive colonic DRG 
neurone population. Here it was also observed that the number of galanin expressing 
neurones in this nociceptive population does not significantly increase in our model of 
acute inflammation, nor did the galanin concentration in whole colon extracts, which 
takes into account that galanin is expressed by multiple cell types in the distal colon in 
addition to sensory neurones, including enterochromaffin cells and fibroblasts 
(Schäfermeyer et al., 2004; Yamamoto et al., 2014). These data align with those of a 
previous study, which showed that galanin was upregulated in models of neuropathic 
pain (sciatic nerve transection), but not inflammatory pain (hind-paw injection of 4% 
carrageenan; Zhang et al., 1998). 
 
However, the pattern of galanin expression and inflammation is not necessarily so 
straightforward, such that it has been observed that galanin mRNA and peptide levels 
do change in some acute (Jimenez-Andrade et al., 2006) and chronic (Butler et al., 
1992) models of inflammation. For example, following hind-paw injection of 
carrageenan in rats, an ipsilateral decrease in galanin levels was observed 5 days 
later, followed by an increase in galanin levels above control levels after 21 days 
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(Calzà et al., 1998). This could suggest that galanin levels may increase in a chronic 
model of colitis. Also, following hind-paw injection of carrageenan in rats, GalR1 
mRNA expression in DRG neurones (L4 and L5) has been shown to decrease (Xu et 
al., 1996), whereas GalR2 mRNA expression is transiently upregulated (Sten Shi et 
al., 1997). In this study, galanin was observed to lose its inhibitory modulatory effect 
on the LSN in DSS mice compared to healthy (Fig.5-11) and thus a similar down 
regulation of GalR1 in colonic sensory neurones to that observed by Xu et al. in the 
carrageenan model could account for the loss of galanin’s inhibitory effect.  
 
With regard to the lack of inhibitory effect observed by galanin on LSN activity from 
DSS mice, a further point to consider is that multiple inflammatory mediators will be 
released from the colon tissue during DSS-induced colitis (Spiller and Major, 2016), 
which would have their effects on a broad range of afferents. Therefore, any effect of 
galanin on the whole-nerve response may simply be overcome by the overall level of 
sensitisation, across a broad range of nerve fibres. The absence of reliable tools to 
investigate GalR protein levels and the validity of current antibodies being uncertain 
(Lu and Bartfai, 2009) makes quantifying the protein level of GalR in colonic afferents 
a significant challenge. Single cell qPCR of colonic retrograde labelled DRG neurones, 
isolated from both healthy and DSS-treated mice was utilised to discern if there was 
any change in the levels of galanin receptor mRNA during inflammation, however, the 
initial study produced unreliable results, which are outlined in Section 7.2, but this 
would still be an interesting area of further investigation in future studies and this, 
alongside further explanations for the findings in this chapter, are discussed in the 
future work section in Chapter 6.  
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Chapter 6 – Conclusions and Future Directions 
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6.1 Summary  
Visceral sensory neurones are responsive to a wide range of both chemical and 
mechanical stimuli in physiological and pathophysiological states (Hockley et al., 2018; 
Brierley et al., 2018). The inflammation observed in IBD causes visceral 
hypersensitivity, such that physiological bowel movements produce pain. Identification 
of regulators of visceral afferent excitability represents an attractive target in 
developing novel analgesics to manage IBD pain and other visceral pain conditions. 
When considering future therapeutic avenues for visceral pain, modulation of 
galaninergic signalling is a potential target due to prior demonstration of galanin being 
a potent regulator of gastro-oesophageal afferent excitability (Page et al., 2005b), but 
to date there has been no published study that extensively investigates galaninergic 
signalling in the distal colon. 
 
6.2 Overview of results 
Using immunohistochemistry, I identified that galanin is present in approximately 20% 
of colon innervating sensory neurones (a result confirming published scRNA-seq data; 
Hockley et al., 2019), which is significantly higher than galanin’s expression in the 
whole DRG neurone population (approximately 5%) suggesting a key role for galanin 
in colon-innervating afferents. The data presented also demonstrate high 
coexpression of galanin with markers of nociceptive populations (e.g. TRPV1 and 
TrkA) further suggesting a potential role for galanin in the modulation of visceral 
nociception. 
 
The impact of galanin on mechanosensitivity in healthy mice was investigated using 
whole-nerve electrophysiological recordings of LSN activity in a tubular, ex vivo colon 
preparation, which enables the physiologically relevant method of activating LSN 
sensory neurones by colonic distension. Both phasic and ramp distension to noxious 
pressure were used to determine the impact of galanin on both low- and high-threshold 
sensory neurones. The data obtained demonstrate that galanin modulates colonic 
afferent excitability and responsiveness to innocuous mechanical and noxious 
chemical and mechanical stimuli. Specifically, the data show a potent, dose-
dependent inhibition of LSN responses to innocuous and noxious mechanical stimuli 
under control conditions and in a state of hypersensitivity evoked by application of 
inflammatory mediators. Pharmacological experiments further suggested that GalR1 
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mediates the inhibitory effect of galanin and that there is no obvious role for GalR2 in 
colonic sensory neurones, and, as discussed in Chapter 1, previous studies have yet 
to show that GalR3 produces any modulating role in GI-innervating afferents (SNAP 
37889; Page et al., 2005b; Swanson et al., 2005). The data from this study thus fit 
alongside galanin’s reported predominantly inhibitory role in the upper GI tract (Page 
et al., 2005b, 2007) and parallels the inhibitory function of galanin in somatic sensory 
innervation (Flatters et al., 2003; Heppelmann et al., 2000). Overall, these results 
highlight the potential anti-nociceptive effects of galanin in the distal colon. 
 
Multiple mediators are released during tissue damage and inflammation that activate 
and sensitise the afferent endings and thus likely contribute to chronic visceral pain 
(Hockley et al., 2018; Brierley et al., 2018). I thus investigated the effects of galanin in 
the presence of an IS, consisting of mediators known to be released from stressed or 
damaged cells and shown to cause visceral afferent sensitisation that is associated 
with IBD in humans (Grundy, 2004). The data obtained show that galanin reduces the 
LSN hypersensitivity induced by these mediators when applied intraluminally to a 
healthy mouse colon. Therefore, these results suggest that under certain 
circumstances that galanin may be beneficial in counteracting inflammation-induced 
visceral hypersensitivity. 
 
The impact of disease-derived inflammatory mediators was further investigated by 
using a mouse model of acute colonic inflammation. The data presented demonstrate 
that the DSS model of chemically-induced colitis produces robust and reliable colonic 
inflammation in C57BL/6J mice, as others have shown (Cooper et al., 1993; Munyaka 
et al., 2016; Solomon et al., 2010). The data presented further show that the LSN from 
mice treated with DSS display hypersensitivity to colonic distension and an increased 
LSN basal firing rate, but that galanin no longer has any inhibitory effect on this 
hypersensitivity.  
 
6.3 Galanin signalling in colonic sensory neurones 
Galanin is expressed by multiple cell types in the distal colon including 
enterochromaffin cells,  fibroblasts (Schäfermeyer et al., 2004; Yamamoto et al., 
2014), and, as shown here, a subset of colonic sensory neurones. Galanin has been 
implicated as a modulator of numerous activities in the GI tract including regulation of 
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neurotransmitter release, motility and secretion (Benya et al., 1999; Sternini et al., 
2004). With regard to nociception in the GI tract, galanin has been shown to modulate 
mechanosensitivity of gastro-oesophageal vagal afferents with predominantly 
inhibitory actions on individual fibres via GalR1 (Page et al., 2005b, 2007). The data 
presented here builds on this by demonstrating that galanin also inhibits LSN 
mechanosensitivity and likely does so though GalR1 activation.  
 
Mechanical distension of the colon is capable of producing pain in humans and 
nociceptive behaviour in animals (Gebhart, 2004; Ness et al., 1990) and thus colonic 
distension is a useful tool when examining hyperexcitability in models of colonic 
inflammation. Multi-unit recordings presented in this thesis show the overall influence 
of galanin on LSN activity, but the effect of galanin on specific afferent populations 
(defined either by transcriptomics or activity; Hockley et al., 2019; Brookes et al., 2013) 
remains unknown and should be a future research objective. It is seen that from multi-
unit recordings of LSN activity, not only does galanin inhibit baseline firing, but it also 
inhibits mechanically-evoked responses to distension of the distal colon to noxious 
pressures and the hypersensitivity following addition of inflammatory stimuli. This 
suggests that GalRs, specifically in the case of the LSN GalR1, function as integral 
regulators of neuronal excitability. Single-unit recordings could distinguish the type of 
mechanosensitive afferent (e.g. stretch, stroke and von Frey hair probing of their 
receptive fields; Brierley et al., 2004) and whether or not they are equally inhibited by 
galanin. The fact that the inhibitory effect of galanin was observed across the full range 
of distension pressures from physiological through to noxious (i.e. 0 – 80 mmHg) 
suggests that galanin is not only expressed by high-threshold nociceptors, but likely 
also wide dynamic range (WDR) afferents. When examining galanin expression, both 
colonic sensory neurone RNA-sequencing and immunohistochemistry demonstrate 
that galanin is expressed in putative nociceptors (Hockley et al., 2019). The 
observation that galanin modulates mechanosensitivity in the LSN and that it is 
contained within sensory neurones innervating the colon could indicate a potential 
autoregulatory role of galanin, in addition to the role of galanin from other sources. 
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With regard to GalR1, single-cell RNA-sequencing of colonic sensory neurones 
indicates that GalR1 is predominantly expressed in neurones expressing nociceptor 
markers, such as TRPV1 and the bradykinin B2 receptor, as well as in a population of 
neurones expressing the mechanosensitive ion channel Piezo2 (i.e. putative low-
threshold mechanosensory afferents), an expression pattern that likely explains the 
inhibitory impact of galanin on LSN activity across a wide range of pressures. The 
GalR1 receptor is coupled to GIRKs giving rise to hyperpolarization (Smith et al., 1998; 
Walker et al., 1997), an effect that would account for the inhibitory activity of galanin 
observed in this study. This conclusion is further supported by data demonstrating that 
inhibition of LSN activity was also produced by the GalR1 agonist M617, but not the 
GalR2 agonist spexin. Further work to reinforce this would be to use a non-peptide 
GalR1 antagonist potentially to show reversal of galanin’s inhibitory effect in healthy 
mice, however a non-peptide GalR1 antagonist is currently unavailable. GalR1 KO 
mice (used in previous studies; (Jacoby et al., 2002; Malkmus et al., 2005) could also 
potentially be used, such that a loss of the inhibitory effects of galanin in healthy mice 
in GalR1 KO mice would indicate the critical role of GalR1 in mediating the effects 
observed in this study. 
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Figure 6-1. Schematic of the potential signalling pathway activated by galanin in colonic 
afferents 
Once galanin is released from colonic sensory neurones or other cell types in the colon (such 
as enterochromaffin cells – EC) it can bind to GalR1, the β/γ subunit of the dissociated G 
protein then activates GIRK channels. This causes K+ efflux leading to hyperpolarisation of 
the colonic sensory afferent and consequently reduces neuronal activity. 
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6.4 Role of galanin in inflammatory pain pathways 
As observed in previous studies (Hockley et al., 2018; Brierley et al., 2018), the data 
presented here also demonstrate that intraluminal application of an IS produced robust 
LSN hyperexcitability to multiple noxious mechanical stimuli. Part of this 
hyperexcitability likely results from recruitment of ‘silent’ or mechanically insensitive 
afferents in both the LSN and PN (Feng and Gebhart, 2011), potentially through 
disinhibition of Piezo2 (Prato et al., 2017). The ability of galanin to reverse the 
mechanically hypersensitivity induced by the IS correlates with the fact that a variety 
of inflammatory mediator receptors are present in colonic sensory neurones that also 
express GalR1 (Hockley et al., 2019). This finding could be further expanded upon by 
investigating the effects of individual components of IS or different mediators. One 
example being unpublished data from the Smith lab (Katie Baker) shows that it might 
be interesting to investigate the effects of galanin on the hypersensitivity induced by 
TNFα and/or NGF. Interestingly, by contrast to its effects upon IS-induced 
hypersensitivity, galanin was not able to reduce the mechanical hypersensitivity 
present in LSN isolated from colitic mice that had been treated with DSS. Inflammation 
in the colon has the potential for increased enzymatic activity which could lead to an 
increase in the rate galanin is broken down, which could contribute to the reduced 
effects seen with galanin in DSS-treated mice at a comparable dose to healthy mice. 
A higher concentration of galanin could be used to overcome any enzymatic galanin 
breakdown and thus reproduce the inhibitory effects seen in healthy mice. 
 
Why is it that galanin counteracts the acute effects of inflammatory mediators on LSN 
activity, but has no such effect on LSN activity in a mouse model of colitis? It has been 
observed that GalR expression is altered in certain models of inflammation and hence 
differential receptor expression could lead to galanin no longer exerting an inhibitory 
effect. For example, following hind-paw injection of carrageenan in rats, GalR1 mRNA 
expression in DRG neurones (L4 and L5) decreases (Xu et al., 1996) and therefore it 
is possible that a similar decrease in GalR1 expression occurs in the DSS model and 
hence galanin is no longer able to inhibit mechanically-evoked LSN activity. 
Alternatively, there could be an increase in the expression of excitatory GalR2. The 
absence of reliable tools to investigate GalR protein levels and the validity of current 
antibodies being uncertain (Lu and Bartfai, 2009) makes quantifying the protein level 
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of GalRs in colonic afferents a significant challenge. However, there are also 
alternative explanations for the lack of measurable galanin activity. For example, 
multiple inflammatory mediators are released from inflamed colon tissue (Spiller and 
Major, 2016), which would act upon a broad range of afferents, i.e. both GalR1+ve 
and GalR1-ve afferents, and thus the mechanical hypersensitivity observed in LSN 
isolated from DSS treated mice is likely at least partially mediated via GalR1-ve 
afferents. Therefore, any effect of galanin on the whole-nerve response may simply 
be overcome by the overall level of sensitisation. A further explanation would be that 
the coupling of GalR1 is altered in inflammation due to altered expression of G proteins 
and/or that the signalling of galanin at GalR1 becomes biased towards different 
pathways. 
 
6.5 Further work 
As described above, there are a number of studies that could be conducted to extend 
and consolidate the data presented here and further determine the mechanisms by 
which galanin inhibits LSN mechanosensitivity and IS-induced LSN hypersensitivity. 
Further investigation into the impact of galanin on different afferent subtypes 
innervating the distal colon could further define the role of galanin in visceral 
nociception. These experiments would involve electrophysiological recordings using a 
flat-sheet preparation where the colon is opened along the antimesenteric border and 
pinned mucosal side up to expose receptive fields and enable single-unit recordings 
to interrogate which subtypes are affected by galanin (Brierley et al., 2004). Of the 4 
afferent subtypes identified functionally, the serosal and mesenteric fibres are believed 
to represent major populations of visceral nociceptors (Feng and Gebhart, 2011) and 
therefore I hypothesise that galanin will inhibit mechanosensitivity in both serosal and 
mesenteric afferent subtypes. 
 
As previously discussed, the loss of galanin’s inhibitory effect in the acute model of 
colonic inflammation could be partially due to changes in GalR1 expression. Although 
the initial SC-qPCR study (see Section 7.2) yielded inconclusive results, with further 
optimisation this technique could help address whether or not galanin receptor 
expression in colonic sensory afferents changes between healthy and acute 
inflammatory conditions. However, such analysis only examines mRNA levels and 
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another approach would be to examine GalR expression using immunohistochemistry.   
Currently, there is an absence of reliable tools to investigate GalR protein levels and 
the validity of current antibodies is uncertain (previous unsuccessful attempts, data not 
shown; Lu and Bartfai, 2009). However, knock-in mice expressing fluorescently tagged 
GalR1 and GalR2 have been generated and provide the potential to examine some 
GalR expression at a protein level (Kerr et al., 2015). Furthermore, to determine the 
involvement of different GalRs in modulating afferent sensitivity in acute inflammation, 
GalR specific agonists (as demonstrated in Chapter 3 using healthy mice) could be 
used. As shown in Chapter 3, the GalR1 agonist (M617) demonstrated a similar level 
of inhibition to galanin, whereas the GalR2 agonist (spexin) showed no significant 
effect on mechanosensitivity. If repeated in DSS-treated mice the results could 
establish if there is a functional change in the functional contribution of GalR1 and 
GalR2 to LSN activity. I would hypothesise that M617 would lose its inhibitory effect 
seen in healthy mice in a similar way to galanin’s loss of effect in an acute model of 
colitis. Ideally, using non-peptide agonists would be preferable as they would be 
resistant to enzymatic breakdown. 
 
  
Previously published studies have shown that although galanin is downregulated in 
acute peripheral inflammation it is then later upregulated suggesting a greater role for 
galanin in chronic inflammation (Calza et al., 1998, 2000).  The DSS model utilised in 
this study focused only on the acute inflammatory state. However, using cycles of DSS 
administration, at lower concentrations, provides a more chronic model of colonic 
inflammation where it is possible to examine LSN function in relapse and remission as 
occurs in humans with IBD (Wirtz et al., 2007). Using the same multi-unit 
electrophysiological recordings as presented here, it would thus be possible to 
determine whether the inhibitory effect of galanin returns during periods of remission 
from overt inflammation, further supporting the hypothesis of galanin having a more 
prominent role in chronic inflammatory conditions.  
 
Finally, to further investigate whether galanin or its receptors are a valid therapeutic 
target for treating IBD-associated visceral pain, an in vivo model of colitis could be 
used. Intracolonic application of galanin, a GalR1 agonist (M617), or ideally a small 
molecule, non-peptide GalR1 agonist, will provide insight to any changes in pain-
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related behaviours. Results obtained could also be built upon by using different GalR 
KO mice (Drexel et al., 2018; Malkmus et al., 2005).  
 
6.5  Conclusions 
In conclusion, the data presented in this thesis show a new role for galanin in the 
modulation of LSN function in the distal colon: galanin inhibits LSN mechanosensitivity 
and acute mechanical hypersensitivity induced by an IS. Future work should elucidate 
more detail on the mechanisms underpinning why galanin is unable to exert any 
inhibition on LSN mechanical hypersensitivity following prolonged (in vivo) 
inflammation. Nevertheless, overall, the data suggest that targeting GalR1 could 
provide a new route for treating visceral pain under specific circumstances and support 
further investigation. 
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Chapter 7: Appendices 
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7.1 Antibody Optimisation 
The quality of staining in immunohistochemistry is influenced by the primary antibody 
concentration, the diluent used, the incubation temperature and time. These variables 
may need to be optimized for each antibody and sample in order to achieve specific 
staining with minimal background. Usually, the antibody concentration is varied while 
maintaining a constant incubation time and temperature in order to optimize staining. 
Incubation times can be lengthened to ensure antibody penetrates tissues and 
combined with lower temperatures to promote specific binding. The optimal incubation 
time and temperatures are reported in section 2.2.2. Results for testing for optimal 
concentration shown here with secondary-antibody-only controls to show the staining 
is the result of the primary antibody only. In the case of galanin, as a control, the 
primary antibody was also incubated with 1 µM galanin peptide. If the antibody is 
specific it will bind only to the galanin and not to the tissue, resulting in no staining. 
 
 
Figure 7-1. Goat anti-CGRP primary antibody optimisation  
Goat anti-CGRP primary antibody with donkey anti-goat IgG-Alexafluor 488 tested at dilutions: 
1:300 (top left), 1:500 (top right), 1:1000 (bottom left), and secondary only control (2°Ab; 
bottom right). Scale bar 50 µm. 
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Figure 7-2. Goat anti-Gfrα3 primary antibody optimisation  
Goat anti-Gfrα3 primary antibody with donkey anti-goat IgG-Alexafluor 488 tested at dilutions: 
1:300 (top left), 1:500 (top right), 1:1000 (bottom left), and secondary only control (2°Ab; 
bottom right). Scale bar 50 µm. 
 
 
Figure 7-3. Goat anti-TrkC primary antibody optimisation  
Goat anti-TrkC primary antibody with donkey anti-goat IgG-Alexafluor 488 tested at dilutions: 
1:300 (top left), 1:500 (top right), 1:1000 (bottom left), and secondary only control (2°Ab; 
bottom right). Scale bar 50 µm. 
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Figure 7-4. Guinea-pig anti-TRPV1 primary antibody optimisation  
Guinea-pig anti-TRPV1 primary antibody with donkey anti-Guinea-pig IgG-Alexafluor 488 
tested at dilutions: 1:300 (top left), 1:500 (top right), 1:1000 (bottom left), and secondary only 
control (2°Ab; bottom right). Scale bar 50 µm. 
 
 
 
Figure 7-5. Goat anti-TrkA primary antibody optimisation  
Goat anti-TrkA primary antibody with donkey anti-Guinea-pig IgG-Alexafluor 488 tested at 
dilutions: 1:500 (left), 1:1000 (middle), and secondary only control (2°Ab; right). Scale bar 50 
µm. 
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Figure 7-6. Rabbit anti-Galanin primary antibody optimisation  
Rabbit anti-Galanin primary antibody with donkey anti-rabbit IgG-Alexafluor 568 tested at 
dilutions: 1:300 (top left), 1:500 (top middle), 1:1000 (top right), secondary only control (2°Ab; 
bottom left) and 1:1000 + galanin peptide (bottom right). Scale bar 50 µm. 
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7.2 Single cell qPCR 
To further determine galanin’s mechanism of action on LSN activity under 
inflammatory conditions the change in galanin receptor levels between healthy and 
inflammatory conditions (induced by DSS treatment) was investigated. As there are 
currently no reliable tools to investigate galanin receptor protein levels (as mentioned 
in section 6.3) an approach to determine general increases or decreases in galanin 
receptor mRNA expression in colonic afferents was used. Single cell qPCR is a 
method that involves the isolation of single cells (in this case retrograde labelled DRG 
neurones) and, with the use of probe conjugated primers, monitors the amplification 
of a targeted DNA molecule (Fig 7-7). This technique can be used in a quantitative or 
semi-quantitative manner to either calculate the amount of starting copies of mRNA in 
the original sample or determine if the original sample has above/below certain 
amounts of copies of the DNA relative to a reference gene. In this experiment I used 
semi-quantitative single cell qPCR to determine the changes in mRNA levels of 
galanin and its receptors relative to a commonly used reference gene (Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH); White et al., 2011; Li et al., 2016; Hockley et 
al., 2019) in both healthy and inflammatory conditions. Based on previous studies of 
galanin receptor levels in peripheral neurones and my functional electrophysiological 
data I hypothesised that GalR1 would be downregulated or GalR2 would be 
upregulated in inflammatory conditions. 
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Figure 7-7. A schematic of workflow depicting single cell qPCR  
C57BL/6J mice had colonic afferents retrograde labelled with FB before 3 mice underwent 
DSS treatment to induce colitis and 3 mice remained on standard drinking water. Both 
groups then had their TL (T13 & L1) and LS (L6 & S1) DRGs dissected and dissociated. FB 
positive neurones were then isolated through the process of cell-picking. Targeted mRNA of 
genes of interest were then pre-amplified and converted to cDNA ready for qPCR. 
 
As described in section 2.4, six male C57BL/6J mice between the ages of 8-12 weeks 
underwent retrograde labelling of colonic afferents. Then 3 of the 6 mice were treated 
with DSS to induce colitis while the remaining three remained on normal drinking 
water. From each mouse 20 FB-labelled DRG neurones were isolated from TL DRG 
(T13 & L1) and 20 from LS (L6 & S1) giving a total of 60 cells for each condition 
(healthy TL and LS DRG neurones, DSS TL and LS DRG neurones). Negative controls 
included bath samples (PBS being perfused whilst DRG neurone isolation occurred), 
and “no-template” controls (wells containing all PCR components apart from the 
sample DNA) which all came out negative. GAPDH was used as the reference gene 
due to being widely used in previous literature (Hockley et al., 2019; Li et al., 2016; 
White et al., 2011). As the experiment was run across 15 95-well plates, interplate 
calibrators (IPC) were used to remove the plate to plate variability. The IPC was cDNA 
extracted from whole DRGs as these should contain mRNA from all genes of interest. 
 
The outcome of the experiment was unfortunately inconclusive due to high variability 
within the IPCs and also the gene of reference, GAPDH. The summation of variability 
meant no robust conclusions could be drawn from the data. The IPC calibration is a 
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calculation procedure to detect and remove inter-plate variation. Identical samples of 
DNA are used in the different plates and the difference in ct values can be used to 
calculate the correction factor to correct the readings from that plate removing inter-
plate variability (Hellemans et al., 2007). For this experiment, mRNA extracted from 
whole DRGs (T9 - L6) and converted to cDNA was used and the results are shown in 
Table 5 below. Correction factors above 0.5 or below -0.5 are usually considered high, 
thus the range of values obtained suggests the IPC may not have worked on all plates. 
 
 
 
 
 
 
 
 
 
 
 
Table 5 – IPC values obtained for GAPDH  
 
Reference genes are expressed in all cells under normal and patho-physiological 
conditions. GAPDH plays an important role in glycolysis and is a commonly used 
housekeeping gene used in gene expression studies (Hockley et al., 2019). The 
expression of GAPDH in the 240 cells collected in this study seemed to vary greatly 
(Table 6) and in many cases produced higher Ct values than the gene of interest.  
 
 
 
 
 Interplate 
Calibrator Average 
Ct value 
Correction 
factor 
Plate 1 18.06 -5.48 
Plate 2  19.01 -4.53 
Plate 3  17.67 -5.87 
Plate 4  23.55 0.01 
Plate 5  35 11.45 
Plate 6  22.10 -1.44 
Plate 7  25.21 1.67 
Plate 8  24.67 1.13 
Plate 9  26.31 2.76 
Plate 10  23.35 -0.19 
Plate 11  22.14 -1.40 
Plate 12  24.69 1.14 
Plate 13  24.18 0.63 
Plate 14  24.05 0.50 
Plate 15  23.17 -0.36 
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Table 6 – Sample of GAPDH Ct values from one healthy mouse. 
 
The variation seen in IPC and reference gene values could be the result of 
inexperience with the technique. Future attempts should incorporate multiple 
reference genes (such as 18S rRNA; Kuchipudi et al., 2012), further optimisation of 
DRG dissociation and isolation, and qPCR preparation. 
 
 
 
 
 
 
 
 GAPDH Ct Values 
Healthy 1 26.66 
Healthy 2 17.16 
Healthy 3 13.58 
Healthy 4 17.79 
Healthy 5 20.41 
Healthy 6 17.65 
Healthy 7 23.80 
Healthy 8 21.16 
Healthy 9 19.39 
Healthy 10 17.98 
Healthy 11 27.34 
Healthy 12 26.79 
Healthy 13 27.72 
Healthy 14 26.94 
Healthy 15 29.69 
Healthy 16 22.54 
Healthy 17 35.75 
Healthy 18 26.62 
Healthy 19 27.16 
Healthy 20 18.92 
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